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AIM Of THIS THESIS 
Oman is one of the countries of the Arabian Peninsula that, in a few decades, has changed 
from a traditional nomadic culture to a modern industrialized society. In this rapid process, 
public health has made dramatic progresses fighting against diseases endemic in the country 
and is now facing the problem of severe hereditary recessive conditions like sickle cell disease 
(SCD) and beta thalassemia major (BTM). Carriers of this disease are frequent in the country 
because they were protected against Malaria during millennia of evolution and being in Oman 
consanguinity a socio-cultural habit, the incidence of children born with hemoglobinopathy is 
high in many areas of the country. 
As shown by experiences made in other countries, management of these severe diseases 
consists of identifying the mutation spectrum, drawing a genotype-phenotype correlation, 
selecting the best possible supportive treatment and implementing primary prevention 
methods for couples at risk. 
Oman has an extended network of structured hospitals where local patients receive care 
and treatment free of charge. Pre-matrimonial counseling clinics are widely distributed in the 
country; their policy is to identify carrier couples prior marriage, offering as the only option to 
alter the partner choice whenever a presumed genetic risk has been suspected at the protein 
level. However, healthy carriers of SCD and BTM may have progeny with striking variability in 
phenotype and response to therapy may depend on the inheritance of more or less severe 
mutation and other complex genetic factors. The precise genetic changes prevalent in the 
different regions of Oman and analysis of the genotype/phenotype relationship of the disease 
still remain inadequately studied in the country.
The aim of this thesis is to study in detail the molecular spectrum of globin gene mutations 
and other modifying factors among the different regions in the country by studying a 
large number of samples to cover the entire population to a) reflect the geographical and 
historical backgrounds of each region from the described mutations; b) document the 
mutation spectrum of β- and α- thalassemia to facilitate national screening and educational 
programmes; c) facilitates genetic pre-matrimonial counseling and testing for the purpose of 
better risk prediction; d) allow a more tailored treatment for the affected children based on 
a well characterized genotype and e) the possibility to offer prevention by prenatal diagnosis 
and the option of medical interruption of pregnancy when necessary, with approval by public 
health and religious authorities, as is the case in other modern Muslim countries.
Chapter 1 (General introduction) includes general knowledge on the hemoglobinopathies, 
the relevant genes, modifying factors, world prevalence and treatment options. Chapter 2 
focuses on the country of Oman and gives a general view on the problem of hemoglobinopathies 
in Oman. Chapter 3 describes prevention options and the bottlenecks. Chapter 4 describes the 
general molecular spectrum of β-thalassemia and α-thalassemia in Oman. A broader spectrum 
of regional epidemiology and distribution of β-thalassemia and β-variants mutations among 
the different Omani subdivisions is outlined in Chapter 5. Chapter 6 presents two cases that 
were characterized during our studies; the first describing a novel Omani mild beta-thalassemia 
mutation; the second presenting an alpha gene variant in an Omani family that was assumed to 
lead to a lethal condition in the offspring. The spectrum of alpha-thalassemia in Oman including 
14
large deletions and point mutations is described in Chapter 7. The molecular spectrum of delta-
thalassemia in Omani cases associated with low HbA
2
 levels is illustrated in Chapter 8. Chapter 9 
describes the map of the haplotype distribution of homozygous HbS/S sickle cell disease as 
well as sub-haplotypes in otherwise identical beta clusters to support genotype/phenotype 
correlation. Chapter 10 studies the effect of Hydroxyurea treatment in Omani sickle cell disease 
in association with XmnI polymorphism. Alpha thalassemia whether a risk or a modulation factor 
in homozygous Omani HbS/S is underlined in Chapter 11. Chapter 12 describes the design of uni- 
and bi-directional barcoded new generation molecular methodology using Ion Torrent PGM to 
detect β-mutations in a cohort of Omanies with β-hemoglobinopathy to keep up with the new 
technologies and scientific advances. Chapter 13 focuses on the views of Omani carrier-couples 
towards prevention options in view of the ethnic, social and cultural background. Chapter 14 
includes the final discussion and conclusion on hemoglobinopathies in Oman and presenting 




















CHAPTER 1  -  GENERAL INTRODUCTION
1.1 Anemia 
Anemia is a common clinical condition characterized by low levels of hemoglobin (Hb). The 
main causes of anemia include blood loss or insufficient production of red blood cells and/or 
Hb as a result of a pathological condition. Most common are iron or vitamins deficiencies (Folic 
acid and B12), which are generally easy to treat. More problematic can be anemia secondary 
to severe infections and hemolysis or to clinical conditions associated with disrupted bone 
marrow function. Anemia can be hereditary and caused by red cell enzyme defects, such as 
glucose-6 phosphate dehydrogenase deficiency (G6PD), or red cell membrane defects, such 
as congenital spherocytosis. However, the most common hereditary conditions causing 
anemia worldwide are the Hemoglobinopathies which are caused by abnormal synthesis of 
hemoglobin, the main focus of this thesis.
1.2 Hemoglobin
Hemoglobinopathies (HBP) are diseases characterized by changes in the production and 
function of the vital protein hemoglobin, one of the most essential proteins that transport 
oxygen from the lungs to all tissues, supporting oxidative metabolism. The hemoglobin 
molecule (Hb) is the main component of the red blood cells (RBC) and is a tetramer, consisting 
of two pairs of β-like and α-like globin chains. To fulfill the oxygen transport function, Hb 
tetramers have 4 oxygen binding prosthetic groups (hemes) each containing one iron atom 
(1) (Figure 1.1). The production of globin chains is coded by globin genes that have a strictly 
regulated pattern of expression in different tissues and stage of development (2, 3). 
During early embryonic development, erythropoiesis takes place in the yolk sac, 
transitioning to the fetal liver and finally to the bone marrow as development proceeds 
through fetal and then postnatal life (4) (Figure 1.2). Furthermore with respect to hemoglobin 
expression there are also two main switches during prenatal development. The first switch 
from embryonic-to-fetal hemoglobin expression takes place early in gestation. The second 
from fetal-to-postnatal hemoglobin expression starts during the last months of gestation and 
is completed during the following 12 months of postnatal life (4).
At birth, the average content of the red blood cells consists of approximately 80% fetal 









After the age of 2 years and in normal conditions, HbA will make up »97% of the total 
circulating Hb, and HbA
2




), will be expressed at a much 
lower level (»2.5%) while HbF expression will have almost disappeared, although it remains 
detectable at a very low levels (<1%). 
All postnatal hemoglobins are synthesized in the bone marrow in the erythroid red cell 
precursors. After maturation erythroid cells loses their nucleus and are released in the peripheral 
circulation where, as young red cells (reticulocytes), they quickly mature into regular red cells 




















Figure 1.1: Schematic representation of the hemoglobin molecule consisting of two β 





Figure 1.2: Depicting the expression of the globin genes during the switch from 











Figure 1.1: Schematic representation of the hemoglobin m lecule consisting of two β 
and two α subunits, each containing an oxygen binding heme group. (Figure adapted 




Figure 1.2: Depicting the expression of the globin genes during the switch from 






figure 1.1. Schematic representation of the hemoglobin molecule consisting of two β and two α subunits, 
each containing an oxygen binding heme group. (Figure adapted from http://resources.med.fsu.edu/
gsm/hp/program/section4/4ch5/asidpg16.htm).
figure 1.2. Depicting the expression of the globin genes during the switch from embryonic, fetal and 















1.3 Hemoglobin evolution 
The basic structure and function of the hemoglobin protein is highly conserved among 
different species making it an interesting model for evolutionary and biochemical investigation. 
Gametic mutations are the key of the evolutionary mechanism of all living organisms. The 
mechanism is based upon selection of random de novo mutations passed to the progeny 
to be tested for their advantage or disadvantage. Hemoglobin in its current form has a long 
evolutionary history. Globin genes coding for the basic protein in vertebrates are believed to 
be older than 500 million years (5). The relationship between the primary sequences and the 
three-dimensional structures shows that the human α- and β-globin genes family is derived 
from a monomeric myoglobin, the oxygen storage and delivery proteins still present in our 
muscular tissues (6). During the last 200 million years splitting between ancestral alpha and 
beta like genes, duplications and rare point mutation events have differentiated the ancestral 
proto-myoglobin gene into the current alpha- and beta- like genes present in the human gene 
clusters (7) (Figure 1.3). 
1.4 Malaria and globin gene selection 
As briefly mentioned above, evolution depends on many factors among which the most 
important are the adaptation to the environment and the fitness of the individuals in providing 
healthy progeny (8). Hemoglobinopathies (HBP) are caused by mutations on the globin genes 
that had probably not been particularly selected for until man developed agriculture and had 
to share the environment with malaria mosquitoes. Carriers of a globin gene mutation were 
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Figure 1.3: Evolution of 500 million years of the human globin gene clusters from proto-
myoglobin to the actual  and -like genes (From Giordano PC. Dissertation 1998). 
Active genes are in black, open boxes are non-active pseudo () genes. 
 
1.4 Malaria and globin gene selection  
 
As briefly mentioned above, evolution depends on many factors among which the most 
important are the adaptation to the environment and the fitness of the individuals in 
providing healthy progeny (8). Hemoglobinopathies (HBP) are caused by mutations on 
the globin genes that had probably not been particularly selected for until man developed 
agriculture and had to share the environment with malaria mosquitoes. Carriers of a 
globin gene mutation were advantaged in malarial-infested areas (9,10,11).  
figure 1.3. Evolution of 500 million years of the human globin gene clusters from proto-myoglobin to the 
actual α and β-like genes (From Giordano PC. Dissertation 1998). Active genes are in black, open boxes 
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Figure 1.4
Haldane observed that the geographical distribution of HBP and the distribution of malaria 
greatly overlap, and published the hypothesis that individuals carrying sickle cell disease (SCD) 
or thalassemia must have a selective advantage over non-carriers in terms of survival and 
reproduction in malarial-infested areas (12,13,14,15).
Regarding the protecting mechanisms, it has been postulated that the sickle cell 
hemoglobin (HbS) mutation confers a protection against malarial infection because the deoxy 
HbS cells infected with malaria become sickled and are subsequently destroyed by the T-cells 
and macrophages, reducing acute malarial infection in the carriers (16,17). Similarly, it has been 
shown that α-thalassemia protects against severe malaria by the same mechanism as HbS, 
ameliorating the pro-inflammatory effects of cytoadherence (18). In vitro studies have shown 
that there is reduced malarial growth in erythrocytes and enhanced removal of parasitized 
cells by the immune system in individuals that are thalassemia carriers or heterozygote for 
Hb S (19).
1.5 The human hemoglobin genes
The human globin genes are clustered on different chromosomes, the β- like genes on 
chromosome 11 and the α- like genes on chromosome 16. The beta cluster contains an inactive 
pseudo beta gene (ψβ), the embryonic epsilon (ε) gene as well as the fetal G-gamma (Gγ) 
(HBG2) and A-gamma (Aγ) (HBG1) and adult delta (δ) (HBD) and beta (β) (HBB) genes (20). As 
mentioned above, the main genes responsible for the hemoglobin composition in postnatal life 
(HbA) are the β and the α genes. The beta gene is 1.6 Kb in length. About 50 to 70 kb upstream 
of the beta globin gene is the locus control region (LCR) which regulates the activation and 
expression of the β globin gene cluster (21, 22). 
The alpha cluster located on the telomeric region of chromosome 16, contains several 
inactive pseudo genes (ψζ, ψα2, ψα1) and a θ gene of unknown function, an embryonic zeta 




) (HBA2 and HBA1) both 1.2 kb long. The 
main regulatory element (MRE) of the alpha globin genes is located about 60 kb upstream (23). 
All alpha- and beta- like genes consists of three coding regions (exons) and two introns known 
as intervening sequences (IVS) (Figure 1.4). The genes are linearly arranged 5’ to 3’ in the order 
expressed during development (Figure 1.5) (4). While the beta globin chains are needed for 




















). This difference explains some of the postnatal pathology of beta gene defects and the 
pre- and post-natal pathology of alpha gene defects. The hemoglobin tetramers formed during 
embryonic, fetal and adult development are summarized in Table 1.1.
figure 1.4. Schematic representation of the basic structure of the globin genes, showing the promoter, 















1.6 The Hemoglobinopathies 
Hemoglobinopathies (HBP) are the most frequent inherited autosomal recessive disorder in 
man. In an autosomal recessive disorder two copies of an abnormal gene must be present in 
order for the disease to develop. Both males and femailed can be carriers or affected. 
A carrier couple will transmit the disease to their children in a Mendelian fashion, which 
means that statistically speaking, half of the progeny will be carriers of one of the two parental 
mutations and be unaffected like their parents (heterozygous), ¼ will not be carriers (normal) 
and ¼ will have both parental mutations and be affected by the disease (Figure 1.6). The severity 
of the disease will depend on the type of mutation and/or complex gene combinations and 
present with variable form of thalassemia.
As mentioned above, HBP are caused by mutations on the globin genes that, due to 




Figure 1.5: Schematic representation of the globin gene clusters on chromosome 16 and 
11 respectively with the embryonic  and  genes, the fetal  genes, the embryonic, fetal 
and postnatal  genes and the postnatal  and  genes. The corresponding Hb tetramers, 
Hbs Gower-I and -II, Hb Portland, Hb F, Hb A2 and Hb A are depicted from left to right 
with their different globin chain compositions. Pseudo genes are not shown (Giordano 
PC, 2012, reference 24). 
 
Embryonic hemoglobins Fetal hemoglobins Adult (post-natal) hemoglobins 
Hb Gower I (ζ2/ε2) 
Hb GowerII (α2/ ε2) 
Hb Portland (ζ2/γ2) 
Hb F (α2/γ2) Hb A (α2/β2) 
Hb A2 (α2/δ2) 
Table 1.1 Summary of the different hemoglobin synthesized during normal human 
developmental stages. 
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and Hb A are depicted from left to right with their different globin chain compositions. Pseudo genes are 
not shown (Giordano PC, 2012, reference 24).
Table 1.1. Summary of the different hemoglobin synthesized during normal human developmental stages.
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subtropical areas of the world. From there, they spread by ancient migrations and slavery and 
today, due to recent massive migrations, are found in many non-endemic areas worldwide (25). 
Mutations on the globin genes can change the primary structure of the gene products 
causing abnormal hemoglobins, can decrease the expression of the gene causing thalassemia 
and anemia and finally some are silent (polymorphisms). 
Most mutation events are limited to one or few nucleotides (point mutations) while other 
involves larger defects. Large deletions which eliminate parts of genes or even entire genes or 
locus control regions are associated with a reduced synthesis of the relevant globin chain and 
hence an expression of thalassemia or it can result in an elevated expression of Hb F (e.g HPFH 
deletions – section 1.13). 
Point mutations can be associated with either thalassemia or abnormal hemoglobins, the 
latter typically caused by changes on the coding regions of the genes (exons). Point mutations 
associated with reduced globin synthesis may occur in all parts of the globin genes starting 
from the locus control regions, the promoter regions, the initiation and stop codons, the 
coding exons, the exon/intron splice junction sites, deeper intronic sequences, the 5’ and 3’ 
untranlsated regions and finally the poly A addition site. Point mutations may generate a stop 
codon directly or indirectly because of a frame shift due to a deletion or an insertion event 
of more than one nucleotide causing thalassemia. Exonic point mutations that change a 
particular amino acid lead to an abnormal hemoglobin, which may or may not have phenotypic 
consequences. Rarely exonic mutations affect the normal splicing of genes (for example 
HbE). not all mutations affect the structure or function of the hemoglobin molecule and it is 
important to define the correlation between the mutation and the phenotype to predict the 
severity of the conditions in homozygous or compound heterozygous form. 
Hundreds of point mutations causing Hemoglobinopathy have been characterized (26). 





Figure 1.6: Inheritance of an autosomal recessive mutation causing SCD or BTM 
following a Mendelian fashion. 
  
As mentioned above, HBP are caused by mutations on the globin genes that, due to a 
selective advantage in the presence of malaria, have become endemic in the tropical and 
subtropical areas of the world. From there, they spread by ancient migrations and slavery 
and today, due to recent massive migrations, are found in many non-endemic areas 
worldwide (25).  
Mutations on the globin genes can change the primary structure of the gene products 
causing abnormal hemoglobins, can decrease the expression of the gene causing 
thalassemia and anemia and finally some are silent (polymorphisms).  
Most mutation events are limited to one r few nucleotides (point mutations) while other 
inv lves l rger delet ons. Large deletions which eliminate parts of genes or even entire 
genes or locus cont ol regions are observed to be associated with a reduced synthesis of 
the relevant globin polypeptide and hence an expression of thalassemia or it can result in 
an elevated expression of Hb F (e.g HPFH deletions – section 1.13). 
Point mutations can be associated with ither thalas emia or abn rmal hemoglobins, the 
latter typically caused by changes on the coding regions of the genes (exons). Point 
mutations associated with reduced globin synthesis may occur in all parts of the globin 
genes starting from the locus control regions, the promoter regions, the initiation and stop 
codons, the coding exons, the exon/intron splice junction sites, deeper intronic sequences, 
the 5’ and 3’ untranlsated regions and finally the poly A addition site. Point mutations 
may generate a stop codon directly or indirectly because of a frame shift due to a deletion 
or an insertion event of more than one nucleotide causing thalassemia when localized in 
the regulatory elements, including the donor and acceptor sites of the introns. Exonic 
point mutations that change a particular amino acid lead to an abnormal hemoglobin, 
which may or may not have phenotypic consequences. Rarely exonic mutations affect the 
normal splicing of genes (for example HbE). Not all mutations affect the structure or 
function of the hemoglobin molecule and it is important to define the correlation between 
the mutation and the phenotype to predict the severity of the conditions in homozygous or 
compound heterozygous form.   
 
Hundreds of point mutations causing Hemoglobinopathy have been characterized (26).  
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A minority are common in specific geographical areas or ethnic groups while many are rare 
and may or may not be associated with an ethnic origin. We investigated the common HBP’s in 
Oman in chapter 4 to reaveal the common spectrum of HBP mutations.
1.7 The structural and the expression defects 
As mentioned above, hemoglobin disorders are divided into two main groups: the structural 
(hemoglobin variants) and the expression defects (the thalassemias). 
The structural hemoglobin variants result in most of the cases from point mutations causing 
single amino-acid substitutions mainly in the β or α globin chains (27) and have generally little 
or no adverse effect in the carriers. However, structural mutations may alter in some cases, the 
stability, the expression or the functional properties of the hemoglobin tetramer and lead to a 
clinical disorder in the carrier as well. 
More than thousand structural hemoglobin variants have been described but the most 
common worldwide are Hb S, Hb C, Hb E and Hb DPunjab. 
Although all recessive, the homozygous state for Hb S as also the combination of HbS/β-
thalassemia and HbS/HbC, E or DPunjab variants results in sickle cell disease (SCD) (Table 1.2). The 
compound heterozygous state for Hb S and Hb C is associated with a clinically milder SCD while 
the other combinations are usually severe. The HbE variant, although mild in the carrier and in 
the homozygous state, it may result in both severe SCD and thalassemia major in combination 





Table 1.2. Cross table showing the combination of HbS and of other common  gene 
defects (double-lined squares) and of the common  gene traits and the genetic risk 
deriving from their combinations. (For rare, unknown Hb X variants: ? stands for 
unknown risk and ?! for possible risk.). Hb S: [6(A3)GluVal, GAG>GTG; HBB: 
c.20A>T]; Hb E: [26(B8)GluLys, GAG>AAG; HBB: c.79G>A]; Hb C 
[6(A3)GluLys, GAG>AAG; HBB: c.19G>A]; Hb D: Hb D-Punjab 
[121(GH4)GluGln, GAA>CAA; HBB: c.364G>C] (courtesy of P.C Giordano). 
 
1.8 Sickle cell disease: history and clinical condition 
 
The disease long known in Africa with several local names (Abotutuo, Chwechweechwe, 
Nwiiwii or Nuiduidui), was firstly reported in 1910 by Herrick (29) as a severe hereditary 
condition affecting young children of African origin. Sickle cell disease or anemia (SCD 
or SCA) has probably expanded in West Africa, most likely before the desertification of 
the Sahara, which took place about 10,000 years ago (30). Herrick proposed the 
association with a cellular abnormality because of the peculiar elongated sickle like shape 
of the red cells observed in the blood smear of the patients.  
In the 1930's, it was shown that the sickle shape was induced by low oxygen pressure and 
was reversible after oxygenation. Pauling et al. separated in 1949 the abnormal 
hemoglobin fraction and because of the sickle shape of the cells they called this 
hemoglobin HbS (31). Later, methods such as the starch gel electrophoresis, allowed an 
easy detection of HbS and of the other common Hb variants.  
In the middle of the 50’s, Ingram demonstrated, by separation and analysis of tryptic 
peptides on combined paper electrophoresis and chromatography (fingerprinting), that the 
glutamic acid residue at position 6 in the N-terminal peptide of the β chain was replaced 
by a valine (32). More than twenty years later DNA analysis and the identification of the 
β globin gene (33) allowed the characterization of the single amino acid substitution 
resulting from an adenine to thymine transversion at codon 6 (GAGGTG) which results 
in the formation of hemoglobin S when the abnormal β-chains combine with the α-globin 
Table 1.2. Cross table showing the combination of HbS and of other common β gene defects (double-lined 
squares) and of the common α gene traits and the genetic risk deriving from their combinations. (For rare, 
unknown Hb X variants: ? stands for unknown risk and ?! for possible risk.). Hb S: [β6(A3)Glu→Val, GAG>GTG; 
HBB: c.20A>T]; Hb E: [β26(B8)Glu→Lys, GAG>AAG; HBB: c.79G>A]; Hb C [β6(A3)Glu→Lys, GAG>AAG; HBB: 















Expression defects of the β-globin genes, most of them recessive in the carriers, are 
virtually all associated with severe or intermediate forms of β-thalassemia, with SCD being the 
main concern for public health and prevention in endemic and immigration countries.
Due to the presence of 4 active alpha globin genes, structural mutations of these genes 
express at a lower percentage (<25%) and their phenotype is usually mild. Expression defects of 
the alpha genes (deletion or point mutations) express in mild to severe phenotypes depending 
from the number of genes affected. Loss of expression of all 4 alpha genes results in a lethal 
condition usually incompatible with post-natal life. When 3 alpha genes are not expressed the 
phenotype is severe or intermediate (HbH disease). Loss of expression of one or two alpha genes 
results in a very mild phenotype. Exceptions are those mutations causing unstable α-globin 
products or mutated Poly A addition signal sequences resulting in severe HbH diseases when 
in homozygous or hemizygous forms. An example of a possibly severe homozygous alpha-
thalassemia case is described in Chapter 6. 
1.8 Sickle cell disease: history and clinical condition
The disease long known in Africa with several local names (Abotutuo, Chwechweechwe, 
nwiiwii or nuiduidui), was firstly reported in 1910 by Herrick (29) as a severe hereditary 
condition affecting young children of African origin. Sickle cell disease or anemia (SCD or SCA) 
has probably expanded in West Africa, most likely before the desertification of the Sahara, 
which took place about 10,000 years ago (30). Herrick proposed the association with a cellular 
abnormality because of the peculiar elongated sickle like shape of the red cells observed in the 
blood smear of the patients. 
In the 1930’s, it was shown that the sickle shape was induced by low oxygen pressure and 
was reversible after oxygenation. Pauling et al. separated in 1949 the abnormal hemoglobin 
fraction and because of the sickle shape of the cells they called this hemoglobin HbS (31). Later, 
methods such as the starch gel electrophoresis, allowed an easy detection of HbS and of the 
other common Hb variants. 
In the middle of the 50’s, Ingram demonstrated, by separation and analysis of tryptic 
peptides on combined paper electrophoresis and chromatography (fingerprinting), that the 
glutamic acid residue at position 6 in the n-terminal peptide of the β chain was replaced by 
a valine (32). More than twenty years later DnA analysis and the identification of the β globin 
gene (33) allowed the characterization of the single amino acid substitution resulting from 
an adenine to thymine transversion at codon 6 (GAG→GTG) which results in the formation 
of hemoglobin S when the abnormal β-chains combine with the α-globin chains. To date, 
more than 1000 hemoglobin variants have been reported and new ones keep coming. The 
pathological implications of the common variants are well known and that of the rare ones is 
a matter of continuing research. One century later and the diseases caused by these recessive 
hereditary traits are quite well treated but not yet cured and therefore carrier identification and 
primary prevention are the main issues faced by public health. 
Being a recessive condition, HbS carriers are mainly asymptomatic and their red cells do 
not sickle to any significant degree at normal venous oxygen tension. Only at a very low oxygen 
tension the erythrocytes will temporarily sickle when a carrier is exposed to high altitude (34), 















conditions (35). under environmental stress, HbS carriers are prone to a reduced red blood 
cell (RBC) deformability, which is thought to increase blood viscosity, raising the risk for vaso-
occlusion events (36). Although it is very rare for sickle cell trait (SCT) subjects to experience 
any of these complications, it is of great importance that SCT individuals are aware of their 
carrier state to avoid potential genetic risk and risk of complications during anesthesia and 
pregnancy (37).
Patients affected with SCD suffer of a cascade of pathological events causing chronic 
and acute infarctions, excruciating painful crises, progressive organ and tissues damage and 
hemolysis (38), drastically shortening the RBC life span (39). HbS tend to polymerize when 
deoxygenated, resulting in sickle shaped cells causing chronic and acute infarctions (Figure 1.7). 
As a consequence of vaso-occlusion, dactylitis is one of the first symptoms observed in infants, 
affecting about 30% of patients in the first year of life (40). Other severe symptoms include 
splenic sequestration, acute chest syndrome, leg ulcers, avascular necrosis and gallstones. The 
disease is caused by different β-globin genotypes (always including at least one Hb S allele) 
and modulated by quite a few genetic and external causes. Therefore not all SCD patients 
have the same severe outcome of the disease and it is not easy to predict a genotype / 
phenotype correlation. 
Chapters 9, 10 and 11 of this thesis are based on correlation studies between clinical severity 
of SCD with identical beta genotype and haplotype, subhaplotypes, XmnI polymorphism and 
response to hydroxyurea drug and finally in relation to alpha-thalassemia genotypes. These 
studies were conducted in order to draw associations between genotype and phenotype for 
better risk assessment and selection for the best treatment.
The life expectancy of well-treated SCD patients is considerably shorter than that of the 
general population and the survival greatly depends on the genotype. If well treated, male 
and female patients with intermediate SCD genotypes are reported to have a median life 
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When HbS is combined with a β+ mutation, HbA is synthesized at a reduced rate, and  
with milder beta defect the SCD condition can be less severe (44). We describe an 
example of a mild beta-thal nucleotide transversion in association with HbS in chapter 6.    
 
Figure 1.7: Schematic representation of the vaso-occlusion caused by the formation of 
sickle cells in the post capillary veins under oxygen deprivation (adapted from 
http://www.cixip.com/index.php/page/content/id/559). 
 
Traits Combinations  Predictions 
HbS S/S or S/β-thal ! 
HbC C/S intermediate ! 
HbE E/S severe or intermediate or E/β-thal ! 
HbDPunjab D/S severe ! 
HbOArab O/S severe ! 
Hb Lepore L/S or L/β-thal severe or L/E ! 
HbS Antilles (HbS + β23) Dominant in carrier, severe in combination ! 
HbC Ziquichor (HbS + β58) S/S, C/S, D/S, E/S... or S/β-thal severe ! 
HbC Harlem (HbS + β73) S/S, C/S, D/S, E/S... or S/β-thal severe ! 
HbS Providence (HbS + β82) S/S, C/S, D/S, E/S... or S/β-thal severe ? 
HbS Oman (HbS + HbOArab) Dominant in carrier, severe in combination ! 
HbS South End (HbS + β132) S/S, C/S, D/S, E/S... or S/β-thal severe ? 
HbS-Sao Paulo (HbS + β65) S/S, C/S, D/S, E/S... or S/β-thal severe ? 
Hb Ndjamena (HbS + β37) S/S, C/S, D/S, E/S... or S/β-thal intermedia ? 
HbS Travis (HbS + β142) S/S, C/S, D/S, E/S... or S/β-thal severe ? 
HbS Cameroon (HbS + β90) S/S, C/S, D/S, E/S... or S/β-thal severe ? 
HbS Wake (HbS + β139) S/S, C/S, D/S, E/S... or S/β-thal severe ? 
HbS Jamaica Plain (HbS + β68) S/S, C/S, D/S, E/S... or S/β-thal severe ? 
HbS Clichy (HbS + β8) S/S, C/S, D/S, E/S... or S/β-thal severe ? 
HbS san Martin (HbS + β105) S/S, C/S, D/S, E/S... or S/β-thal severe ? 
HbS/thal+ (HbS + -88C>T) S/S or S/β-thal intermedia ? 
HbC Rothschild (HbC + β37) C/S intermediate  ? 
Hb Arlington Park (HbC + HbNBaltimore) C/S intermediate  ? 
Hb Corbeil (HbE + β104) E/S intermediate, E/β-thal severe ? 
HbTCambodja (HbE + HbOArab) E/S intermediate, E/β-thal severe ? 
Hb Cleveland (HbDPunjab + β92) D/S severe ? 
Hb Korle-Bu KB/S intermediate ? 
All β°-thalassemia defects S/β-thalassemia severe ! 
All β+-thalassemia defects S/β-thalassemia severe or intermediate !? 
All β-variants with thalassemic effect S/β-thalassemia severe or intermediate !? 
GγAγδβ-deletions Del/S, Del/E, Del/β-thalassemia severe !? 
figure 1.7. Schematic representation of the vaso-occlusion caused by the formation of sickle cells in 
















Table 1.3. Summary of the common and rare mutations in the HBB gene, including the common variants 
HbS, HbC, HbDPunjab, HbE that may cause SCD or TM. The phenotype prediction is either described (!) or 
presumed (?). Adapted from Giordano, 2013 (reference 45).
Traits Combinations Predictions
HbS S/S or S/β-thal !
HbC C/S intermediate !
HbE E/S severe or intermediate or E/β-thal !
HbDPunjab D/S severe !
HbOArab O/S severe !
Hb Lepore L/S or L/β-thal severe or L/E !
HbS Antilles (HbS + β23) Dominant in carrier, severe in combination !
HbC Ziquichor (HbS + β58) S/S, C/S, D/S, E/S... or S/β-thal severe !
HbC Harlem (HbS + β73) S/S, C/S, D/S, E/S... or S/β-thal severe !
HbS Providence (HbS + β82) S/S, C/S, D/S, E/S... or S/β-thal severe ?
HbS Oman (HbS + HbOArab) Dominant in carrier, severe in combination !
HbS South End (HbS + β132) S/S, C/S, D/S, E/S... or S/β-thal severe ?
HbS-Sao Paulo (HbS + β65) S/S, C/S, D/S, E/S... or S/β-thal severe ?
Hb ndjamena (HbS + β37) S/S, C/S, D/S, E/S... or S/β-thal intermedia ?
HbS Travis (HbS + β142) S/S, C/S, D/S, E/S... or S/β-thal severe ?
HbS Cameroon (HbS + β90) S/S, C/S, D/S, E/S... or S/β-thal severe ?
HbS Wake (HbS + β139) S/S, C/S, D/S, E/S... or S/β-thal severe ?
HbS Jamaica Plain (HbS + β68) S/S, C/S, D/S, E/S... or S/β-thal severe ?
HbS Clichy (HbS + β8) S/S, C/S, D/S, E/S... or S/β-thal severe ?
HbS san Martin (HbS + β105) S/S, C/S, D/S, E/S... or S/β-thal severe ?
HbS/thal+ (HbS + -88C>T) S/S or S/β-thal intermedia ?
HbC Rothschild (HbC + β37) C/S intermediate ?
Hb Arlington Park (HbC + HbnBaltimore) C/S intermediate ?
Hb Corbeil (HbE + β104) E/S intermediate, E/β-thal severe ?
HbTCambodja (HbE + HbOArab) E/S intermediate, E/β-thal severe ?
Hb Cleveland (HbDPunjab + β92) D/S severe ?
Hb Korle-Bu KB/S intermediate ?
All β°-thalassemia defects S/β-thalassemia severe !
All β+-thalassemia defects S/β-thalassemia severe or intermediate !?
All β-variants with thalassemic effect S/β-thalassemia severe or intermediate !?
GγAγδβ-deletions Del/S, Del/E, Del/β-thalassemia severe !?
Aγδβ-deletions Del/S, Del/E, Del/β-thalassemia intermediate !?
εγδβ-deletions Del/S, severe !?
δβ-deletions Del/S, Del/E, Del/β-thalassemia intermediate !?















expectancy of 42 and 48 years respectively (41) whereas if untreated, the disease is usually 
lethal in childhood (42).
As shown in Table 1.2, patients with SCD can either be homozygous for the HbS allele (HbS/S), 
compound heterozygous with other common Hb variants or hemizygous with a β thalassemia 
mutation (HbS/β). Severe conditions can also result from less common combinations such 
as HbOArab (43) or with a list of rare traits (Table 1.3). Inheritance of HbS with β° thalassemia 
mutations results in absence of HbA and in the presence of HbS % similar to HbS/S condition 
but generally associated with marked microcytic anemia. When HbS is combined with a β+ 
mutation, HbA is synthesized at a reduced rate, and with milder beta defect the SCD condition 
can be less severe (44). We describe an example of a mild beta-thal nucleotide transversion in 
association with HbS in chapter 6.  
1.9 The thalassemias
As mentioned above, the thalassemias are defects caused by globin gene mutations affecting 
gene expression. Consequently, thalassemias are classified according to the particular globin 
chains ineffectively synthesized (46). The pathological conditions associated to thalassemia 
can be very variable. While generally asymptomatic and only associated with a mild microcytic 
anemia in the carrier, thalassemia can be lethal in utero and/or very severe in postnatal life 
depending from upon the genotype at the β-gene locus and to some extent other globin and 
non-globin genes. Because of the prenatal expression of the alpha genes, alpha thalassemias 
can present symptoms before birth in mild, severe or lethal forms, while beta thalassemias 
are usually asymptomatic until about six months after birth, at the time when the postnatal 
HbA normally takes over from the fetal HbF. In addition, patients may present with different 
phenotypes due to the kind of mutation or defect combinations. As previously mentioned, 
the majority of beta thalassemias are caused by point mutation defects. The majority of alpha- 
and a few beta- thalassemias are caused by large deletions. Alpha deletions may affect one 
or both alpha genes of the specific allele and homozygosity for two fully deleted genes is not 
compatible with life. Some large deletions of the beta genes may include the fetal and the 
embryonic genes in the beta globin gene cluster and in the heterozygous form may be severe 
in utero but transforming to a mild beta thalassemia heterozygosis in adult life (47).
1.10 The beta thalassemia: history and clinical conditions 
How old thalassemia can be was shown by J. Lawrence Angel who in 1964 found porotic 
hyperostosis and thickening of the diploic space prominent in skeletal remains of children from 
the Bronze Age in Cyprus and Greece as a result of thalassemia major (9,48). 
The disease has remained clinically unclassified until the 20th century probably due to the 
general high infant mortality and to the fact that the condition was not associated with the 
humoral theory of Greek medicine developed by Hippocrates which was rather philosophical 
but not that far from the truth. 
Greeks believed that not only the blood itself but blood vessels carried air, food and 
emotions, while Romans associated all kind of unhealthy state with the stinking marshes that 















Only in the 20th century two publications both published in 1925, one in Italy and the other 
in the uSA, defined the severe form of the disease. 
Rietti called the disease IERGA (Ittero Emolitico con Resistenza Globulare Aumentata) 
because of jaundice, hemolysis and the classical increased osmotic resistance of the red cells 
(49). Cooley and Lee reported the same pathology in children of Italian and Greek immigrants 
in the uSA (50). Subsequently the disease was given many names such as Rietti-Greppi-Micheli 
disease, Cooley anemia, erythroblastic anemia and all this became confusing until the definition 
“Thalassemia” from the Greek word for sea was proposed in 1932 by Whipple and Bradford, due 
to the high incidence of the disease in Mediterranean populations (51). 
At the same time, population geneticist J.B.S. Haldane, had elaborated the theory of 
malaria selection for thalassemia and his hypothesis was published with the first mathematical 
models for evolution due to selection (52). Between 1944 and 1947 Silvestroni and Bianco 
studied many affected families and defined the hereditary character of the disease (53). In 1955 
Kunkel and Vallenius separated the HbA
2 
fraction (54) and in 1957 Silvestroni and Bianco again 
demonstrated that an elevated HbA
2
 fraction was present in the parents of affected children 
(55). From that time on, many developments have followed at the biochemical and molecular 
level and today thalassemia is perhaps the most well studied recessive disorder in man. As 
mentioned above, beta-thalassemia (β-thal) is mainly caused by prevalent or less common 
point mutations in the β-globin gene due to substitutions or deletional/ insertional defects. 
Defects can either lead to reduced synthesis of the β-globins (β+) or complete absence (βo). 
In distinction to the classical and common recessive forms of beta-thalassemia, some rare 
dominant beta globin mutations may result in the synthesis of extremely unstable beta globin 
variants causing intermediate thalassemia phenotype in the heterozygous state (56). usually 
mutations in the promoter and 5’ uTR affect gene transcription while mutations in the splice 
junction, 3’ uTR and polyadenylation site affect mRnA processing and mutations in initiation 
codon or frame shift mutations affect mRnA translation. The very mild or silent mutations 
are associated with normal red blood cell indices and normal or borderline HbA
2 
(57) raising 
difficulty in carrier screening at the hematological level.
 
We describe in chapter 6 an example of 
a mild beta-mutation associated with near borderline HbA
2
 %.
Clinically and hematologically, thalassemia is classified into three conditions of increasing 
severity; the mild beta-thalassemia carrier state, the thalassemia intermedia, and the severe 
thalassemia major. 
As mentioned above, carriers of β-thalassemia are usually asymptomatic with a hematological 
parameters characterized by a mild anemia, reduced MCV and MCH values (60–70 fL and 
19–23 pg), a raised level of HbA
2
 (3.5–9.0 %), and normal or slightly elevated HbF (58). 
Homozygous or compound heterozygous for severe mutations become severely anemic 
around six months of age, once the delayed expression of the normal HbF has become 
insufficient in absence of HbA. Children are usually diagnosed within the first two years 
of life due to severe anemia, hemolysis and failure to thrive. The hematological picture 
of a non-transfused patient will show a severe erythromorphology with numerous of 
erythroblasts, very low Hb, MCV and MCH values, absence of HbA with HbF and HbA
2
 as the 















transfusion that will maintain the Hb value at a reasonable level for 2-3 weeks when the need 
for a continuous transfusion regime will become evident. Subsequently these patients will 
accumulate transfusional iron up to a toxic level and thus require continuous iron chelation 
therapy. Other complications occurring in transfusion-dependant patients include growth 
retardation, delay or failure of sexual maturation, cardiac disease and complications in liver 
or endocrine glands (59). Individuals who are regularly transfused and get state of the art 
management may survive beyond the age of 40. Cardiac complications are the cause of death 
in 71% of the patients with thalassemia major (60). The clinical presentation of thalassemia 
major is listed in Table 1.4.
Beta-thalassemia intermedia is a milder conditions that includes a very heterogeneous 
group ranging in severity from a transfusion free carrier-like state to the delayed severe 
transfusion-dependent type (61). Intermediate cases with the severe forms present severe 
clinical symptoms usually between the ages of 2 and 6 years. The mild condition may 
present with complications later in life or may go on without requiring blood transfusion 
till adulthood or during pregnancy. The intermediate state result from complex genotypes 
involving coinheritance of homozygous or compound heterozygous mild β-thalassemia 
alleles and may also result from the co-inheritance of alpha- and beta-thalassemia mutations 
or co-inheritance of additional alpha globin gene genotypes (triplicated or quadruplicated 
alpha globin gene rearrangements) when interacting with typical heterozygous beta-
thalassemia (62). 
Beta thalassemia subjects with no functional beta globin synthesis  may present as beta 
intermedia due to amelioration by high Hb F expression caused by HPFH deletions (63) or rare 
mutations in the beta-LCR regulatory sequence (64). Essentially, the clinical severity of beta 
thalassemia major is related to the extent of imbalance between the alpha globin and non alpha 
globin chains (62). When the beta globin chains are reduced or absent, the free alpha chains 
precipitate and lead to oxidative damage of the cell membrane, hemolysis and ineffective 
Table 1.4. List of the variable clinical presentation possibly seen in a β-thalassemia major individual divided 
per different age groups.
Age group Clinical phenotype





Spleen and liver enlargement





















erythropoesis (65). Although differentiation between thalassemia major and thalassemia 
intermedia is not always easy, it is needed to plan state of the art management and to avoid 
starting unnecessary transfusions (66). 
In conclusion, analysis of both the alpha and beta genotypes and testing for the presence 
of ameliorating genetic factors is essential for risk prediction, treatment and / or prevention 
of the hemoglobinopathies. In order to define these factors in the Omani population we have 
described the beta-thalassemia spectrum in the country in an extensive study presented in 
chapter 5. 
1.11 The alpha thalassemias 
While humans have only two beta globin genes, one on the maternal and one on the paternal 
chromosome 11, the alpha gene cluster on chromosome 16 is characterized by two active alpha 
genes, two inherited on the maternal allele and two on the paternal, resulting in a total of four 
alpha globin genes. 
As already mentioned, most α thalassemias are caused by deletions that may remove 
one or both α-globin genes of each allele. In the first case, when one of the two genes is 
still expressed, the condition is called α+ thalassemia. When both α genes of the same allele 
are deleted the condition is called α° thalassemia. The presence of 4 alpha genes and the 
occurrence of partial expression of an affected allele make risk assessment somewhat 
complex. In general, carriers of α+ or α° thalassemia will show mild anemia if any, with minimal 
to evident microcytosis (reductions in MCV values) and hypochromia (low MCH values) and 
sometimes a slight reduction in HbA
2 
levels. However, the genetic risk of the two conditions 
will be very different. While an individual homozygous for α+ thalassemia will not be affected 
and present with mild anemia, homozygosis for α° thalassemia will be a lethal condition and 
combinations of α° with α+ conditions will result in the intermediate forms of variable severity 
called HbH disease. 
The phenotype of Hb H patients is variable depending on the nature of the mutation. HbH 
caused by deletional mutations results in a moderately severe hypochromic microcytic anemia 
but clinically these patients are less severely affected than patients with HbH caused by point 
mutations who have a more severe manifestation and may require frequent hospitalization and 
recurrent blood transfusions (67).
The severe form α° homozygosis (Hb Bart’s Hydrops Fetalis), which results from four 
defective α-globin genes, is a severe conditions leading to perinatal death. The common 
genotypes of these conditions are summarized in Table 1.5.
Most cases of alpha thalassemia trait in the world are caused by relatively large deletions rather 
than point mutations. The most common alpha thalassemia mutations are the -α3.7 kb rightward 
deletion (RW) followed by the -α4.2 kb leftward deletion (LW) which are both α+ defects. The 
former involves the deletion of the 3’ part of (HBA2) gene and 5’ of (HBA1) gene, forming a 
hybrid gene while the latter consists of full removal of HBA2 gene and 5’ of the HBA1 gene. Both 
defects are α+ conditions. 
Other large deletions involving the alpha cluster include the -α20.5, the SEA, the Med I, the 
Thai and the Fil (68) (Figure 1.8). These deletions involve both alpha genes and are therefore 















deletional alpha thalassemia mutations are also regularly found. Among the most common are 
the penta-nucleotide 5nt deletion (HBA2: c.95+2_95+6delTGAGG), the polyadenylation tail (+94) 
AATAAA>AATAAG mutation (HBA2: c.*94A4G) and Hb Constant Spring (CS) (HBA2:c.427T>C) 
(69). We have studied the spectrum of alpha-thalassemia in Oman including deletional and 
non-deletional mutations in chapter 7 to decipher the common and rare alpha mutations in 
the population.
Carrier identification of alpha thalassemia is important as it has a similar hematological 
picture to iron deficiency anemia (70). Carriers of alpha thalassemia are often wrongly 
diagnosed and empirically treated with iron therapy where in fact they only need information 
and eventually folic acid supplement.
Table 1.5. The symbolic indication of the different alpha genotypes and the accompanied phenotype.
Genotype No. of defective genes Phenotype
(-α/αα) 1 Silent or mild carrier α+
(αα/--) 2 Mild α° carrier
(-α/-α) 2 Mild homozygous α+
(-α/--) 3 Intermediate (HbH)
(--/--) 4 Severe Hb Bart’s (hydrops fetalis)
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kb rightward deletion (RW) followed by the -α4.2 kb eftward deletion (LW) which are 
both α+ defects. The former involves the deletion of the 3’ part of (HBA2) gene and 5’ of 
(HBA1) gene, forming a hybrid gene while the latter consists of full removal of HBA2 
gene and 5’ of the HBA1 gene. Both defects are  conditions.  
Other large deletions involving the alpha cluster include the -α20.5, the SEA, the Med I, 
the Thai and the Fil (68) (Figure 1.8). These deletions involve both alpha genes and are 
therefore called the α° thalassemia conditions associated with the severe for s of the 
disease. Non-deletional alpha thalassemia mutations are also regularly found. Among the 
most common are the penta-nucleotide 5nt deletion (HBA2: c.95+2_95+6delTGAGG), 
the polyadenylation tail (+94) AATAAA>AATAAG mutation (HBA2: c.*94A4G) and 
Hb Constant Spring (CS) (HBA2:c.427T>C) (69). We have studied the spectrum of 
alpha-thalassemia in Oman including deletional and non-deletional mutations in chapter 7 
to decipher the common and rare alpha mutations in the population. 
 
Carrier identification of alpha thalassemia is important as it has a similar hematological 
picture to iron deficiency anemia (70). Carriers of alpha thalassemia are often wrongly 
diagnosed and empirically treated with iron therapy where in fact they only need 




Figure 1.8. The common deletions of the alpha-globin gene cluster. The extent of each 
deletion is represented by an arrow line. Adapted from Tan et al, 2001 (reference 71).  
 
1.12 Delta thalassemia  
 
The delta globin gene coding for the globin chains needed to form hemoglobin A2 
(2/2 is located on chromosome 11 between the β- and the -globin genes (see section 
1.5). The  gene (HBD) is similar to the -gene but with a much less active promoter. 
Therefore, the  gene expression in normal individuals is approximately 2.5–3.5% of the 
total hemoglobin resulting in a similar level of expression of HbA2. Defects of the  
genes have no clinical significance but may compromise the diagnosis of -thalassemia 
trait. Thalassemic or structural defects of the  may reduce HbA2 expression (<2%) and 
this in co-inheritance with a β-thal allele, may lead to diagnostic mistakes due to the 
reduction to normal ranges of the HbA2 level that should have been found elevated in that 
particular -thalassemia carrier (72,70). Similarly, structural mutations of the delta globin 
genes may cause the splitting of HbA2 in two fractions, and if the abnormal fraction is 
overlooked, it many cause a wrong estimation of the HbA2 level as well. 
  
figure 1.8. The common deletions of the alpha-globin gene cluster. The extent of each deletion is 
represented by an arrow line. Adapted from Tan et al, 2001 (reference 71). 
1.12 D lta thalassemia 







located on chromosome 11 between the β- and the γ-globin genes (see section 1.5). The δ 
gene (HBD) is similar to the β-gene but with a much less active promoter. Therefore, the δ gene 
expression in normal individuals is approximately 2.5–3.5% of the total hemoglobin resulting in 
a similar level of expression of HbA
2
. Defects of the δ genes have no clinical significance but 
may compromise the diagnosis of β-thalassemia trait. Thalassemic or structural defects of the 




(<2%) and this in co-inheritance with a β-thal allele, may lead 
to diagnostic mistakes due to the reduction to normal ranges of the HbA
2















have been found elevated in that particular β-thalassemia carrier (72,70). Similarly, structural 
mutations of the delta globin genes may cause the splitting of HbA
2
 in two fractions, and if the 
abnormal fraction is overlooked, it many cause a wrong estimation of the HbA
2
 level as well.
As in β-thalassemia, also in δ-thalassemia, each population has its own spectrum of common 
mutations which should be taken into consideration when confirming or excluding a presumed 
carrier of β-thalassemia with less elevated or normal HbA
2
 levels (73). For that we investigated 
cases with low HbA
2
 readings to define the spectrum of δ-thalassemia in the Omani population 
in chapter 8.  
1.13 Hereditary persistence of fetal hemoglobin (HPfH) and δβ-thalassemia
The clinical definition of hereditary persistence of fetal hemoglobin (HPFH) goes back to the 
time when molecular analysis of gene deletions was not yet available and in fact most of these 
defects are mild δβ-thalassemias resulting from large deletion in the β-gene cluster enhancing 
the HbF expression. Today, the real HPFH defects are considered those caused by non-deletion 
events, that is by point mutations in the promoters of the γ globin genes. 
More than 40 different types of HPFH like δβ deletions with varying 5′ and 3′ breakpoints 
have been reported usually all mild in the carriers (74). These disorders are characterized by 
high HbF levels and can be distinguished from one another by comparing their clinical and 
hematological parameters and deletion break points (75). Individuals heterozygous for HPFH 
deletions present with elevated red blood cell (RBC) counts and with HbF levels ranging from 
(15-30%) (76). Rare cases homozygous for HPFH deletions have been described with near 100% 
HbF and very high RBC counts (77).
The elevated RBC counts are due in these cases to the higher oxygen affinity of the HbF 
tetramer which is delivering lesser O
2
 to the tissues causing hypoxia in spite of the elevated 
Hb levels of these patients. Depending on the level of the HbF expression, deletions in 
combinations with β-thalassemia can be associated with thalassemia intermedia phenotypes 
(75) and in general compound heterozygous with β-thalassemia are clinically mild due to the 
high levels of γ-globin synthesis compensating for absence of β-globin chains, thus reducing 
the level of excess alpha globin chains. 
1.14 Hb Lepore
Hemoglobin Lepore (Hb Lepore) defects are caused by unequal cross over between 
homologous regions on the δ and the β genes resulting in several δβ-fusion genes with β+ 
thalassemia expression. Several Hb Lepore mutations have been described of different kind 
of δβ-globin hybrid chains (78). The reason why the δβ-globin hybrid chain is transcribed at a 
decreased rate is because it is controlled by the δ gene (HBD) promoter which is normally less 
efficient than the β gene (HBB) promoter. Due to decreased quantity of the δβ hybrid chains 
produced, the clinical phenotype in the heterozygote is associated with mild hypochromic, 
microcytic anemia with a normal or reduced HbA
2
 and eventually elevated HbF level and 
a relatively low percentage of Hb Lepore (6-15%). Cases with homozygosity or compound 
heterozygosity of Hb Lepore and β-thalassemia, may present with a severe thalassemia major 
or intermedia phenotype (79). Therefore, molecular characterization is essential, especially in 















1.15 The classic modulating factors (β-globin cluster haplotypes, high Hbf, XmnI 
polymorphisms and coexisting alpha thalassemia) 
Thalassemia and sickle cell disease risk prediction is a complex matter. Different thalassemia 
mutations may have different reduction in expression, compensation with higher HbF expression 
can be present or absent, and coexisting alpha thalassemia or alpha gene triplications and 
duplications may ameliorate or aggravate the phenotype in both patients and carriers. As these 
and other still incompletely defined factors can either ameliorate or exacerbate the phenotype, 
genetic analysis of modulating factors helps the geneticist and the clinicians to predict the 
severity and prognosis of the disease. We have approached these elements in chapters 9, 10 
and 11 of this thesis.
1.16 Haplotype 
The β-globin haplotypes on which the mutation is carried was originally defined based 
on the pattern generated by restriction enzymes – so-called restriction fragment length 
polymorphisms or RFLPs (30). In the case of sickle cell disease (SCD), the HbS mutation has 
been described on different haplotype backgrounds, named after the regions in which they 
were first identified (80). The Asian (Arab-Indian) haplotype was first found in the Middle 
East and India (81). The Benin haplotype was first reported from central and West Africa 
whiles the Central African Republic (CAR) or Bantu haplotype from Central Africa around 
Angola and Congo. The Senegal haplotype was described on the Atlantic coast of West 
Africa (80).
Differential HbF expression is associated with the different haplotypes and may influence 
the clinical course of SCD. Thus analysis of βS haplotype aids in predicting disease severity. The 
Senegal and Asian haplotypes are associated with higher levels of Hb F and a milder disease (82), 
while the CAR haplotype is associated with a more severe disease and the Benin and Cameroon 
haplotypes are intermediate in severity (30). Although several studies have been conducted to 
establish a clear relation between βS-haplotypes and disease, the correlation remains unclear 
(83). Therefore we have charted the haplotypes and sub-haplotypes in homozygous Omani S/S 
patients and we have studied the correlation between different haplotype genotypes and SCD 






) is the major ameliorating factor of beta thalassemia and sickle cell disease (84). 
Post-natal reactivation of fetal hemoglobin expression has been the aim of many studies. 
However, so far none means has been identified which permanently reactivates the expression 
of γ genes, to levels sufficient for therapeutic effect in postnatal life. Temporary reactivation 
however has been obtained to some extent by continuous use of different cytotoxic drugs, 
among which hydroxyurea (Hu) is the only one without significant adverse effects, and is 
currently used routinely in the clinic (85).
The HbF expression is mainly regulated by elements linked to the β-globin gene cluster that 
switch off expression after birth. Some elements associated with the promoter sequences of 
the gamma globin genes are known to enhance HbF expression in postnatal life, among which 















levels have also been observed significantly elevated in a number of bone marrow malignancies 
and slightly elevated during a pregnancy or at the laboratory which are likely due to a variety 
of mechanisms (87). 
In case of sickle cell disease, high HbF concentration in the red cell dilutes the concentration 
of Hb S, increases the oxygen tension and inhibits Hb S polymerization (88), improving the 
phenotype significantly. In one study, reduced HbF level was associated with higher risk of stroke 
(89) and increased risk of brain infarcts in young children (90). However, these studies are often 
not sufficiently categorized; mixing ethnicity, genotypes, age of the patients, sample sizes and 
analytical approaches, all factors that are bound to bias the observations.
In our studies presented in chapters 9 and 10, we have tried to overcome this problem, 
categorizing patients more precisely and showing the correlation between genotype, haplotype 
and phenotype and the response to hydroxyurea treatment in the presence and absence of the 
XmnI polymorphism.
1.18 XmnI polymorphism and other natural beta cluster enhancers
As mentioned above, XmnI genotype variability can explain the considerable difference in HbF 
levels among patients and the variable responses to hydroxyurea in sickle cell disease and beta-
thalassemia patients. As mentioned above, the XmnI -158 C>T mutation on the G-gamma gene 
promoter is one of the main single nucleotide polymorphism associated with high HbF%. It 
is usually silent in normal subjects but may become active in beta-thalassemia heterozygote 
under some hematopoietic stress and even fully active in cases of beta-thalassemia major 
and sickle cell disease, sometimes leading to notably raised levels of HbF production (91). 
Other HbF determinants not linked to the beta globin gene cluster have also been reported 
such as HBS1L-MYB intergenic region chr6q23, BCL11A mutations chr2p15, and KLF1 mutations 
chr19p13.2 (92). The less common genetic variants influencing Hb F levels that are linked to the 
beta globin gene cluster are summarized in Table 1.6. 
1.19 Coexisting alpha – thalassemia
Alpha-thalassemia may also modulate the phenotype of sickle cell disease (SCD) patients 
(82) by reducing the intracellular concentration of HbS, which in turn decreases the chance 
of polymerisation, cellular damage and hemolysis (93). Alpha thalassemia also lowers the 
MCV value and this should favor the rheology of the red cells and reduce the chance of HbS 
polymerization, the number of irreversibly sickled cells and the chance of infarctions (94). 
The modulating effect of α-thalassemia has been proposed to be proportional to the number 
of deleted α-globin genes (93) and the coinheritance of α-thalassemia has been reported 
to modify the phenotype of SCD by decreasing hemolytic rate, risk of stroke, pulmonary 
hypertension and leg ulceration while increasing the frequency of acute painful vaso-occlusive 
episodes and acute chest syndrome (95). However, also for alpha thalassemia the correlation 
studies are controversial and in our opinion this could be due to the fact that the studied 
cohorts are insufficiently categorized at the genotype level. 
In our study presented in chapter 11 we have tried to overcome this problem by studying 
the effect of alpha thalassemia on well categorized cohorts of patients showing the correlation 















By this we can again underline that the analysis of genotype, haplotype and modulating 
factors can help define the prognosis and the genetic risk allowing better counseling and 
rational based interventions before the onset of organ damage. nevertheless, besides genetic 
and molecular modifiers, environmental factors such as physical activity, diet, toxins and 
socioeconomic status may also influence the clinical course of SCD (82). understanding both 
the environmental and the genotype factors associated with the clinical variability between 
patients could dramatically improve patient care, and prevention.
1.20 Diagnosis of hemoglobinopathies
Hematology laboratories play an essential role in the diagnosis of sickle cell and thalassemia 
carriers and affected individuals. The two main basic methods of HBP diagnosis which are used 
in almost all laboratories are a) the complete blood count (CBC) which can detect hypochromic 
microcytic parameters, and b) separation and estimation of the hemoglobin fractions by high 
performance liquid chromatography (HPLC) or capillary electrophoresis (CE). These methods 
can putatively detect heterozygosis, homozygosis or compound heterozygosis of the common 
conditions with great sensitivity and specificity. 
Table 1.6. new and known molecular determinants associated with elevated HbF. *=new mutations, 
**=common polymorphism present on many haplotypes (adapted from Amato et al, 2014, reference 87).
Mutation Gene Ethnic prevalence Hbf% in carrier
−4 bp (−225/−222) Aγ African 6–7
−202 C>G Gγ African 15–20
−202 C>T Aγ African 3
−198 T>C Aγ English 4–12
−196 C>T Aγ Italian/Chinese 21–15
−197 C>T* Aγ Italian 6
−195 C>G Aγ Brazilian 4–5
−175 T>C Aγ Afro American 17–38
−175 T>C Gγ Afro American, English, Italian 28–29
−161 G>A Gγ African 1–2
−158 C>T Gγ African and multiethnic <1 unless stress
−158 C>T** (Xmn-I) Gγ Afro American 2–5
−117 G>A Aγ Mediterranean 8–10
−114 C>G Gγ Australian? 8.6
−114 C>T Gγ Japanese 11–14
−114 C>T Aγ Afro American 3–6
−114 C>G Gγ Australian ? 8.6
−13 bp (−114/−102) Aγ African 30
−113 A>G* Aγ Italian 6.5















Since carriers of the common HbS, C and D variants are often normochromic, CBC should 
not preclude Hb separation but should be done in parallel. By measuring the main hemoglobins; 
HbF, HbA and HbA
2
, all carriers of “high HbA
2
 beta thalassemia” will be diagnosed. Any other 
Hb fraction putatively identified, as HbS, C, E or D will detect carriers of the variant and/or 
combination of these traits. The CBC should always match the putative HPLC/CE diagnosis 
and if not, further examination should be done at the molecular level (96). Alpha thalassemia 
will be characterized by microcytosis in the presence of a slightly reduced HbA
2
 but will need 
molecular confirmation, particularly in case of risk assessment. Only HbS can be confirmed by 
much simpler techniques such as sickle or solubility tests (24). 
Although the provisional diagnosis of the common variants made by CBC and Hb 
separation are reliable, molecular confirmation is essential to decipher the underlined 
genotype, haplotype and modulating factors. The main method for molecular diagnosis is 
based on polymerase chain reaction (PCR) technique. The so-called GAP PCR (using primers 
complimentary to the breakpoint sequences amplifying a deletion-specific fragment that 
spans the deletion if present) is used for the common alpha deletions. Basic PCR reactions 
using specifically targeted gene primers followed by direct DnA sequencing are used to 
detect point mutations. Analysis of large deletions/insertions within the alpha and beta 
clusters can be performed by multiplex ligation-dependent probe amplification (MLPA). 
Figure 1.9 shows the basic flow chart of the methods used during HBP screening diagnosis in 
multi ethnic countries.
We have shown the validity of these technologies in our publications on the molecular 
spectrum in Oman reported in chapters 4 and 5. We have shown the possibilities of advanced 
screening technologies in our paper reported in chapter 12. 
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Figure 1.9: Flow chart of HBP screening/diagnosis (courtesy of P.C. Giordano). 
 















1.21 Epidemiology in endemic countries (Worldwide epidemiology)
The World Health Organization (WHO) estimates that at least 5.2% of the world population is 
at risk for having children with a severe hemoglobin disorder (97), that over 7% of the pregnant 
women carry a hemoglobin variant (97) and that 300–400 thousand babies with severe forms 
of these diseases are born each year (98) (Figure 1.10). Although these conditions occur at 
their highest frequency in Africa and other tropical regions, population migrations have 
ensured that these conditions are now encountered in many non-endemic countries.
The most wide spread hemoglobin disorder is sickle cell disease (SCD). Thousands of 
children with this severe disease are born worldwide each year, largely in Sub-Saharan Africa 
(85%) (97), the Middle East and parts of the Indian sub-continent, where carrier frequencies 
are ranging from 5 to 40% (98). In India, around 40,000 SCD children are born each year. 
In America and Eastern Mediterranean the figure is estimated at 10,000 while 2000 are 
born in Europe (99). It is calculated that 10,000-15,000 SCD patients are living in the united 
Kingdom and France (100) while it is estimated that worldwide 1.1% of the couples are at risk 





Figure 1.10: Geographical map showing the distribution of HBP disorders around the 





Beta- thalassemia major patients rely entirely on regular blood transfusions to avoid the 
complications of severe anemia. Blood transfusions allows normal development 
throughout childhood but lead rapidly to iron overload that can be fatal in the second 
decade of life. For that reason, iron-chelating therapy has been developed. A drug named 
Deferoxamine mesylate was first introduced in the 1960s as a standard iron chelating 
therapy to improve the survival of thalassemia patients (103).  
The pathophysiology in SCD is quite different to that of Thalassemia Major. In sickle cell 
disease children, immunizations through vaccination are the key to prevent the body from 
infections due to their damaged spleens that are unable to protect the body from bacteria. 
Much effort has been and continues to be directed to design drugs that could promote 
HbF synthesis, prevent red cell dehydration, and inhibit HbS polymerization. Only 
hydroxyurea has been proven thus far to be a useful drug to alleviate the symptoms of 
SCD such as acute vaso-occlusive complications, episodes of acute pain, acute chest 
syndrome, along with blood transfusion in highly symptomatic patients (104). Besides 
raising HbF %, hydroxyurea also reduces red cell–endothelial interaction and decreases 
erythrocyte density (105). However, it is estimated that 40% of patients do not respond to 
hydroxyurea treatment at all (106). Furthermore, long-term exposure to hydroxyurea 
treatment still raises concerns due to its side effects such as myelosuppression and the 
potential risk of malignancies (106). 
figure 1.10. Geographical map showing the distribution of HBP disorders around the world in terms 
















Globally, a total of 269 million persons are estimated to carry thalassemia (β-thalassemia 
and α-thalassemia) (98). High incidences of thalassemia are reported for the Mediterranean 
region, parts of Africa, the Middle East, the Indian sub-continent, the Pacific Islands and in 
South-East Asia where carrier frequency for β-thalassemia and α-thalassemia ranges from 1 to 
20% and from 10 to 20% respectively (98). However, α thalassemia do not pose a huge global 
health problem as β-thalassemia (98) because 20% of the world population carry α+ thalassemia 
(99) which is a less problematic condition for global public health than the α° thalassemias (due 
to large deletion of the α-globin cluster) which has a restricted distribution, occurring mainly 
in South-East Asia and the Mediterranean basin. 
High prevalence of beta-thalassemia is present in Mediterranean populations, the Middle-
East, Central Asia, India and Far East with the highest incidences reported in Cyprus, Sardinia 
and South East Asia (102). Due to migration, β-thalassemia is now common in Europe, north 
and South America, Caribbean, and Australia.
1.22 Treatment
Beta- thalassemia major patients rely entirely on regular blood transfusions to avoid the 
complications of severe anemia. Blood transfusions allows normal development throughout 
childhood but lead rapidly to iron overload that can be fatal in the second decade of life. For 
that reason, iron-chelating therapy has been developed. A drug named Deferoxamine mesylate 
was first introduced in the 1960s as a standard iron chelating therapy to improve the survival of 
thalassemia patients (103). 
The pathophysiology in SCD is quite different to that of Thalassemia Major. In sickle cell 
disease children, immunizations through vaccination are the key to prevent the body from 
infections due to their damaged spleens that are unable to protect the body from bacteria. 
Much effort has been and continues to be directed to design drugs that could promote HbF 
synthesis, prevent red cell dehydration, and inhibit HbS polymerization. Only hydroxyurea 
has been proven thus far to be a useful drug to alleviate the symptoms of SCD such as acute 
vaso-occlusive complications, episodes of acute pain, acute chest syndrome, along with 
blood transfusion in highly symptomatic patients (104). Besides raising HbF %, hydroxyurea 
also reduces red cell–endothelial interaction and decreases erythrocyte density (105). 
However, it is estimated that 40% of patients do not respond to hydroxyurea treatment at 
all (106). Furthermore, long-term exposure to hydroxyurea treatment still raises concerns 
due to its side effects such as myelosuppression and the potential risk of malignancies (106).
Bone marrow transplantation (BMT) is the only cure available for severe Hemoglobinopathy 
(HBP), but it is only used in patients when a sibling donor with identical human leukocyte 
antigen (HLA) is matched. Its use is limited by the toxicity and morbidity associated with 
the procedure, the difficulty in finding a suitable family donor (107) and the availability of 
transplant centers. Bone marrow transplantation has been carried out from unrelated 
donor, as long as the HLA genotype is near-compatible, and some patients have become 
transfusion free following BMT (108). Cord blood transportation from an unaffected HLA 
compatible newborn also offers a good chance of curing an affected sibling (109). Moreover, 
hematopoietic stem cells and homologous recombination techniques are being actively 















defect by transferring a normal gene via a suitable vector or transfecting the embryonic stem 
cells from the affected mice with a DnA fragment containing a normal and active beta globin 
gene construct (110). 
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OMAN: THE COUNTRy AND HEMOGLOBINOPATHIES
2.1 Geography
The Sultanate of Oman with Muscat as the capital city, is a Middle Eastern country, located 
in the Arab Peninsula. It covers a total land area of approximately 309,500 km2 consisting of 
varying topographic features. Valleys and desert account for 82 % of the land, mountain for 15% 
and the remaining 3% covers the long 1700 km coastline. Oman is flanked by the Arabian Sea, 
the Gulf of Oman, the Persian Gulf and the Rub Al Khali desert. The top northwestern part of 
Oman is bordered by united Arab Emirates, by Saudi Arabia to the west and by Yemen to the 
southwest. In the past, the country’s contacts with the rest of the world were by sea. Today 
Oman’s strategic location on the Musandam Peninsula facing the Strait of Hormuz, plays a vital 
role for the transit of world crude oil transport. The Rub Al Khali desert forms a barrier between 
Oman and Saudi Arabia due to difficulty in travelling across. Oman’s climate is hot and dry in the 
interior but humid along the coast and Southern Dhofar. 
2.2 Economy
Historically, Oman has always been on the trade routes between the Middle East, India and 
Africa. Oman’s most prominent economical role was in trading and seafaring activities in 
Zanzibar, East of Africa, and India. nowadays Oman’s main trading partners are united Arab 
Emirates, China, Korea, Thailand, Italy, Germany, the united Kingdom and the united States of 
America. Economically, Oman is a middle-income country that is heavily dependent on crude 
oil, natural gas production, agriculture and fishery.
2.3 Population
According to the last census (2013), Oman’s population has risen to 3.87 million inhabitants 
including more than 500 thousand foreigners coming from Egypt, India, Pakistan, Bangladesh 
and the Philippines. The population growth rate is about 2% while birth and mortality rates are 
about 24/1000 and 3/1000 respectively. The median age is 24.7 years, life expectancy is around 
74 years and infant mortality rate is 14.5 per 1000 live births. About 50% of the population lives 
in the capital city, Muscat, and in the Al Batinah coastal region, northwest of the capital. The 
main spoken language is Arabic but other languages such as English, Baluchi, Sawahili and Hindi 
are also spoken based on population tribal origins. 
2.4 The origin of the Omani population (historic migrations)
The Omani population is heterogeneous, with mixed ethnicity tracking their ancestral roots 
to neighboring countries via tribal migrations and trading contacts. The main ethnicities are 
Arab, Baluchi, Sindi and African. Arabs migrated from what was known as Arabia since the 9th 
century BC onward and settled in Oman. Baluchis originated from Pakistan and the Iranian 
coasts. Sindhi tribe descends from Indian sailors while others originated from Africa, due to 
the historical trade between Oman, Zanzibar and Mombasa favored by the Indian Oceans 
monsoons. Oman was a Portuguese colony from 1508 to 1741, and when the Portuguese were 
forced out, Oman became an empire that expanded to Zanzibar. This lasted until 1861, when 
Zanzibar was separated from Omani control. Also many Omanis migrated to India, Pakistan and 




























a modern government was established and the wealth of the oil industry was used to aid the 
people in the country.
understanding population heterogeneity is important to study the mutation spectrum of 
disease such as hemoglobinopathies (HBP), which in turn is essential for molecular diagnosis 
and prevention. We have extensively studied the correlation between ethnicity and molecular 
spectrum of HBP in Oman. Our results are outlined in chapters 4-8.
2.5 The Omani tribes and their geographical distribution 
The north and south parts of the country became united only about 100 years ago. Today the 
country is divided into eight different governorates (Muhafathat); Muscat, being the capital 
center, Al Dakhiliyah, Al Batinah, Al Wusta, Al Sharqiyah, Al Dhahirah, Musandam and Dhofar 
(Figure 2.1). As mentioned above, Oman has a multi-ethnic society in which Arabs constitute 
the majority. non-Arab descendants such as the Baloch, who originally migrated to Oman from 
Iran and Pakistan over several centuries, currently live in Muscat and in the Al-Batinah region. 
A significant number of tribes of Sindi ethnicity, South Asian ancestry and African origin live 
in Muscat, along the coasts of Al-Batinah and in the interior regions (1). Some inhabitants of 
Persian origin are also present in the Musandam region. The existence of multi-origins among 
the Omani populations would be of a great intrest when studying the molecular spectrum of a 
disease such as hemoglobiopathies which was identified in this thesis.
Muscat
Muscat is the capital with an area of approximately 1500 km². The city has been known since the 
second century AD and is considered as one of the oldest in the Middle East. Today Muscat is a 
large city with residential, commercial and industrialized districts. 
Musandam
Musandam is the northernmost area of the country adjacent to Strait of Hormuz, between the 
Gulf of Oman and the Persian Gulf. This strategic area of 1800 km² is on a vital transit point for 
the world oil transportation. Musandam is separated from the rest of the country by mountains 
and a territory belonging to united Arab Emirates.
Al Batinah
Al Batinah is a highly populated coastal area that runs from the lower northern part of Oman, 
below Musandam, to just above Muscat.
Al Dakhiliyah
Al Dakhiliyah occupies a distinctive location with a belt of mountains on the western side and 
desert in the south.
Al Wusta
Al Wusta is a flat rock desert in the center of Oman and is populated by the Bedouins.
Al Dhahirah
Al Dhahirah lies towards the west of the coastal areas. It is separated from Muscat by the 





























Al Sharqiyah is the eastern region of Oman. It is considered a natural reserve in the country.
Dhofar
Dhofar, at the bottom south and bordering Yemen is a mountainous area covering 99,300km².




Al Dakhiliyah occupies a distinctive location with a belt of mountains on the western side 
and desert in the south. 
 
Al Wusta 
Al Wusta is a flat rock desert in the center of Oman and is populated by the Bedouins. 
 
Al Dhahirah 
Al Dhahirah lies towards the west of the coastal areas. It is separated from Muscat by the 
western Al Hajar Mountains. 
 
Al Sharqiyah 








Figure 2.1: Map of Oman. 
 
 
2.6 Religious and cultural practice (consanguinity) 
Conversion to Islam in Oman occurred during the lifetime of the prophet Muhammad in the 
7th century and the Arab tribes living in Oman were among the first people to embrace Islam. 
nowadays the majority of the populations belong to the Abadhi subgroup, comprising 75% 
of the Muslims in the country. The second Muslim subgroup (the Sunnies) and the third (the 




























obligations. The government follows the Abadhi subgroup doctrine and appoints a Mufti 
who has the authority to maintain the Islamic fatwas for the whole country. Culture is deeply 
influenced by the Arabian traditions and Islamic religion and differs slightly between different 
groups based on ethnicity, social and tribal stratification. 
Consanguineous marriages are very common among Omani as it is perceived to ensure 
trust and to strengthen family bonds. According to the Oman national Health Survey, 52% of 
the marriages in Oman are consanguineous (2). Moreover, another large study conducted by 
Rajab and Patton (3) among more than 60,000 couples reported that 35.9% of the marriages 
take place between first or second cousins and another 20.4% between members of the same 
tribes, giving a rate of consanguineous marriage of over 50%. Another study calculated that 
marriages between first cousins was 34 % and the total consanguinity rate including second 
cousin relationships and beyond was 58 % (4). 
2.7 Hemoglobinopathies in Oman
Hemoglobinopathies are the most frequent autosomal recessive disease in Oman where 
malaria was endemic. Malaria eradication activities started in Oman in 1971 and included house 
and open space spraying operations. These measures were followed by rapid reduction in 
malarial incidence. Most of sickle cell disease (SCD) cases in Oman are found in agricultural 
areas consisting of a continuous chain of villages situated along the coast, which provided 
favorable conditions for malaria transmission. One exception is Dhofar, an area with higher 
rainfall than other regions, abundance of mosquitoes and tropical vegetations but no SCD. The 
reason is probably due to the presence of a strain of mosquitoes (Anopheles Coustiani) that 
does not allows the malaria parasite to complete its life cycle (sporogony) efficiently. 
In the past, the majority of the Omani patients with severe SCD or β-thalassemia major were 
not surviving infancy. With advanced health management, early diagnosis and comprehensive 
treatment, the survival of patients with hemoglobin disorders has significantly improved. 
nevertheless, these patients are in need of intensive therapy with poor life expectations 
and always in need of special support by public health services which in terms have to face 
economical stress for treatment coverage that is free of charge in Oman. 
A comprehensive national program was developed in 1999 in Oman aiming at forming a 
national committee and a unit in each region specialized in educating and training all regional 
teams through seminars and workshops and developing a registry document of all cases. By 2003, 
counseling services were incorporated in community education through mass media taking 
all ethical, legal and social issues into consideration. Collaboration with experts and reference 
laboratories of neighboring countries was undertaken, as well as consulting with international 
western countries was made in order to establish and design a controlled program (Diagnostics 
and management of genetic blood disorders in Oman, 2008, ISBn number 978-90-807039-3-3).
In spite of the public health improvements made in Oman, patients with hemoglobin disorders 
are still born at a high rate. For this, a comprehensive knowledge on hemoglobinopathies in 
Oman had to be derived to prevent the occurrence of such severe conditions and to give a 
better life to the affected patients.
As previously mentioned, understanding the molecular and genomic make up is essential 




























counseling to the families helping them in making the right choice to avoid getting infants with 
severe diseases. 
For this we have studied in this thesis the molecular spectrum of beta and alpha gene defects 
essential for diagnosis, early screening and risk assessment of the young Omani generation 
(chapters 4, 5 and 7).
2.8 Mutation spectrum and variability in prevalence in Oman 
The annual birth rate in Oman consists of 82, 000 newborn (5). According to Al Riyami et al. the 
birth prevalence of β-hemoglobinopathies is 3.1/1000 live births while the national incidence of 
sickle cell disease (SCD) is 2.7/1000 among 2-5 years old children (6).
Various studies have been conducted thus far to calculate the prevalence of different 
hemoglobin disorders in Oman generating similar or discrepant figures. The first Omani 
population study on hemoglobinopathies was done by White et al. in 1986 on a relatively 
small cohort looking for cases with α-thalassemia. Homozygous α+-thalassemia was found at 
a frequency of 0.39. In 1993 (7), White et al, studied a larger cohort (n=952) and found a higher 
frequency of homozygous α+-thalassemia (0.45). The frequencies of β-thalassemia trait and 
sickle cell carriers (SCT) were also estimated to be 0.015% and 6.1% respectively. 
From January 2001 to December 2004, more than 30,000 blood samples were collected 
by Adly et al. and analyzed using the sickle cell solubility method for HbS detection and high 
performance liquid chromatography (HPLC) for beta gene variant analysis (8). The total 
prevalence rate of hemoglobinopathies (HBP) was found to be around 8.1%; SCT 7.5 %, SCD 
0.46% and 0.102% for other β gene defects (HbD, HbE, HbS-Oman, beta-thalassemia) (8).
In 2003 a large national survey was undertaken by Oman’s Ministry of Health in which a total 
of 6103 households were interviewed and 6,342 children under 5 years of age were screened. 
The total HBP prevalence rate was 9.5%; SCT (6%), β-thalassemia trait (2%), BTM (0.07%) and 
SCD (0.2%), Hb D (0.6%), Hb E (0.3%) and Hb C traits (0.02%) respectively (4). Compound 
heterozygosis of HbS with other abnormal Hb was detected at a very low prevalence (4). When 
the prevalence of SCT was compared between the different regions, variability in frequency 
was noted. Al Sharqiya had the highest prevalence (13.9%) followed by Al Batinah (10.8%), Al 
Dakhiliya (9%), Muscat (8%) Musandam (4.7%) and Al Dhahira (3.9%). The prevalence of β-thal 
trait was the highest in the Al Batinah region (5.4%) followed by Muscat (2.8 %), Al Sharqiya 
(2.3%), Al Dakhiliya (2 %), Al Dhahira (1.7 %) and Musandam (1.6 %). The prevalence of SCT and 
β-thal trait in Dhofar was very low (0.2 %) and no cases were detected in Al-Wousta region (4).
During a neonatal screening program on cord blood samples in 2009, a total of 7,837 Omani 
neonates were analyzed for complete blood counts and for hemoglobin profile by HPLC. no case 
with Hb H disease (-α/αα) was detected, α-thalassemia traits were observed with a frequency 
of 48.5% while β-globin-defects accounted for 9.5% of the samples (4.8% SCT, 2.6% β-thal trait, 
0.9% Hb E trait, 0.8% Hb D trait, 0.08% Hb C trait, 0.3% SCD and 0.08% homozygous β-thal) (9). 
It was also found that the birth rate of newborns affected with major hemoglobinopathies was 
4.3/1,000 live births (3.5/1,000 for SCD and 0.8/1,000 for β-thalassemia) (9).
Recently, it was reported that about 400 patients with β-thalassemia major (BTM) and 3,000 
with SCD are treated in different hospitals in Oman (10). Around 10 % of Omanis are HbS carriers 




























At the genetic level, one study was carried on to decipher the molecular spectrum among 
beta thalassemia patients which was conducted in 1998 where fifteen different β-determinants 
were identified (11). Due to the historical migration of the local and trading links with 
neighbouring countries, ethnic admixing is expected in the country and thus broader spectrum 
of hemoglobinopathy mutation was needed and this was looked at in (Chapters 4-7).
In year 2000, a study was conducted on Omanie sickle cell disease with the aim to 
identify the coexisting haplotypes for genetic epidemiology purposes to demonstrate the 
uni- or multicentric origin and genetic flow of sickle cell mutation in northern part of Oman 
(12). However, no genotype-phenotype correlation studies were drawn which is important 
for risk assessment and treatment selection. This association was studied and extended in 
(Chapters 9-11).
The high birth rate of affected neonates results in huge suffering for patients and families, 
increasing the financial burden on health resources and for this reason, great attention should 
be given to appropriate cost-effective prevention strategies and measures. In addition, state 
of the art medical care has improved the survival age of HBP’s and, in absence of prospective 
primary prevention, the number of patients requiring care in the country is likely to multiply 
by three times in the next 20 years with a stable population of at least 1,000 patients with BTM 
and 7,000 with SCD. 
Such an increase correlates directly with an increased health burden as patients are largely 
hospital dependent. At present, the cost of treating all Omani patients with a HBP disorder is 
estimated to be about 10 million uS$/year. In the absence of primary prospective prevention, 
this will rise to at least $30 million in the next 20 years. Considering the rising costs of treatment, 
other authors have recently published much higher figures for beta thalassemia reaching levels 
of 2 million uS$ per life treatment for a single patient (13). 
To find a sensible solution to this problem, we have evaluated the attitudes of Omani carrier 
couples towards prenatal diagnosis and medical abortion in chapter 13, showing that primary 
prevention of hemoglobinopathies by prenatal diagnosis and selective pregnancy termination 
could be culturally acceptable also in Oman 
2.9 The role of public health and religious authorities
Considerable time is needed to establish a developed program for the control and management 
of severe disorders such as hemoglobinopathies. 
As mentioned above, the first community genetic program in Oman was introduced in 1999 
by trained regional teams as the national program for the control of genetic blood disorders. 
The program consists of providing the best possible patient care, raising community awareness 
through education programmes, screening couples at risk and offering genetic counselling 
(14). During the last decade, health care in Oman has shown great achievements in medical 
services in both the preventive and the curative fields and in 2001, Oman was ranked number 8 
by the World Health Organization. Although efforts are made by public health centers to raise 
awareness regarding the burden caused by hemoglobin disorders, a sector of the population 
still remain unaware of the disease and more efforts should be made by the responsible 





























Especially β-thalassemia major patients need intensive treatment as they present with 
continuous life-threatening problems. As briefly mentioned above, the disease poses a 
significant burden not only on patients and families but also on public health due to high costs 
of medications and treatments, requiring constant highly qualified multidisciplinary care, 
life-long and frequent blood transfusions and very expensive chelation therapy which are 
offered for free to all Omani citizens. 
Bone marrow transplant (BMT) as the only “curative” option was introduced in Oman in 1995 
with a two-bed unit in one of the specialised hospitals. The infrastructure can perform only a 
few transplants per year, whereas hundreds of patients, of which approximately 72% suffer from 
β-thalassemia major, remain on the waiting list (15). Although in Oman, due to large families, 
the possibility of finding human leukocyte antigen (HLA) matched sibling is high, the BMT 
capacity is insufficient. 
Alternatively, primary prevention not only spares the suffering and the burden of expensive 
treatment, with little hope to become cured, but is also highly cost-effective as it has been 
shown in many country with a considerable carrier frequency, where offering this option to 
couples at risk has become established (11).
In Oman, premarital carrier screening service for sickle cell disease and β-thalassemia 
carrier state is available in all primary health centers. nonetheless, the service is not mandatory 
as it is in neighboring Arab countries such as Saudi Arabia (16) and Bahrain (17) and where the 
incidence of severe hemoglobinopathies has gradually decreased since the carrier screening 
test has become compulsory prior to marriage.
A study done in the Al Batinah region to estimate the knowledge and the attitude of the 
population towards premarital testing showed that majority of the responders believed that 
premarital testing is necessary in Oman. While about half of them supported the option of 
making this screening mandatory by law about one third was less in favour of being tested 
before marriage (18). This shows that the level of awareness in the general population still needs 
more attention by the health affair directorates who are responsible for the development, 
control and implementation of health policies (10).
Moreover, religious authorities should be made aware of the severity of the condition 
and of the burden of the disease for an affected child and the family in order to allow free 
decisions concerning prenatal diagnosis (PD) and pregnancy termination (if indicated) based 
upon serious medical grounds. Given that religion still contextualises decision making about 
termination of pregnancy, it is important for policy makers and public health providers to 
consult the country’s main religious scholars to discuss the issue of offering PD to all at-risk 
couples in the first trimester of pregnancy. Although Islam is one religion, permitting medical 
abortion in one Islamic country and forbidding it in another is not logical in spite of the fact that 
it could be explained by the differences of the sub-religion practiced in each country, which 
includes Shiaa, Sunni and Abadhi. Coming to a common decision that precludes or diminishes 
human suffering and public health problems which affect a large share of the population in 




























2.10 The involved parties (pediatricians, hematologists, laboratories, general 
practitioner, ethics, politics, insurances) 
Multidisciplinary teams are needed to care for patients with severe hemoglobinopathies. 
Pediatricians, general practitioners (GP) and midwifes are crucial partners of the families that 
require their patients and their pregnancies, to be managed along with the aid of hematologists, 
geneticists, laboratory doctors and technicians. Chronic complications manifest 6 months after 
birth, aggravate with age and need to be managed by an integrated team of devoted specialists 
including psychologists. 
Dedicated medical teams have shown that comprehensive care focusing on the education 
of patients and their families, may improve physical growth and decrease acute events in sickle 
cell disease (SCD) children (19). Screening for hemoglobinopathies is usually community based, 
starting with the GP or the midwife who sees the couple before marriage or the woman early 
in pregnancy respectively. In case of individual premarital testing, when one partner is found 
to carry a relevant hemoglobinopathy, the other partner will be offered testing, and if both are 
found to be carriers, the couple will be offered genetic counseling. This also involves the efforts 
of a team that will have to rely upon in the work of molecular geneticists and counselors that 
will provide all data and advice needed for informed reproductive choice (20).
The Omani Ministry of Health follows the Islamic perspectives of medical ethics and world 
health organization medical policy. The concept of informed consent has been implemented. 
The patient is given full autonomy to accept or reject a treatment (e.g.: Hydroxyurea for SCD 
patients) or to choose or not for primary prevention in full patient confidentiality. Although many 
international health insurance companies exist in Oman, it is not compulsory to have one as it is 
the case in many countries in the world. Omani nationals receive free treatment in public hospitals 
thus locals rarely seek to apply and pay for a private medical insurance. Foreign immigrants residing 
in the country may face financial issues if not insured and since many immigrates who come to 
Oman, are from countries endemic for hemoglobinopathies (Egypt, Indian, Pakistan, Indonesia 
and the Philippines), Oman may face the same problem being faced by other western immigration 
countries (21) in which it may be difficult to reach carriers at risk in the immigrant populations and 
unable to provide them with sufficient counseling information and thus prevention. 
2.11 The implementation of our research 
Social medicine is point of care in Oman, a country in which public health has dramatically 
improved in the last few decades. However, recessive genetic diseases such as 
hemoglobinopathies remain a substantial burden in the country. Prevention can be dramatically 
improved by offering prenatal diagnosis and for this, comprehensive molecular studies are 
required. As mentioned, Oman is a country with a wide range of ethnic groups (3) and thus an 
extensive spectrum of mutations is expected. Knowledge of the distribution of these mutations 
is essential in health care planning and management of diseases with a complex molecular 
pathology such as the hemoglobin disorder. For this, an accurate database with all patients 
and carriers in all regions with hematological and molecular analysis is needed to aid in the 
treatment and prevention programs. Advances in this field will be a breakthrough in applied 
public health science and will put Oman at the state of the art level in treatment and prevention 




























contribute to this process, to reduce the birth prevalence of sickle cell disease, beta- and alpha-
thalassemia in the country, with a relevant gain in public health as well as a substantial reduction 
in treatment related expenses for severely affected patients that are and might dramatically 
increase in the near future if primary prospective prevention is not implemented (22).
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CHAPTER 3:  PREVENTION IN ENDEMIC AND NON-ENDEMIC 
IMMIGRATION COUNTRIES
Hemoglobinopathies  were originally endemic only in tropic and sub-tropic areas of the Old 
World but in the past centuries sickle cell disease (SCD) and thalassemia have spread world-
wide as a consequence of slave trade, colonization and recent migrations. 
national programs consisting of information, screening and counseling have been 
implemented in many endemic countries in order to prevent the birth of children with severe 
hemoglobinopathies, while emerging countries are beginning to acknowledge the importance 
of starting prevention strategies focusing at population screening, genetic counseling and 
developing reference centers to identify healthy couples at risk (1).
Primary prevention can be prospective if offered before conception or retrospective if 
made available after the birth of the first affected offspring (2). Different prevention strategies 
are available that are differently accepted in various cultures, influenced by social and religious 
background, economy and politics. In some countries religion plays a major tolerant or 
restrictive role when prevention involves pregnancy termination, in other the strategy involves 
mandatory premarital screening. 
In some cultures carrier screening may result in changing the candidate partner if the 
diagnosis is made prior marriage but if the couple at-risk still decide to marry, the options they 
have are to a) avoid getting pregnant, b) ask for prenatal diagnosis (PD), c) opt for a non-carrier 
gamete donation or d) choose to adopt. However not all these options are widely accepted and 
most couples at-risk would opt for PD if legally permitted or pre-implantation genetic diagnosis 
(PGD) (3). Some cases may even take the risk and hope for a healthy child. When newborn 
screening (nBS) is available, it may help these couples to plan for the best-tailored treatment 
and to reduce the risk of the severe symptoms in case of an affected child. It is evident that 
the earlier carrier detection is done, the more options are available for primary prevention (4).
Most endemic countries with long prevention experience focus on early carrier detection 
while non-endemic countries with large populations of immigrants at risk offer mainly nBS. 
Although nBS is not an efficient option for primary prevention, it allows secondary (morbidity) 
prevention and eventually retrospective or even prospective primary prevention for the 
following child if the nBS procedures are properly managed and all new born carriers are 
reported. This is the case in the uK and to some extend in Holland where, besides national nBS, 
early pregnancy screening is also offered universally or regionally. 
A positive aspect in hemoglobinopathy screening is that carriers can be identified by simple, 
fast and relatively inexpensive hematological and biochemical tests which most laboratories 
can offer and afford. This is fairly unique amongst human genetic diseases.
Once couples at risk are identified or suspected, accurate molecular characterization might 
be required to avoid misdiagnosis that can lead to potential pitfalls in genetic counseling and 
prenatal diagnosis when it is offered, especially in countries where the spectrum of mutations 
is very heterogeneous and the conditions are widespread (5). 
Below we describe the available prevention option in endemic and non-endemic countries 
and highlight the bottlenecks of  carrier diagnostics and early screenings in Muslim Arab 







































3.1 Prevention of severe hemoglobinopathies in different countries
Prevention of hemoglobinopathies is offered to couples that are at risk for getting a child with 
a severe phenotype and that, although treatable at great expenses, it is associated with heavy 
suffering and premature death. 
The most relevant hemoglobinopathies are those caused by defects on both beta genes, 
such as beta-thalassemia major and sickle cell disease. Being most forms of alpha thalassemia 
mild due to the presence of 4 alpha genes (6), prevention is only relevant for couples who are 
carriers of severe alpha genotypes (usually alpha-zero deletions) that are at risk of getting a 
child with hydrops fetalis, or for couples with combinations of alpha zero carriers and certain 
alpha+ defects that might cause severe HbH disease. Severe hemoglobinoapthy conditions for 
which prenatal diagnosis is generally justifiable are summarized in Table 3.1.
Table 3.1. Six categories of severe HBP states, for which genetic counseling, and possibly PD is needed. 
The first 3 being the most common, adapted from Traeger-Synodinos, 2013 (38). 
Category of hemoglobin disorder Most frequent causes
Thalassemia major Severe β- and/or δβ-thalassemia mutations
Sickle cell disease S/S, S/C, S/β-thal, S/D, S/OArab, S/Lepore, S/E etc.
Hb E/ β-thalassemia Co-inheritance of β-thal mutations with HbE
Hb Lepore and other thal variants Co-inheritance of β-thal and Hb variants with thal or 
instable phenotype
Hb Bart’s Hydrops Fetalis syndrome Homozygous α°-thalassemia deletions
Hb H intermediate or severe Interaction of α°-thalassemia deletions with severe 
nondeletion α-thal mutations or homozygous severe 
nondeletional α-thal mutations
3.1.1 Pre-conception carrier diagnostics/screening and premarital counseling
The first prevention strategy which has been made available in endemic countries is premarital 
carrier screening followed by genetic counseling, where couples at risk are provided with 
information for a reproductive decision making. Detecting couples at risk before marriage has 
been made mandatory in several Middle Eastern and Muslim countries like Iran (7), the uAE (2), 
Saudi Arabia (8) and Tunisia (9) (Table 3.2). Premarital testing resulted in dramatic decrease of 
affected births either preventing at-risk marriages through adapting partner choice, remaining 
childless (10) or prenatal diagnosis where it is offered. Successful examples of preconception 
counseling have been reported in many countries (9, 11) with Sardinia and Cyprus as the first 
endemic countries to develop awareness and screening to detect carriers (1, 12) with significant 
decline in the incidence of thalassemia major.
Early carrier detection in high schools is also a good example of prospective prevention 
at the preconception level (13). This has been shown to be effective in some countries such as 







































resulted in a dramatic fall of beta-thalassemia major over the years in these regions. Identified 
carriers kept the information and remembered their status, despite the time lapse between 
screening at school and reproduction time, had their partner tested and inquired about 
prevention options (4, 14, 15). High school screening has been carried out as a national project 
in some Arab countries including Bahrain (16) and Egypt (17), aiming at raising awareness 
among the young generation. However, in Egypt, low acceptability was observed due to limited 
number of premarital centers and high costs. Knowing the individuals carrier status as early as 
school age, allows sufficient time to understand the consequences of getting an affected child 
in the future and to come up with a decision calmly after considerate thinking. Although school 
screening programs sounds feasible, they are not widely implemented. A drawback includes 
the risk of ethnic discrimination between the students, since the recessive diseases may be 
more common in people of specific ethnic origin or tribe compared to others (2). 
Should premarital screening be made compulsory in Oman? And if so, should a marriage at 
risk be interfered by the legal system? In China, premarital genetic examination was mandated 
by law in 1995 and couples at risk were not permitted to marry without contraception or 
tubal ligation (18). This rather awkward law was redrawn as a flagrant violation of medical 
ethics and human rights, and premarital testing became voluntary in 2003 (19). It should be 
emphasized that in western countries in particular, many couples have children without a 
formal or legal marriage. This is unlike in Muslim communities where couples are not allowed 
to have children unless legally married. Although premarital screening has shown some 
positive outcomes in regions where the test has been mandatory, on its own is not sufficient 
enough to be the basis of a national prevention program if prenatal diagnosis and medical 
abortion are not considered as part of the process.
3.1.2 Carrier diagnostics early in pregnancy, prenatal diagnosis and pregnancy 
termination
In most cases of recessive inherited disorders, healthy carrier couples discover their risk only 
when an affected child is born. Alternatively, specific testing early in pregnancy may allow 
prospective prevention. At this point however, only two choices are left, accepting the risk or 
asking for prenatal diagnosis (PD) and medical abortion in case of an affected fetus.
As mentioned above, PD is offered to the pregnant mother mainly by testing fetal cells 
obtained by amniocentesis (after the sixteenth week of gestation) or a few weeks earlier in 
pregnancy by chronioc villi sampling (20). In most developed countries comprehensive 
programs for PD to address severe inherited conditions are available (21). In case of 
hemoglobinopathies, PD is mostly relevant in countries endemic for beta-thalassemia major 
and sickle cell disease. For alpha-thalassemia, as most forms compatible with postnatal life 
are mild (6), PD, as mentioned above, is only indicated for couples who are at risk of having 
a child with hydrops fetalis or severe HbH disease. In some cases, attempts to keep alive a 
homozygous alpha°-thalassemia fetus have been made by intrauterine transfusions and post-
natal chronic transfusions (22). Due to the ambivalent effectiveness of such management, this 
practice is subject to ethical question. Examples on hemoglobinopthy (HBP) cases on which PD 







































PD and medical abortion has shown to be the most effective prevention option available 
either as a national program or on request in endemic countries such as Hong Kong, Taiwan, 
India, Iran, Maldives and Singapore as well as non-endemic countries such as Australia, new 
Zealand, north America and parts of the Caribbean (23). A remarkable success in the decline of 
β-thalassemia major cases in regions where high thalassemia carrier rate exist were observed in 
northeast Thailand (24), Greece (25), Sardinia (26) and Cyprus (27).
Screening early in pregnancy is not offered routinely at the national level in Arab countries. 
This might be because it is socially not always accepted or due to lack of education about 
PD among the health workers and the population at large (1). Moreover, screening early in 
pregnancy leaves medical abortion as the only prevention option. This option however, is not 
legally or religiously permitted in many Muslim countries since, as previously mentioned, most 
Islamic institutions prohibit pregnancy termination at any time, unless the life of the pregnant 
woman is threatened. In some countries, (see below) it is allowed before the 120th day of 
gestation under specific circumstances (28).
under civil law, selective abortion of an affected fetus is permissible in some Muslim 
countries such as Tunisia (29), Egypt (30) and Iran (31) with the last representing one of 
the classic examples of dramatic reduction of severe HBP incidences (32). Another recent 
prevention success have been reported from northeastern Iraq (33) with 65% reduction in 
number of affected births over five years of implementing premarital screening and PD for HBP’s. 
Although the Quran does not explicitly state whether termination of pregnancy is permissible 
in case of a severely affected fetus, PD and selective abortion remains a controversial issue in 
different Muslim Arab cultures (28,34,35). Some countries such as Iran and Iraq are led by a 
Shiaa scholar while others such as Egypt by a Sunni scholar. Oman is the only country led by an 
Abadhi scholar and all have different views towards PD in terms of legality of medical abortion. 
A release of a fatwa in each country based on the sub-religion (Islamic sector) is necessary as 
it provides guidance necessary to facilitate decision-making to those who need to base their 
decision upon their religious believe. Moreover, when the carrier status of the couples is found 
during pregnancy, it might be too late for any decision, or the time to make a decision may be 
too limited to understand the disease and the decision may be difficult to take under stressful 
circumstances (15). 
Deciding to interrupt a pregnancy, even if in an early fetal stage, is a difficult and an emotional 
process for most couples involving their moral feelings and religious believes (2). On the other 
hand, knowing that the fetus will have a shorter life, devastated by a severe progressive disease 
that can be treated but not cured and with the high likelihood of a premature death, involves 
parent’s responsibility as well as anxiety and fear to cope with a severely affected child. Moreover, 
the cost of PD can be an obstacle as well as the procedure itself, which is considered invasive 
and carries a risk of 1-2% of a miscarriage. The recent discovery of free fetal DnA in maternal 
plasma has opened a new possibility of noninvasive PD by identifying informative SnPs within a 
gene cluster. The method may offer an alternative to couples at risk but is only applicable in on 
average 50% of the cases and for HBP is thus far only done on a research basis (36).
Pre-implantation genetic diagnosis (PGD) may represent an alternative prevention 







































embryo immediately after in vitro fertilization, allowing pre-selection and transfer of normal 
pre-embryos to the women uterus (11). PGD is permissible under Islamic law, provided that 
the sperms and oocytes are from the husband and wife (37). The main advantage over PD 
is the avoidance of terminating an affected pregnancy. However, PGD is costly, laborious, 
psychologically and physically burdening to the woman and requires highly experienced 
operators for the procedure and pregnancy rates rarely surpass 30–35% (38). 
Studies of the applicability of PGD have been reported mainly from Greece (39), Sicily (40), 
Scotland (41) Hong Kong (42), the united Kingdom (43) and Sardinia (44). In some countries 
PGD is only restricted to cases of infertility. 
We have interviewed Omani couples at risk and studied their attitude towards PD and 
medical abortion. Our results reported in chapter 13 show that if PD was legalized and approved 
by the Omani religious authorities, this option would be most probably accepted by the Omani 
couples at risk as the alternatives of choice to prevent severely affected progeny, and leading 
to a dramatic reduction in the number of affected births in the country. 
3.1.3 Newborn screening
newborn screening (nBS) for hemoglobinopathy (HBP) allows the identification of affected 
infants soon after birth, allowing secondary (morbidity) prevention, offering tailored 
management through prophylactic treatment and vaccination and comprehensive care prior to 
the development of severe clinical complications (3). national systematic newborn screening for 
HBP has been implemented in many countries during the last decade (45) including Arab countries 
such as Bahrain (46), and the uAE (47). In north America (48), the uK (49) The netherlands (50) 
France and other northern European countries nBS is either national or regional (51,52,53). As a 
consequence of nBS one may expect that parents of affected infants would become informed 
and aware of their risk and would follow the available prevention methods for subsequent 
pregnancies and an eventual decline in the number of affected birth should be noticed. However, 
this was not the case in The netherlands where after 7 years of applying newborn screening, no 
reduction of HBP incidence has been noticed. Possible explanations could be due to counseling 
directing toward treatment rather than prevention, lack of awareness in poorly informed parents 
(54) and potential conflict of interest on the part of clinicians and institutions (55). 
In a study conducted by Al Kindi et al (56) on cord blood samples from Omani neonates, 
high prevalence of HBP in newborns was confirmed, emphasizing the need of implementing 
neonatal cord blood screening as a national strategy program in the management and 
prevention of HBP. Although newborn screening cannot identify and alert couples at risk when 
they have a non-carrier newborn child, it could be a useful secondary and primary preventative 
tool in Oman (57). 
Donor insemination and gamete donation are not acceptable in the traditional Islamic 
culture and gamete donation is forbidden as it involves the use of egg and / or sperm that are 
not from the husband and wife, meaning that the born child belongs to one parent only and to 
the donor person. Adoption, although encouraged in Islam, it has many ethical and religious 
implications. 








































Table 3.2. Available HBP preventive carrier screening methods for; premarital, prenatal and neonatal 
screenings and their status in some Arab countries. (nA = service not available). note: newborn screening 
is mainly implemented for SCD and G6PD.
Country Premarital Prenatal & medical abortion Neonatal
Oman Optional nA optional
UAE Mandatory nA mandatory in Abu Dhabi
KSA Mandatory nA optional
Bahrain Mandatory nA mandatory
Qatar Mandatory nA optional
Kuwait Mandatory nA ???
Lebanon Mandatory nA optional
Jordan Mandatory Optional mandatory
Palestine Mandatory Optional ???
Iraq Mandatory Optional ???
Egypt Optional optional optional
Tunisia Mandatory optional mandatory
3.2 The molecular spectrum of mutations and pitfalls in hemoglobinopathy diagnosis 
The molecular basis of hemoglobinopathies is extremely heterogeneous. Over a thousand 
different mutations are reported worldwide and many of them may interact in homozygous 
or compound heterozygous modes, producing a wide range of disorders of varying degrees 
of severity (Table 3.1). The mutations are regionally specific, with each country having a 
characteristic spectrum of abnormal hemoglobins and thalassemia mutations. The mutation 
spectrum in Oman is already quite heterogeneous and the recent migration of foreign laborers 
is bound to expand the ethnic profile of the Omani population with different variants and 
defects may arise in unexpected combinations. 
The usual screening of carrier couples at risk of having children with a β-thalassemia 
major or sickle cell disease (SCD) or sickle cell thalassemia (β/S) is achieved through basic 
hematology methods such as cell blood count (CBC) together with hemoglobin separation 
and measurement on High Performance Liquid Chromatography (HPLC) or Capillary 
Electrophoresis (CE). However, in some cases the interpretation by these basic methodologies 
can be compromised and are insufficient to give provisional results, especially in cases when 
multiple mutation genes are co-inherited or rare variants are involved (58). 
Abnormal hematology readings and Hb separations should always be further investigated 
during premarital screening and risk prediction, including for the large share of non-Omani 
citizens residing in the country which were excluded in this project. 
As mentioned in Chapter 1, the standard reading of HPLC value of 30-40% HbS will usually 
indicate a HbS carrier status (59). nonetheless, some rare abnormal hemoglobins (at least 33 







































Although the provisional diagnosis of HbS carrier made by traditional HPLC or CE is quite 
robust, and a second confirmatory test such as solubility test or the simple sickle test might be 
sufficient in most cases, in rare cases DnA analysis is essential to avoid pitfalls and to confidently 
report the risk assessment when more complex genotypes are present. (58). 
The pitfalls: Few examples on problematic cases are for instance those of carriers of 
unstable hemoglobin variants either undetectable or with isoelectric point and hydrophilic 
interaction identical to HbA and not separable with any of the available technologies. These 
variants may cause severe conditions in combination with β-thalassemia or HbS (58) and will 
never be diagnosed unless DnA analysis is done. The differential diagnosis of hemoglobin 
variants in homozygous or hemizygous states (Hb variant/β-thalassemia) is also crucial as the 
conditions cannot always be diagnosed by basic hematology methods. In adults, the microcytic 
hypochromic red cell indices and the HbA
2
 measurement might help to discriminate to some 
extent, but not during newborn screening when HbA
2
 is not yet expressed. 
Another problematic cases can be those in which a β°-thalassemia point mutations is 
present in one parent while an unknown deletion in the β-globin gene cluster (normal HbA
2
 and 
elevated or normal HbF) is present in the other. This may result in a progeny affected with mild 
or intermediate or a severe phenotype, depending from the type of deletion (with or without 
significant HbF expression). Deletions involving not only the b but also both γ-globin genes 
may result in severe compound heterozygosity due to the absence of the compensatory effect 
of fetal hemoglobin (62). 
As mentioned in Chapter 1, association of β- and δ-thalassemia may also lead to misdiagnosis. 
That’s why it is important to consider δ-thalassemia during β-thalassemia screening when 
borderline/normal HbA
2
 value are observed risking false-negative results in the detection of 
couples at-risk (63). 
Although the α+-thalassemia trait is very common in Oman and it does not represent a 
major burden for public health in the native population, coexisting α-thalassemia could make 
the diagnosis more complex (58). For instance, α+-thalassemia is important to predict to some 
extend the modulation and prognosis of the β-thalassemia and SCD patients. Conversely, α° 
thalassemia common in immigrant populations living in Oman may either improve β thalassemia 
major, or generate intermediate or severe phenotypes in couples of Asian origin. 
Defective α-globin genes alongside the common mutations in any population generates 
atypical combination of these mutations with variable phenotype severity making molecular 
diagnostics at the DnA levels crucial especially in risk assessments. Moreover, alpha-
thalassemia is not always easily diagnosed at the hematological level as it does not have 
specific characteristics on electrophoresis, HPLC, or CE except for a marginal reduction in HbA
2
 
expression (64) or in case of α-variants with known peaks (e.g.: Hb Constant Spring) and HbH 
disease, which may be associated with a rapidly eluting but unstable and disappearing HbH (β4) 
fraction (65). On the other hand α thalassemia can be easily diagnosed if screened at birth by 
the presence of detected Hb Bart’s (γ4) fraction. 
Finally, although most of the hemoglobin variants are either rare or silent and few semi-







































basic technologies and need to be characterized at the molecular level (66). Then, in order 
to overcome most of these pitfalls, it is necessary to cover the full mutation spectrum in the 
country and keep in mind that new, rare or unexpected mutations will continue to be found in 
a multi-ethnic population and that consanguinity will increase the chance of homozygosis for 
rare conditions.Some examples of basic diagnostics and possibly associated pitfalls using the 
common parameters are given in Table 3.3.
Table 3.3. Summary of the basic hematological parameters used to obtain a provisional or definitive 











↓= Iron deficiency , ↑= thalassemia
↓= Iron deficiency or thalassemia
Typical in Thalassemia
Lower in Thalassemia
Positive in trait and disease
Folic acid insufficiency 
Coexisting vitamin B12 deficiency
Old specimen
Old specimen
Old specimen, technical failure
Elevated (HbF) δβ- or γδβ-thalassemia or HPFH Raise due to HbA1c overlapping 
RDW ↓= thalassemia , ↑= iron deficiency Cardiac and hepatic conditions
Elevated HbA
2





 β-thalassemia δ defect or α-gene variants
Low HbS value Coexisting α-thalassemia in HbS 
carrier [HbS<35-40%→(-α/αα), 
HbS~25-35%→(-α/-α) or (--/αα), 
HbS<25%→HbH (-α/--)] or non HbS 
variant eluting at the same spot or 
iron depletion.
Transfusion with an HbS blood donor 
carrier in a HbA/A individual and vice 
versa.
Low HbC or HbE Coexisting HbH disease HbH instability
Hb Bart’s (γ
4
) at birth Hb Bart’s of 0-5%→(-α/αα), 
5-10%→(-α/-α) or (--/αα),  
10-30%→HbH (-α/--).
Old sample
3.3 The process of changing attitude
As mentioned, the attitudes of the Arab-Muslim countries toward genetic screening, prenatal 
diagnosis (PD) and medical abortion is changing in some areas as more people are educated 
and aware of the consequences. In other countries screening and primary prevention remains 
limited due to many factors such as low economic resources, limited premarital screening 
centers, religious beliefs, culture and traditions, literacy, education and government policy. 
If no preventative measures are taken in these endemic regions, in time the cost of treatment 
would consume the entire health budget of the country. However, before establishing any 
prevention option, it is necessary to assess the interest of the community in a preventive 







































ethical issues in handling prevention options such as PD and pregnancy termination and finally 
is essential to have policy makers aware of the magnitude of the problem. 
Efforts are then needed to establish a comprehensive infrastructure for pre-conception 
clinics as an essential community based primary prevention measures (11) and to stimulate 
general practitioner and midwifes to change their passive attitude of “no complaints = no 
actions” into an active behavior of referral for carrier diagnostics for prevention purposes. 
Finally, to avoid stigmatization, awareness campaigns should be directed to the whole of the 
population rather than to immigrants or tribes/ethnic groups at high carrier frequency. 
A number of studies have examined the attitude of Muslim couples at risk towards early 
genetic screening, PD, medical abortion and PGD and variable results were obtained. A recent 
study conducted in Saudi Arabia, showed that 90% of the couples at risk who were diagnosed 
prior marriage and advised to choose a different partner, proceeded with their marriage intention 
(8). When these couples were questioned, around 50% thought it is a good thing to undergo a 
screening test but before the engagement stage because of the difficulties in cancelling familial 
commitment, the wedding ceremony preparation, and because of social stigma (8). Similar 
cultural feelings have been observed in neighboring Middle Eastern countries, as well as the 
desire to have early preventive genetic services to reduce the incidence of HBP in these regions 
with high frequency of consanguineous marriages. Studies from Saudi Arabia (67) and Lebanon 
(68) have shown that couples considered PGD to be preferable, as their opinion towards PD was 
influenced by the religious authorities in the country. 
not all Muslim cultures accept the Fatwa of the official Islamic jurisprudence allowing 
selective abortion within the first trimester of pregnancy in case of an affected foetus (Council 
of the World Islamic League, 15-22/07/1410 Hijri/ 10-17 February 1990). However, all Muslim 
jurists, have agreed regardless the different Islamic streams that PGD for genetic disorders is 
permissible provided that the gametes are from husband and wife and this on the basis that 
IVF does not conflict with God’s desire nor is considered a modification of God’s creation, but 
rather a way of treatment because PGD and embryo selection is done when embryos are only 
at the eight-cell stage (69). The question is why should PD, followed by early medical abortion 
in vivo within 120 days of conception be unacceptable to all Islamic sectors, while PGD which 
could be considered in fact an early medical abortion in vitro be acceptable? In both cases 
there is interruption to fetal growth to prevent the birth of a severely affected child. 
3.4 Diagnostics and management of hemoglobinopathies in Oman 
Since sickle cell disease (SCD), β- and α- thalassemia are the most common autosomal recessive 
gene disorders in Oman, premarital testing for hemoglobinopathies (HBP) is provided as a 
national program for identifying couples at risk. The service is voluntary and is offered free of 
charge to the Omani citizens. The first line of diagnostic tool is based on the measurement of 
the hematological parameters (CBC) and on the separation and estimation of the hemoglobin 
fractions on high performance liquid chromatography (HPLC). 
A normal individual after the age of 2 will present with about 96-97% HbA, ±3% HbA
2
 and 
<1%HbF. Any change in this pattern will be anomalous and might indicate an HBP disorder. 
Frequent traits are confirmed by simple additional analysis, solubility test for HbS, alkaline 







































confirmed biochemically, DnA test is requested. Figure 3.1 summarizes how the value of HbA
2
 is 
interpreted in the Omani population. 
Molecular analysis is used to confirm a diagnosis when hematological and biochemical 
parameters are complex or unclear. The main technologies involved are direct DnA sequencing 
for the β- and α- globin genes. Gap-PCR is used to detect the common α-thal deletions when 
microcytic and hypochromic red cell indices are observed. Multiple ligation probe amplification 
(MLPA) is the ultimate solution for defining unknown deletion defects of either the β- or 
α-globin genes cluster and should be considered to be implemented in the genetic laboratory.
For the development and quality of a molecular laboratory one needs to keep up with 
new technologies and scientific advances. Robust and fast screening methods should be used 
once premarital testing for HBP becomes mandatory in the country. The referral hematology 
laboratory should have more than one method for hemoglobin analysis besides HPLC, for 
example Capillary Electrophoresis (CE). The serum ferritin test should be replaced by the zinc 
protoporphyrin method and be made mandatory on all samples. Serum ferritin is usually normal 
or elevated in β-thalassemia carriers who have increased iron absorption in the intestine but 
might also be borderline or low in α-thalassemia carriers. Moreover, ferritin is an acute-phase 
protein and might be falsely elevated in the presence of a coexisting infection (58). In some 
clinics, genetic counseling is not provided by a certified professional genetics counselor, but 
by a local health practitioner who has sufficient experience and training to convey the results. 
Efforts should be directed to have more professional specialists in the field.
figure 3.1. The criteria used to diagnose HBP related cases based on HbA
2 
value, indicating when 
DnA analysis is performed. Tests highlighted in gray are needed and should be considered for future 
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Currently prevention of SCD and β-thalassemia major (BTM) in Oman involves either 
choosing another partner, accepting the risk or seeking for prenatal diagnosis (PD) or PGD 
abroad for those who can afford the costs. A typical premarital screening scenario includes 
the following stages: signing a consent form at the first consultation, sending a blood sample 
to the nearest hematology laboratory, sending a sample for DnA analysis if diagnosis cannot 
be confirmed by hematology tests, receiving results (by fax) and finally reporting the findings 
to the couples by either arranging a counseling session or conveying results over the phone. 
Severely affected patients are treated in the major hospitals. Thalassemia patients are 
offered monthly blood transfusion and chelation therapy. Sicklers are regularly immunized and 
admitted when severe symptoms strike. Recently, Hydroxyurea treatment has been introduced 
but is given to only very severe cases of SCD following stringent criteria. 
The majority of the society of modern Oman may eventually accept selective abortion if 
religiously permitted. Prevention will spare a lot of human suffering to children and families as 
well as the huge expenses to the country necessary for treatment of the ever growing number 
of patients affected with these incurable diseases. Efforts were made to open a constructive 
dialogue with the main religious authority in Oman (country’s Muftee) in order to discuss the 
issue of PD and medical abortion in case of a severely HBP affected fetus. However, to date, the 
religious authority has not agreed to make this service legal as yet. 
A SUMMARy Of THE PATIENTS AND METHODS 
As mentioned at the beginning in “Aim of this thesis” the intention of this study was to investigate 
all possible factors involved with the implementation of a national prevention strategy for Oman 
and in other Muslim countries also endemic for HBP. For this I have studied at the biochemical, 
molecular and clinical level a cohort of 722 Omani subjects (1444 alleles), affected with BTM, 
SCD, alpha thalassemia or presumed to be carriers of HBP. Details of all patients and methods 
used for analysis are included in the publications summarized in Chapters 4-13.
I have provided the widest spectrum of common and rare mutations in Oman and the 
prevalence of specific mutations more common in specific areas of the country (Chapters 4, 
5, 6, 7 and 8), 
I have studied the factors involved in the modulation of severity of SCD such as haplotype 
and coexisting alpha thalassemia and the value of these factors for prognostics, risk assessment, 
state of the art treatment (genotype / phenotype correlation) and for pharmacogenomics 
(Hydroxyurea treatment) (Chapters 9, 10 and 11). 
I have tested the application of next generation technology in identifying large number of 
at risk cases in a rapid period of time (Chapter 12) 
Finally I have studied the attitudes of the Omani couples towards PD and medical abortion 
(Chapter 13). 
I believe that this study has provided new information on different aspect essential for the 









































1. Angastiniotis M, Modell B, Boulinzhenkov V. 
Prevention and control of haemoglobinopathies. 
Bulletin of the World Health Organization. 
1995;73(3):375-386.
2. Giordano PC, Harteveld CL, Bakker E. Genetic 
epidemiology and preventive healthcare in 
multiethnic societies: the hemoglobinopathies. 
Int J Environ Res Public Health. 2014;11(6):6136-46.
3. Traeger-Synodinos J, Harteveld CL, Old JM, Petrou 
M, Galanello R, Giordano P, et al. EMQn Best 
practice guidelines for molecular and haematology 
methods for carrier identification and prenatal 
diagnosis of the haemoglobinopathies. Eur J Hum 
Genet. 2014 Jul 23. doi: 10.1038/ejhg.2014.131.
4. Amato A, Cappabianca MP, Lerone M, Colosimo 
A, Grisanti P, Ponzini D, et al. Carrier screening 
for inherited haemoglobin disorders among 
secondary school students and young adults in 
Latium, Italy. J Commun Genet. 2014;5(3):265-8.
5. Eram SM, Azimifar B, Abolghasemi H, Foulady 
P, Lotfi V, Masrouri M, et al. The IVS-II-I (G>A) 
beta0-thalassemia mutation in cis with HbA
2
-
Troodos delta116(G18) Arg>Cys (CGC>TGC) causes 
a complex prenatal diagnosis in an Iranian family. 
Hemoglobin. 2005;29(4):289-292.
6. Yi JS, Moertel CL, Baker KS. Homozygous alpha-
thalassemia treated with intrauterine transfusions 
and unrelated donor hematopoietic cell 
transplantation. J Pediatr. 2009;154(5):766 –768.
7. Zeinalian M, nobari RF, Moafi A, Salehi M, 
Hashemzadeh-Chaleshtori M. Two decades of 
pre-marital screening for beta-thalassemia in 
central Iran.  J Community Genet.  2013;4(4): 517-
522.
8. Alswaidi FM, Memish ZA, O’Brian SJ, Al-Hamdan 
nA, Al-Enzy FM, Alhayani OA, et al. At-risk 
marriages after compulsory premarital testing and 
counseling for β-thalassemia and sickle cell disease 
in Saudi Arabia. J Genet Couns. 2012;21(2):243–255.
9. Chaabouni-Bouhamed H. Tunisia: communities 
and community genetics. Community Genet. 
2008;11(6):313-323.
10. El-Tayeb En, Yaqoob M, Abdur-Rahim K, Gustavson 
KH. Prevalence of beta-thalassaemia and sickle 
cell traits in premarital screening in Al-Qassim, 
Saudi Arabia. Genet Couns. 2008;19(2):211–218.
11. Czeizel AE, Gasztonyi Z, Kuliev A. Periconceptional 
clinics: a medical health care infrastructure of new 
genetics. Fetal Diagn Ther. 2005;20(6):515-518.
12. Angastiniotis MA, Hadjiminas MG. Prevention of 
thalassaemia in Cyprus. Lancet 1981;1(8216):369–71.
13. Amato A, Grisanti P, Lerone M, Ponzini D, Di Biagio 
P, Cappabianca MP, et al. Prevention strategies 
for severe hemoglobinopathies in endemic and 
non endemic immigration countries: the Latium 
example. Prenatal Diagnosis. 2009;29(12):1171-1174.
14. Mitchell JJ, Capua A, Clow C, Scriver CR. Twenty-
year outcome analysis of genetic screening 
programs for Tay-Sachs and beta-thalassemia 
disease carriers in high schools.  Am. J. Hum. 
Genet. 1996;59(4):793–798.
15. Lena-Russo D, Badens C, Aubinaud M, Merono F, 
Paolasso C, Martini n, et al. Outcome of a school 
screening programme for carriers of haemoglobin 
disease. J. Med. Screen. 2002;9(2):67–69.
16. Al-Arrayed S, Hafadh n, Amin S, Al-Mukhareq H, 
Sanad H. Student screening for inherited blood 
disorders in Bahrain. East Mediterr Health J. 
2003;9(3):344–352.
17. El-Beshlawy A, Youssry I. Prevention of 
hemoglobinopathies in Egypt. Hemoglobin. 
2009;33(1):14–20.
18. Hesketh T. Getting married in China: pass the 
medical first. BMJ. 2003; 326(7383): 277-279.
19. Ebrahim SH, Lo SS, Zhuo J, Han JY, Delvoye P, Zhu 
L. Models of preconception care implementation 
in selected countries. Matern Child Health J. 
2006;10(5):37-42.
20. Kan YW, Chang JC. Molecular diagnosis of 
hemoglobinopathies and thalassemia. Prenat 
Diagn. 2010;30(7):608-610. 
21. Liao C, Mo QH, Li J, Huang Yn, Hua L, Li QM, et al. 
Carrier screening for alpha and beta-thalassemia 
in pregnancy: the results of an 11-year prospective 
program in Guangzhou Maternal and neo natal 
hospital. Prenat Diagn. 2005;25(2):163–171.
22. Chmait RH, Baskin JL, Carson S, Randolph LM, 
Hamilton A. Treatment of alpha(0)-thalassemia 
(--SEA/--SEA) via serial fetal and post-natal 
transfusions: Can early fetal intervention improve 
outcomes?. Hematology. 2014 (Epub ahead of 
print).
23. Modell B, Darlison M. Global epidemiology of 
haemoglobin disorders and derived service 
indicators. Bulletin of the World Health 
Organization. 2008;86(6):480–487.
24. Yamsri S, Sanchaisuriya K, Fucharoen G, Sae-ung 
n, Ratanasiri T, Fucharoen S. Prevention of severe 
thalassemia in northeast Thailand: 16 years of 
experience at a single university center. Prenat 
Diagn. 2010;30(6):540-6. 
25. Theodoridou S, Alemayehou M, Prappas 
n, Karakasidou O, Aletra V, Plata E, et al. 
Carrier screening and prenatal diagnosis of 
hemoglobinopathies. A study of indigenous and 
immigrant couples in northern Greece over the 







































26. Cao A, Rosatelli MC, Monni G, Galanello R. 
Screening for thalassemia: a model of success. 
Obstet Gynecol Clin north Am. 2002;29(2):305–
328.
27. Zlotogora J. Population programs for the detection 
of couples at risk for severe monogenic genetic 
diseases. Hum Genet. 2009;126(2):247-253.
28. Al-Aqeel AI. Islamic ethical framework for research 
into and prevention of genetic diseases. nat 
Genet. 2007;39(11):1293-1298.
29. Chaabouni H, Chaabouni M, Maazoul F, M’rad R, 
Jemaa LB, Smaoui n, et al. Prenatal diagnosis of 
chromosome disorders in Tunisian population. 
Ann Genet. 2001;44(2):99–104.
30. El-Beshlawy A, El-Shekha A, Momtaz M, Said F, 
Hamdy M, Osman O, et al. Prenatal diagnosis for 
thalassaemia in Egypt: what changed parents’ 
attitude? Prenat Diagn. 2012; 32(8):777–782.
31. Samavat A, Modell B. Iranian national thalassaemia 
screening programme. BMJ. 2004; 329(7475):1134–7.
32. nikuei P, Hadavi V, Rajaei M, Saberi M, Hajizade 
F, najmabadi H. Prenatal diagnosis for beta-
thalassemia major in the Iranian province of 
Hormozgan. Hemoglobin. 2008;32(6):539–45.
33. Al-Allawi nA, Jalal SD, Ahmed nH, Faraj AH, Shalli 
A, Hamamy H. The first five years of a preventive 
programme for haemoglobinopathies in 
northeastern Iraq. J Med Screen. 2013; 20(4):171-176.
34. El-Hazmi MA. Islamic teachings of bioethics in 
relation to the practice of medical genetics. Saudi 
Med J. 2007;28(12):1781–1787.
35. Asman O. Abortion in Islamic countries-legal and 
religious aspects. Med Law 2004;23(1):73-89.
36. Mavrou A, Kouvidi E, Antsaklis A, Souka A, Kitsiou 
Tzeli S, Kolialexi A. Identification of nucleated red 
blood cells in maternal circulation: a second step 
in screening for fetal aneuploidies and pregnancy 
complications. Prenat Diagn. 2007;27(2):150-153.
37. Lavery SA, Aurell R, Turner C, Castello C, Veiga A, 
Barri Pn, et al. Preimplantation genetic diagnosis: 
patients’ experiences and attitudes. Hum Reprod. 
2002;17(9):2464-2467.
38. Dreesen J, Destouni A, Kourlaba G, Degn B, 
Mette WC, Carvalho F, et al. Evaluation of PCR-
based preimplantation genetic diagnosis 
applied to monogenic diseases: a collaborative 
ESHRE PGD consortium study. Eur J Hum Genet. 
2014;22(8):1012-8. 
39. Traeger-Synodinos J. Preimplantation genetic 
diagnosis, an alternative to conventional prenatal 
diagnosis of the hemoglobinopathies. Int J Lab 
Hematol. 2013;35(6):571-579.
40. Chamayou S, Guglielmino A, Giambona A, Siciliano 
S, Di Stefano G, Scibilia G, et al. Attitude of potential 
users in Sicily towards preimplanataion genetic 
diagnosis for beta-thalassaemia and aneuploidies. 
Hum Reprod. 1998;13(7):1936-1944.
41. Miedzybrodzka Z, Templeton A, Dean J, Haites 
n, Mollison J, Smith n. Preimplantation diagnosis 
or chorionic villus biopsy? Women’s attitudes and 
preferences. Hum Reprod. 1993; 8(12):2192–2196.
42. Hui PW, Lam YH, Chen M, Tang MH, Yeung WS, 
ng EH, et al. Attitude of at-risk subjects towards 
preimplanatation genetic diagnosis of alpha- and 
beta-thalassaemias in Hong Kong. Prenat Diagn. 
2002;22(6):508-511.
43. Snowdon C, Green JM. Preimplantation diagnosis 
and other reproductive options: attitude of male 
and female carriers of recessive disorders. Hum 
Reprod. 1997;12(2):341-350.
44. Palomba ML, Monni G, Lai R, Cau G, Olla G, Cao 
A. Psychological implications and acceptability 
of preimplantation diagnosis. Hum Reprod. 
1994;9(2):360-362. 
45. Bain BJ. neonatal/newborn haemoglobinopathy 
screening in Europe and Africa.  J Clin Pathol. 
2009;62(1):53-6.
46. Al-Arrayed S, Al-Hajeri A. newborn screening 
services in Bahrain between 1985 and 2010. Adv 
Hematol. 2012; 2012:903219.
47. Al-Gazali LI, Alwash R, Abdulrazzaq YM. united 
Arab Emirates: communities and community 
genetics. Community Genet. 2005;8(3):186-196.
48. Hoppe C. newborn screening for 
Hemoglobinopathies in the u.S. Journal 
compilation, Special Issue, International Journal of 
Laboratory Hematology. 2009;31(1):27–28.
49. Streetly A, Latinovic R, Hall K, Henthorn J. 
Implementation of universal newborn bloodspot 
screening for sickle cell disease and other clinically 
significant haemoglobinopathies in England: 
screening results for 2005–7. J Clin Pathol. 
2009;62(1):26–30.
50. Kaufmann JO, Demirel-Güngör G, Selles A, 
Hudig C, Steen G, Ponjee G, et al. Feasibility of 
nonselective testing for hemoglobinopathies 
in early pregnancy in The netherlands.  Prenat 
Diagn. 2011;31(13):1259–1263.
51. Giordano PC. Starting neonatal screening for 
haemoglobinopathies in The netherlands. J Clin 
Pathol. 2009;62(1):18–21.
52. Bardakdjian-Michau J, Bahuau M, Hurtrel D, et 
al. neonatal screening for sickle cell disease in 
France. J Clin Pathol 2009; 62(1): 31–33.
53. Gulbis B, Cotton F, Ferster A, Ketelslegers O, 
Dresse MF, Rongé-Collard E, et al. neonatal 
haemoglobinopathy screening in Belgium. J Clin 
Pathol. 2009;62(1):49-52.
54. Kaufmann JO, Krapels IP, van Brussel BT, Zekveld-







































introduction into the national newborn screening 
program: who is receiving genetic counseling for 
hemoglobinopathies in the netherlands?  Public 
Health Genomics. 2014;17(1):16-22.
55. Kaback MM. Population-based genetic screening 
for reproductive counseling: The Tay-Sachs 
disease model. Eur J Pediatr. 2000;159:S192–S195.
56. AlKindi S, Pathare A, Al-Madhani A, Al Zadjali S, Al 
Haddabi H, Al Abri Q, et al. neonatal screening 
Mean haemoglobin and red cell indices in 
cord blood from Omani neonates. SQu Med J. 
2011;11(4):462-469.
57. Thuret I, Sarles J, Merono F, Suzineau E, Collomb J, 
Lena-Russo D, et al. neonatal screening for sickle 
cell disease in France: evaluation of the selective 
process. J Clin Pathol. 2010;63(6):548-51.
58. Giordano PC. Strategies for basic laboratory 
diagnostics of the hemoglobinoapthies in multi-
ethnic societies: interpretation of results and 
pitfalls. Int J Lab Hematol. 2013 ;35(5):465-79.
59. Harteveld CL,  Ponjee G,  Bakker-Verweij 
M,  Arkesteijn SG,  Phylipsen M,  Giordano PC.  Hb 
Haaglanden: a new nonsickling β7Glu>Val variant. 
Consequences for basic diagnostics, screening, 
and risk assessment when dealing with HbS-like 
variants. Int J Lab Hematol. 2012;34(5):551–5.
60. Moradkhani K, Riou J, Wajcman H. Pitfalls in the 
genetic diagnosis of HbS. Clin Biochem. 2013;46(4-
5):291-299.
61. Szuberski J, Oliveria JL, Hoyer JD. A comprehensive 
analysis of hemoglobin variants by high-
performance liquid chromatography (HPLC). 
International Journal of Laboratory Hematology. 
2012;34(6):594-604.
62. Phylipsen M, Amato A, Cappabianca MP, Traeger-
Synodinos J, Kanavakis E, Basak n, et al. Two 
new beta-thalassemia deletions compromising 
prenatal diagnosis in an Italian and a Turkish 
couple seeking prevention. Haematologica. 
2009;94(9):1289-92.
63. Li J, Xie XM, Zhou JY, Li DZ. Co-inheritance of 
β- and δ- thalassemia compromising prenatal 
screening in a Chinese souple seeking prevention. 
Fetal Diagn Ther. 2011;30(1):73-6. 
64. Stephens AD,  Angastiniotis M,  Baysal E,  Chan 
V,  Fucharoen S,  Giordano PC,  et al.  International 
council for the standardisation of haematology 
(ICSH). ICSH recommendations for the 
measurement of haemoglobin A
2
.  Int J Lab 
Hematol. 2012; 34(1):1–13.
65. Papassotiriou I,  Traeger-Synodinos J,  Vlachou 
C,  Karagiorga M,  Metaxotou A,  Kanavakis 
E,  et al.  Rapid and accurate quantitation of Hb 
Bart’s and Hb H using weak cation exchange 
high performance liquid chromatography: 
correlation with the alpha-thalassemia 
genotype. Hemoglobin. 1999;23(3):203–11.
66. van den Berg HM, Bruin MC, Batelaan D, van Delft 
P, van Zwieten R, Roos D, et al. Hb nijkerk: a new 
mutation at codons 138/139 of the beta-globin 
gene inducing severe hemolytic anemia in a Dutch 
girl. Hemoglobin. 1999;23(2):135-44.
67. Alkuraya FS, Kilani RA. Attitude of Saudi families 
affected with hemoglobinopathies towards 
prenatal screening and abortion and the 
influence of religious ruling (Fatwa). Prenat Diagn. 
2001;21(6):448-451.
68. Farra C, nassar AH, usta IM, Salameh P, Souaid M, 
Awwad J. Acceptance of preimplantation genetic 
diagnosis for beta-thalassemia in Lebanese 
women with previously affected children. Prenat 
Diagn. 2008;28(9):828-832.
69. El-Hashemite n.  Genetic Malformation in 
Children, its Causes, and the Islamic View in 





EXTEnDED MOLECuL AR SPECTRuM 
OF β-  AnD α-  THAL ASSE MIA In OM An
Hassan SM, Hamza nishat, Al Lawatiya FJ, Mohammed AJ, 





































Sickle cell disease is known to be very common in the Omani population, although data are 
limited concerning β-thalassemia (β-thal). We report the molecular background of 87 unrelated 
patients from the Sultanate of Oman, diagnosed with β-thal major (β-TM), β-thal intermedia 
(β-TI) or minor. Diagnosis was based on clinical and hematological data and confirmed by 
molecular analysis. We found 11 different β-thal determinants in our cohort, which consists 
of subjects from different regions of Oman. Six of these mutations have not been previously 
reported in the Omani population. The prevalence of α-thal single gene deletions (-α3.7 and – 
α4.2) in the same cohort was very high (58.3%). These data will contribute to the implementation 
of a country-wide service for early molecular detection of hemoglobinopathies and for 



































Hemoglobinopathies are the most frequent autosomal recessive disease in man. The most 
common conditions are caused by mutations in the β- or the α-globin genes coding for the 
postnatally expressed Hb A subunits. Mutations may either change the primary structure of 
the gene product [abnormal hemoglobins (Hbs)] or impair the expression of the mutated gene 
(thalassemia). Expression defects are subdivided into α- and β-thalassemia (α- and β-thal), 
resulting from the defective synthesis of α- and β-globin chains, respectively. Carriers of β-thal 
(thalassemia minor) are mostly asymptomatic with mild anemia, while patients with β-thal 
major (β-TM) are severely affected, transfusion-dependent and in need of continuous iron 
chelation therapy. Patients who are carriers of α-thal (−α/αα, −α/−α and – –/αα) are mildly 
anemic, while patients with Hb H disease (−α/– –) present with an α-thal intermedia (α-TI) 
picture with enlarged spleen/liver, and in some cases, may need regular or occasional blood 
transfusions, whereas homozygous α0-thal (– –/– –) is lethal. But for a successful bone marrow 
transplant, these diseases cannot be cured, and for most of these patients the only alternative 
is intensive treatment until premature death. More than 80% of the α+-thal determinants are 
common deletions such as the –α3.7 and – α4.2. Conversely, more than 95% of the β-thal cases 
are due to point mutations, of which only a few are prevalent and population-specific, while 
many others are rare. Population isolates usually present with a narrow spectrum of mutations, 
while admixed populations are characterized by a large number of mutations (1).
After sickle cell disease (SCD), β-TM is the second most common severe hemoglobinopathy 
in Oman, a country with a population of 2.6 million inhabitants, of which 73% are native Omanis 
and 27% are foreign immigrants. The annual birth rate is ±50,000 newborn, of which 250 have 
β –TM and are in need of intensive therapy and the figures continue to rise every year. Although 
there has been a significant improvement in social conditions and medical care for these 
patients during the last three decades, life expectation and quality of life still remains poor with 
severe human suffering and patients remain in continuous need of burdening therapy provided 
by public health services which, being free of charge in Oman, represents a considerable share 
of public health expenses. Prevention being better than treatment, the aim of this study was to 
investigate the molecular spectrum of β-thal in order to enable the study of the geographical 
prevalence of the different thalassemia defects occurring in the different regions of Oman. 
Knowledge of this molecular spectrum is necessary for early diagnosis and prevention of 
morbidity and mortality of these most debilitating inherited disorders.
MATERIAL S AND METHODS
The examined cohort consisted of 87 unrelated individuals of both genders previously diagnosed 
with β-TM, β-TI or minor or with sickle cell disease. Of these, 84 were Omani subjects and three 
were immigrants. Age ranged from 1 to 44 years old (1963–2006). Blood was collected in EDTA 
and patients gave written consent for the procedures to be performed according to the local 
ethical regulations. Routine analyses were performed in The netherlands, by measurement of 
Hb fractions on a high performance liquid chromatography (HPLC) apparatus (Variant, Bio-Rad 


































Sebia, Paris, France), as described elsewhere (2). All patients were analyzed at the molecular 
level. DnA extraction was done by high salt technologies, either manual or automated, using 
the Puregene DnA Purification System (Gentra Systems, Minneapolis, Mn, uSA) (3). Mutation 
analyses of α-thal included multiplex polymerase chain reaction (gap-PCR) as described by Liu 
et al. (4). Point mutation analysis of the β-globin gene was done on a GeneAmp9700 (Applied 
Biosystems, Foster City, CA, uSA) using the QIAGEn® Multiplex PCR kit (Cat. no. 206143; Qiagen 
GmbH, Hilden, Germany), as previously reported (5). DnA sequencing was done on an ABI 
PRISM™ 3730 Genetic Analyzer (Applied Biosystems) using ABI PRISM® Big Dye Terminators v2.0 
Cycle Sequencing kit according to the manufacturer’s instructions.
RESULTS
Routine analyses of samples freshly collected in Oman showed either the pattern of transfused 
β-thal patients, of sickle cell disease, either homozygous or in combinations Hb S [β6(A3)
Glu→Val]/ β-thal, or of carriers of these traits. All patients were examined at the molecular level.
In total we examined 174 alleles and found 11 different β-thal determinants.
In the non Omani, four codon 39 (C>T) and two codons 41/42 (–TTCT) alleles were found. 
In the 168 alleles from Omani subjects, 83 chromosomes with β-thal point mutations were 
characterized with nine different “Omani” mutations. 
The IVS-I-5 (G>C) was the most prevalent (73%), while Hb Monroe [IVS-I (–1) or codon 30 
(G>C), β30(B12)Arg→Thr], codon 5 (–CT) and IVS-I (–25 bp) 3′ end mutations were the second 
in frequency (4.5%) together with codon 39 found in immigrants. Codons 8/9 (+G) was third in 
prevalence (3.3%) and codons 41/42 fourth at 2.2% but in immigrants only. The remaining four 
mutations were observed at lower frequencies (1.1%).
We have observed six β-thal mutations that were not found in the previous study by Daar et 
al. (6) on 99 Omani patients in 1998. Conversely, we have not found nine other mutations that 
were observed by Daar et al. (6). The IVS-I-5 mutation was the most predominant in both studies 
which complement each other, providing an extended spectrum of the β-thal determinants in 
the Sultanate of Oman. The data are summarized in Table 4.1.
Table 4.2 shows the distribution of eight Omani β-thal mutations in four regions. The 
IVS-I-5 mutation was predominant in Batinah, Muscat and Dhakhiliyah (73.7, 86.6 and 83.3%, 
respectively), while the same mutation was absent in Musandam with Hb Monroe being the 
most prevalent. Although the number of alleles studied is too small to provide a precise 
assessment, these preliminary results seem to indicate that the distribution of the mutations is 
not uniform and further studies are required to confirm the data (Table 4.2).
We have examined the same 87 individuals for the presence of the common α-thal deletions 
by gap-PCR (4). In three cases the analysis failed due to technical reasons. In 35 patients no 
α-thal deletion was found. In 25 cases, the −α3.7 deletion was found in the heterozygous state 
(29.8%) and in 22 in the homozygous state (26.2%). One patient was heterozygous for the –α4.2 
deletion (1.2%) and one patient presented with compound heterozygosity for the −α3.7 and −α4.2 
deletions (1.2%). Thus, the prevalence of α-thal alleles in this cohort was 58.3%. The data are 


































Table 4.1. Comparison of the molecular spectrum of β–thalassemia mutations in Oman with the data of 
Daar et al. (6). a : Found in immigrants only
Present study Daar et al. (6)
(chromosomes) (chromosomes)
Mutations n % n %
IVS-I-5, G>C 65 73.0 122 61.6
Codon 5, -CT 4 4.5 1 0.5
Codon 30, G>C, Hb Monroe 4 4.5 0 0.0
IVS-I (-25bp) 3’ end 4 4.5 11 5.5
Codon 39, C>T a 4 4.5 2 1.0
Codons 8/9, +G 3 3.4 0 0.0
Codons 41/42, -TTCT a 2 2.3 0 0.0
IVS-I-1, G>A 1 1.1 2 1.0
Codon 41, -C 1 1.1 0 0.0
Codon 16, -C 1 1.1 0 0.0
Codon 44, -C 0 0.0 19 9.6
Hb Dhofar, β58(E2) Pro→Arg 0 0.0 13 6.6
619 bp deletion 0 0.0 8 4.0
IVS-II-1, G>A 0 0.0 7 3.5
Codons 36/37, -T 0 0.0 2 1.0
Codon 15, G>A 0 0.0 1 0.5
Codon 37, -G 0 0.0 1 0.5
Codon 30, G>A 0 0.0 1 0.5
IVS-I-110, G>A 0 0.0 1 0.5
Hb E, β26(B8) Glu→Lys 0 0.0 1 0.5
unknown 0 0.0 6 3.0
DISCUSSION
We herein describe eleven different β-thalassemic mutations present in Omanis and three 
in immigrant subjects. The imported mutations need to be taken into consideration for two 
reasons: (i) because of their significant contribution (from India, The Philippines, Egypt and 
others) in the past to the present day spectrum of mutations in the Omani population; (ii) given 
the actual percentage (27%) of the immigrant community within Oman, health professionals 
and authorities must be aware of the issues in future planning strategies (7).
As Daar et al. (6) reported, we also found that the IVS-I-5 mutation is the most common 
(73%) in Oman but with uneven distribution across the region. This mutation is most prevalent 
in the northern regions of Oman Batinah, Muscat and Dhakhiliyah (Table 4.2). The second most 







































mutations found Type of mutation
Regional 
prevalence (%)
Musandam 4 3 Codon 30, G>C, Hb Monroe 75.0
1 Cd 8/9, +G 25.0
Batinah 19 14 IVS-I-5, G>C 73.7
4 IVS-I (-25bp) 3’ end 21.0
1 Codon 30, G>C, Hb Monroe 5.3
Muscat 53 46 IVS-I-5, G>C 86.6
3 Codon 5, -CT 5.6
2 Codons 8/9, +G 3.8
1 Codon 16, -C 1.9
1 Codon 41, -C 1.9
Dakhiliyah 6 5 IVS-I-5, G>C 83.3
1 IVS-I-1, G>A 16.7
Total 82 82 8  
Table 4.3. Spectrum of α-thalassemia mutations in Oman
(a) Allele frequencies
Mutation Allele frequency (%) Prevalence (%)
-α 3.7 (rightward) 41.7
-α 4.2 (leftward) 1.2
Total 42.9 58.3
(b) Genotype frequencies
Mutation n Genotype frequency (%)
Rightward homozygotes 22 26.2
Rightward heterozygotes 25 29.8 
Compound rightward/leftward 1 1.2 
Leftward heterozygote 1 1.2 
with a prevalence of 4.5%. These data are different from those reported by Daar et al. (6) in 
which Hb Monroe was not found and the codon 5 mutation was observed at a much lower 
frequency (0.5%). Moreover, the remaining mutations were observed at lower frequencies and 
six were not observed by Daar et al. (6), while nine mutations reported by these investigators 
were not observed by us. This is probably due to differences in the ethnic composition of the 


































to obtain a better picture regarding prevalence and distribution of thalassemic mutations in a 
multi-ethnic society such as Oman.
Geographical and cultural factors separate the tribal populations of Oman causing isolation 
and the high degree of consanguineous marriages. Consanguinity doubles the chance of 
generating couples at risk and if a partner is already a carrier, the chance that the other will also 
be a carrier in a first-cousins marriage will be 1:16. Consequently, unless otherwise appropriate 
prevention measures are taken, the number of affected births will continue to grow.
In spite of the high prevalence of the Hb S and IVS-I-5 mutations, less common defects 
must be taken into consideration. For instance, in the region of Musandam, separated from 
the rest of Oman by the united Arab Emirates, three out of the four unrelated alleles studied 
carried the Hb Monroe mutation. This variant is associated with a β-thal phenotype (8) and at 
risk for β-TM (9). Hb Monroe was also found in Batinah (4.8%), a region close to Musandam 
and was also observed in the united Arab Emirates (10). Apparently, Hb Monroe is prevalent 
in communities of the west coastal area of the Arabian Gulf peninsula, but this needs to be 
confirmed by a larger study.
Since our recruitment strategy was focused on β-thal, our cohort can be considered as 
random (not selected for α-thal). The prevalence of α+-thal mutations, known to be high in 
Saudi Arabians (43.3%) (11), is found to be even higher in the Omani population (58.3%). With 
no less than 22 homozygotes for the – α3.7 deletion and 25 carriers out of the 84 unrelated 
individuals, is probably the highest frequency observed in the Arabian peninsula. On the other 
hand, none of the α0 defects associated with Hb H or Hb Bart’s hydrops fetalis were found. The 
reason for the absence of the α0 defects is probably the high consanguinity due to negative 
selection of such lethal defects in the high consanguineous setting.
CONCLUSIONS
Our analysis has shown the existence of few common mutations but also the presence of a 
number of less common defects. Considering the fact that the Omani population is a society 
consisting of well defined groups (tribes), the distribution of the β-thal determinants is bound 
to be different in different regions. Our cohort was collected mainly from the northern part of
Oman because it has been previously reported by Daar et al. (6) that β-thal mutations are 
prevalent in these regions. nevertheless, we presume that β-thal defects might be present at 
lower frequencies in other regions as well. 
These data are important for organizing prevention and management of severe forms of 
hemoglobinopathies in Oman. Given their high prevalence, young Omani subjects are advised 
to get screened for hemoglobinopathies at a premarital stage either for their choice of a 
partner or for getting informed in advance of the risk and of the available options: not to have 
children, adoption or use of donor gametes or prenatal diagnosis. 
Prenatal diagnosis is available in Islamic countries such as Egypt, Tunisia and Iran, and 
medical abortion is allowed in these countries when the fetus is found to be affected with a 
severe hemoglobinopathy, in accordance with a Fatwa permitting medical abortion prior 
to 3 months of conception in case of a severely affected fetus (Council of the World Islamic 


































remains a matter of debate/discussion in Oman and views of prominent muftis are essential. 
Development of prevention, control and management programs of hemoglobinopathies in 
Oman should aim to reduce the number of affected births and simultaneously must offer the 
best quality of life by medical care to those born affected with an anomaly.
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The objective of this study was to expand and study the molecular spectrum of β-thalassemia 
mutations in Oman by examining cases from 7 different regions and comparing the prevalence 
with neighbouring countries. A total of 446 cases of β-hemoglobinoapthy were obtained and 
analyzed to determine the frequency and distribution of the different β-alleles. The molecular 
spectrum of β-thalassemia in Oman revealed the presence of 32 different mutations of 
different origin and 11 alleles are reported for the first time in the Omani population. The wide 
heterogeneous spectrum of β-thalassemia mutations found can be associated with the history 
of trade and migration as well as the past domination from other countries. The presented data 
































Oman is a country at the south east corner of the Arabian Peninsula. It faces the northern east 
part of the Arabian Gulf, bordering united Arab Emirates and Saudi Arabia in the west, Yemen in 
the south and is separated from Iran by a narrow sea strait from the north east. β-thalassemia is 
an autosomal recessive hemoglobin disorder and one of the most common genetic disease in 
man. Carriers of the disease are found at high frequencies in the tropic and sub-tropic regions 
including Oman. untreated patients with β- thalassemia major are likely to die early in infancy 
and burdening treatment is needed to delay premature death. Prevention options such as 
premarital screening and genetic counselling of couples at risk are offered at the national level 
in Oman. However, this is limited to adapting partner choice as prenatal diagnosis (PD) is not 
offered in the country. As termination of pregnancy is not permitted in Oman, couples at risk 
that marry, may either accept the risk or decide to seek for PD or pre-implantation genetic 
diagnosis (PGD) abroad. As for PD and PGD molecular analysis is needed, knowledge of the 
local spectrum of mutations is essential in order to have a reliable diagnosis. Previous studies 
have reported a provisional spectrum of the β thalassemia alleles in Oman (1, 2). We report 
here the broadest spectrum of β-thalassemia mutations found in the country by examining the 
largest cohort studied thus far. 
MATERIAL S AND METHODS
Our cohort consisted of 446 unrelated individuals of native Omani nationality attending the 
Ministry of Health Hospitals in the country. The subjects were either affected with β-thalassemia 
major (TM), or HbS/β-thal or carriers of β-thalassemia. Age ranged from 1 to 48 years; 49.3% 
were females and 51.7% males. Patients’/parents’ consent form was obtained prior to testing. 
The provisional diagnoses were confirmed by complete blood counts (CBC) performed on a 
Cell Dyn 4000 automated blood cell counter (Abbott Diagnostics, Santa Clara, CA, uSA) and 
by biochemical analysis including high performance liquid chromatography (HPLC) (Variant, 
Bio-Rad Laboratories, Hercules, CA, uSA). Finally DnA was extracted using the QIAamp DnA 
Blood Mini Kit (Qiagen Inc., Valencia, CA, uSA) and the β-globin gene was amplified and 
sequenced on an ABI PRISM™ 3730 Genetic Analyzer (Applied Biosystems).
RESULTS
Among the 446 cases (892 chromosomes), 273 were beta-thalassemia carriers, 102 sickle/β-
thalassemia compound heterozygotes and 71 had TM. In total 32 different β-thalassemia 
mutations were identified among 517 mutated alleles. Eleven of the β-thal alleles are reported 
for the first time in Oman. These include the IVS-I-128 T>G, Hb La Desirade Cd129 TGC>TGT, the 
promoter mutations -88 C>A and -101 C>T, IVS-II-849A>G, Cd8 (-AA), the 5nt poly A deletion 
3’(+108-3’(+112), IVS-I-6 T>C, Hb Iraq Halabja Cd10 GCC>GTC, the Cd22 GAA>TAA and the PolyA 
3’(+113)A>G mutation (Table 5.1).
As expected from our previous data, the IVS-I-5 G>C was still the most frequent mutation 
in each region except for Dhofar. The IVS-I-5 G>C allele frequency was 43.6%, while 30 different 































Table 5.1. The β- molecular spectrum observed in the 7 studied regions in Oman. Determinants observed 
for the first time among Omani are highlighted.




































IVS-I-5 G>C HBB:c.92+5G>C 30 42 120 5 14 15 226
Cd44 (-C) HBB:c.135delC 1 10 12 2 1 15 41
5’ (-71) C>T HBB:c.-121C>T 34 2 5 41
Cd121 GAA>CAA HBB:c.364G>C 5 4 13 2 3 27
IVS-I-128 T>G HBB:c.93-3T>G 2 1 14 1 18
Cd129 TGC>TGT HBB:c.389C>T 1 12 2 15
Cd26 GAG>AAG HBB:c.79G>A 1 4 6 1 2 14
Cd5 (-CT) HBB:c.17_18delCT 4 4 3 2 13
IVS-I-3’ (-25bp del) HBB:c.93-21_96del 6 7 13
Cd58 CCT>CAT HBB:c.176C>A 6 5 2 13
IVS-II-1 G>A HBB:c.315+1G>A 2 6 3 1 12
Cd39 CAG>TAG HBB:c.118C>T 8 1 1 2 12
Cd29 GGC>GGT/Cd58 CCT>CGT HBB:c.90C>T/HBB:c.176C>G 12 12
IVS-I-1 G>A HBB:c.92+1G>A 4 5 1 10
5’ (-101) C>T HBB:c.-151C>T 6 1 7
5’ (-88) C>A HBB:c.-138C>A 3 3 6
Cd15 TGG>TAG HBB:c.47G>A 3 2 5
Cd121 GAA>AAA HBB:c.364G>A 1 4 5
Cd30 AGG>ACG HBB:c.92G>C 3 1 4
Cd(8/9) +G HBB:c.27_28insG 1 2 3
IVS-II-849 A>G HBB:c.316-2A>G 3 3
Cd6 GAG>AAG HBB:c.19G>A 3 3
Cd8 (-AA) HBB:c.25_26delAA 1 1 1 3
3’(+108) - 3’(+112) 5nt del HBB:c.+108_+112delAATAA 2 2
IVS-I-6 T>C HBB:c.92+6T>C 1 1 2
Cd10 GCC>GTC HBB:c.32C>T 1 1 2
Cd22 GAA>TAA HBB:c.67G>T 1 1
Cd63/37 ( - T) HBB:c.112delT 1 1
3’(+113) A>G HBB:c.+113A>G 1 1
Cd30 AGG>AAG HBB:c.92G>A 1 1
IVS-I-110 G>A HBB:c.93-21G>A           1   1































8% while HbD Cd121 G>C was found at 5%. The other mutations were IVS-I-128 T>G and Hb La 
Desirade C>T, occurring at 3.5% and 2.9% respectively. HbE Cd26 G>A was found at 2.7% while 
Cd5(-CT), IVS-I-3’(-25bp del) and Hb-Sheffield Cd 58 C>A were observed both at 2.5%. The 21 
other mutations accounted for the remaining 18.6%. 
In Muscat, 27 β-alleles were found. The distributions of other β-thal alleles are shown in 
(Table 5.1). The origin of each mutation is described in Table 2 along with frequencies observed 
in the 3 countries/regions neighbouring Oman; Southern Iran (Hormozgan), united Arab 
Emirates and Eastern Saudi Arabia. Yemen was not included as no molecular data on beta-
thalassemia were available as yet.
DISCUSSION
Although previous reports did examine the molecular spectrum of β-globin gene mutations in 
Oman, they were somehow limited in sample size and ethnic composition (1, 2). In addition, our 
samples have been randomly collected from 7 different regions, expanding by three regions 
from our pervious study (1). Therefore the present survey gives a better picture regarding the 
β-thalassemia spectrum and the distribution in a country of multi-ethnic tribes. 
When comparing with neighbouring countries, the spectrum of β-thalassemia reported 
in our native Omani cohort (32 mutations, n=446) is higher than that reported in Eastern 
Saudi Arabia (14 mutations, n=196) (3) and uAE (25 mutations, n=412) (4). The most common 
mutation reported in the Eastern Province of Saudi Arabia was the Cd39 C>T followed by 
the IVS-II-1(G>A), IVS-I-5(G>C), IVS-I-25 bp deletion, and IVS-I-6 (T>C) which is also found in 
united Arab Emirates and Oman with varying allele frequencies (3). Among uAE nationals, the 
most frequent mutation found was the IVS-I-5(G>C) followed by the IVS-I-3’ 25 bp del allele 
(4). In the Yemenis (n=10) living in Saudi Arabia, only the IVS-I-110(G>A) and IVS- II-1(G>A) 
mutations were identified (5). Data from Yemen are only preliminary. Although overall 52 
different β-thalassemia mutations have been reported from different parts of Iran (6), the most 
predominant mutations found by the Iranian studies were IVS-II-I (G>A) in the north and IVS-I-5 
(G>C) in the south (7, 8). The Iranian region nearest to Oman is Hormozgan. The β-thalassemia 
molecular spectrum of Hormozgan (9) describing 19 different mutations in 155 β-thal cases was 
used in our comparative study (Table 5.2). 
The genetic heterogeneity of the native population shows the presence of Mediterranean, 
Asian Indian, Kurdish, Iranian and Turkish mutations that reflects the historical background of 
Oman. The Asian-Indian substitution at IVS-I-5(G>C), is the most common mutation in the uAE, 
Hormozgan and Oman but it is the third frequent in Eastern Saudi Arabia. unlike our previous 
study where the IVS-I-5 G>C mutation was reported to constitute about 73 % of all the mutations 
in the Omani population studied (1), the present results revealed that IVS-I-5(G>C) constitutes 
about 43% of the mutations while the remaining 57% of the population carried a heterogeneous 
number of different mutant alleles (Table 5.1). Certain mutations occur in low frequencies and 
are tribe specific, indicating a founder effect. Alternatively some common mutations may vary 
in frequency between tribes as a consequence of bottle-necks which may wipe out certain 
mutations originally present in the founder population on one hand and increase the frequency 































Table 5.2. The β-mutation frequency observed in Oman in comparison to its neighbouring countries; 
Hormozgan (Iran) (13), Eastern Saudi Arabia (5) and uAE (12). The most common mutation in each country 
is depicted in bold. 12 mutations described in Omani but not in other nationalities are highlighted in gray. 
β-determinants observed in other countries but not observed in Oman were not included in the table.
Mutation Allele Origin
Oman Hormozgan East KSA UAE
n=446 n=155 (9) n=196 (3) n=412 (4)
IVS-I-5 G>C Asian Indian 43.7 69 13.3 44.5
Cd44 (-C) Kurdish 7.9 2.5 0.5 0.7
5’ (-71) C>T Omani 7.9      
Cd121 GAA>CAA Indian/Pakistani 5.2 2.2
IVS-I-128 T>G Punjapi 3.5      
Cd129 TGC>TGT Black 2.9      
Cd26 GAG>AAG Asian Indian 2.7 0.1
Cd5 (-CT) Mediterranean 2.5 2 3.1 2.1
IVS-I-3’ (-25bp del) Asian Indian 2.5 1 13 8.6
Cd58 CCT>CAT British/Omani 2.5      
IVS-II-1 G>A East Mediterranean 2.3 9.6 22.2 2.8
Cd39 CAG>TAG West Mediterranean 2.3 2.4 25 2.2
Cd29 GGC>GGT/Cd58 CCT>CGT Omani 2.3      
IVS-I-1 G>A Mediterranean 1.8 3.8
5’ (-101) C>T Turkish 1.4 0.2
5’ (-88) C>A Kurdish 1.2 0.34 1.1
Cd15 TGG>TAG Asian Indian 1 0.34 0.9
Cd121 GAA>AAA Arabian/African 1      
Cd30 AGG>ACG African 0.8 0.7 2.1
Cd(8/9) +G Asian Indian 0.6 0.34 1.5 3
IVS-II-849 A>G Black 0.6      
Cd6 GAG>AAG Black 0.6      
Cd8 (-AA) Turkish 0.6 3.4 2.1 2.2
3’(+108) - 3’(+112) 5nt del Arabian 0.4      
IVS-I-6 T>C West Mediterranean 0.4 0.34 7.1 1.5
Cd10 GCC>GTC Iraqi 0.4      
Cd22 GAA>TAA Reunion Island 0.2      
Cd36/37 ( - T) Kurdish/Iranian 0.2 0.7 0.5 0.1
3’(+113) A>G Kurdish 0.2 2 0.4
Cd30 AGG>AAG Bulgarian 0.2      































may have had a considerable contribution to the variety of Asian and African beta-thal alleles 
as demonstrated in Table 5.2. The broad range of mutations identified in our study suggests a 
large effect of gene flow attributable to historical migration patterns.
Accurate characterization of the mutation at the DnA level is necessary during premarital 
counselling. Therefore it is essential to describe the molecular basis of the mild β+ thalassemia 
alleles such as -71 C>T, IVS-I-128 T>G and Hb La Desirade Cd129 C>T since these mutations may 
cause problems when risk assessment is done during premarital genetic counselling. This is 
because these cases when accompanied with HbS, show an almost equal ratio of Hb A and Hb 
S (50:50) resulting in an asymptomatic phenotype as observed in previously studied cases in 
Omani βS/β-71C>T patients (10). Moreover, variants such as Hb Sheffield Cd 58 C>A which co-elutes 
in the same Hb A
2
 window as HbE Cd 26 G>A on high performance liquid chromatography (11) 
can lead to a wrong interpretation and consequently mis-diagnosis. Differentiating between 
mild conditions such as HbD Cd121 G>C homozygotes and compound heterozygotes (HbD/
β-thalassemia) is important if the other partner is a carrier of β-thalassemia trait as there is 
a 25% risk of having a child affected with a severe β-thalassemia major (12). Hemoglobin 
variants should always be genotyped to differentiate between homozygotes and compound 
heterozygotes with beta-thalassemia for effective genetic counselling. 
The only available option for prevention of severe hemoglobinopathies in Oman is through 
early diagnosis and genetic counselling. Thus molecular investigations and genotype / 
phenotype correlation are essential to reveal the exact β-thalassemia mutations and to make 
a phenotype prediction when possible. Our molecular studies show that the β-thalassemia 
mutations present in Oman vary in severity ranging from very mild β+ form to severe cases, 
taking all studies up to date into account, at least 35 determinants are present in the country 
(1,2,10,11).  
In conclusion, each country and region has its own prevalence and spectrum of β-thalassemia 
defects with a handful of common mutations and several less frequent or rare ones. Therefore, 
extensive knowledge on the heterogeneity of β-thalassemia mutations is needed to offer 
genetic counselling as a service to each population and in the highly consanguineous Omani 
population in particular. Finally, novel mutations will continue to be identified as genetic 
analysis of β-thalassemia is performed at a national level.
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ABSTRACT
We report two examples showing how problematic it can be to define the phenotype of 
new or rare globin genes mutations. We describe two mutations observed for the first time 
in Omani: The first has been found in the consanguineous parents of a deceased newborn 
with hepatomegaly, cardiomegaly and severe hemolytic anemia, putative homozygous for 
the rare Hb-Lansing (α2 cd87 CAC>CAG). The second is a novel β-globin gene promoter 
mutation (-52  G>T) observed in four independent patients. Two with borderline/elevated 
HbA
2
, α-thalassemia and hypochromic red cell indices and two with HbS heterozygosis, alpha 
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INTRODUCTION
Stable and well expressed α globin chain variants have usually no clinical consequences. Those 
unstable or thalassemic, although nearly asymptomatic in the carriers, may present with a more 
severe phenotype in the homozygous state (1) or in association with α-thalassemia mutations, 
while those with abnormal oxygen affinity may lead to polycythemia, cyanosis, tissue hypoxia 
or respiratory distress (2). 
Homozygosis for rare hemoglobin (Hb) variants is rarely observed and generally in cases of 
consanguinity while combinations with thalassemia or with common variants can be found more 
frequently in endemic areas. We present the case of a newborn with hepatomegaly, cardiomegaly 
and severe hemolytic anemia who died shortly after birth. Although examination of the propositus at 
the molecular level was not possible, due to the presence of a rare Hb variant in both consanguineous 
parents, we presume that this could be the first described case of homozygosis for Hb Lansing. 
Screening couples for premarital prevention of Hemoglobinopathies is done in Oman by 
routine hematology and high-performance liquid chromatography (HPLC). The common Hb 
variants will then be putatively recognized while an elevated HbA
2
 will diagnose the β-thalassemia 
carriers. Borderline HbA
2
 measurements can, if disregarded, lead to the misdiagnosis of normal 
HbA
2
 β-thalassemia traits and further investigation at the molecular level might be necessary 
to avoid mistakes and to check for unexpected mutations. In this report, we describe the 
characterization of a novel β+ promoter determinant associated with borderline HbA
2 
found 
in four independent cases
 
and we report how the expression of the mutated allele has been 
assumed.  
MATERIAL S AND METHODS
The putative Hb Lansing homozygosity
[α87(f8)His→Gln; CAC>CAG (HBA2: c.264C4G)]
After the death of a newborn, blood was collected in EDTA from the consanguineous parents. 
A complete blood count (CBC) was performed and was analyzed by high performance liquid 
chromatography using the VARIAnT II_ (Bio-Rad Laboratories, Hercules, CA, uSA), as previously 
described (3). Genomic DnA was extracted from whole blood, using the Qiagen kit as per the 
manufacturer instructions. Alpha-globin genotype was established by GAP-PCR for the seven 




-globin genes were sequenced 
using an ABI Prism 3730 DnA sequencer (Applied Biosystems, Perkin Elmer Corporation, Foster 
City, CA, uSA) as previously described (5). Due to blood transfusion directly after birth, no HPLC 
was performed on the new born, neither was material made available for further DnA studies. 
This was the first child born to the consanguineous couple. 
The putative β+-thalassemia mutation [-52 (G>T)]
Blood was collected in EDTA during premarital screening from four independent Omani 
individuals. Hematological data were obtained from a reference Hematology laboratory. Due 
to borderline HbA
2
 values in two cases and the presence of HbS (HBB: c.20A>T) in the other two 































The infant was born after 37 weeks of gestation. The parents (first cousins) originated from 
southern Oman. Covered with a thick meconium, the newborn, presented in respiratory distress 
with low oxygen saturation (SpO
2
 < 50%). In spite of resuscitation attempts the newborn died 
shortly after birth. The clinical description was pulmonary hypertension, hypoxia, hepato- and 
cardiomegaly, multi-organ dysfunction and severe anemia. Due to urgent transfusion no blood 
was collected and no material was made available for further investigations. 
Parent’s analysis revealed normal hematology (Table 6.1) and unclear HPLC patterns 
with low HbA
2
 levels (data not shown). DnA analysis revealed none of the common alpha 
thalassemia deletions but sequencing showed heterozygosis for Hb-Lansing [α2 (F8) His>Gln 
Cd87 CAC>CAG (HBA2:c.264C>G)] in both healthy parents.
Table 6.1. Hematological and molecular data of the parents heterozygous for Hb-Lansing (SpO
2
 was not 







α- genotype ααT/αα ααT/αα
Hb (g/dl) 14.3 15.9
RBC 4.9 5.4
MCV (fl) 87.1 87.5
MCH (pg) 29 29.3
Case two 
All four cases, carriers or non-carriers of HbS, presented with low-normal Hb levels and 
microcytic hypochromic parameter which is not unusual in Oman due to the high frequency 
of α-thalassemia. The lowest Hb and MCV were measured in a male homozygous for the -α3.7 
alpha thalassemia deletion with nevertheless a borderline HbA
2
 of 3.6%. The second non-
carrier of HbS was a female heterozygous -α3.7 with a border line MCV and a slightly elevated 
HbA
2 
level of 3.9%. 
The two HbS carriers, both females and carriers of the -α3.7 deletions, presented with an 
HbS expression higher than expected for their genotype combination. Their HbA
2
 level was 
decisively elevated (4.1 and 5%) but unreliable because of the overlapping HbS1c. 
DnA analysis of the HBB gene in the two independent non HbS carriers showed a normal 
sequence except for the heterozygous state for a G→T transversion at position −52 relative to 
the Cap site (Figure 6.1). In the other 2 subjects, carriers of HbS, DnA sequencing revealed the 
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gender HbA % HbA
2









β-52/βA 4y/M 84.1 3.6 _ 1.9 10.8 58.8 18.6 -α/-α
β-52/βA 27y/F 86.6 3.9 _ 0.6 12.4 82.6 24.5 -α/αα
β-52/βS 28y/F 45.5 4.1 44.1 2 nD nD nD -α/αα
β-52/βS 20y/F 55.7 5 38.6 0.7 12.6 69.5 22.2 -α/αα
figure 6.1. DnA sequence electropherogram of the β-globin promoter region showing heterozygosity 





Figure 6.1. HPLC separation. But for the reduced HbA2 levels no evident abnormalities 
are visible on the HPLC separation of the parent’s blood.   
 
Case two:  All four cases, carriers or non-carriers of HbS, presented with low-normal Hb 
levels and microcytic hypochromic parameter which is not unusual in Oman due to the 
high frequency of -thalassemia. The lowest Hb and MCV were measured in a male 
homozygous for the -3.7 alpha thalassemia deletion with nevertheless a borderline HbA2 
of 3.6%.  The second non-carrier of HbS was a female heterozygous -3.7 with a border 
line MCV and a slightly elevated HbA2 level of 3.9%.  
     The two HbS carriers, both females and carriers of the -3.7 deletions, presented with 
an HbS expression higher than expected for their genotype combination. Their HbA2 
level was decisively elevated (4.1 and 5%) but unreliable because of the overlapping 
HbS1c.  
DNA analysis of the HBB gene in the two independent non HbS carriers showed a normal 
sequence except for the heterozygous state for a G→T transversion at position −52 
relative to the Cap site (Figure 6.2). In the other 2 subjects, carriers of HbS, DNA 
sequencing revealed the same -52 (G>T) transversion and confirmed the HbS mutations.  
Data are summarized in Table 6.2. 
 
 
Figure 6.2: DNA sequence electropherogram of the β-globin promoter region showing 




This is the first report of a presumed Hb Lansing homozygosis. In spite of the lack of a molecular 
confirmation and of the fact that the condition of the newborn could be caused by other 
unknown congenital conditions (of which we have no knowledge or evidence), we presumed 
that the phenotype we have observed could be caused by homozygosis for Hb Lansing. If this 
is indeed the case and if the variant is relatively frequent in Oman, homozygosis could account 
for other cases of unexplained neonatal mortality in the country. 
Hb Lansing, firstly reported by Sarikonda et al. as unstable but visible in carriers (6), was not 
measurable or visible in the mother and father of our propositus using routine HPLC (Figure 6.1). 
In the original description Hb Lansing was observed in a 24-year-old asymptomatic 
Hispanic man (6) with SpO
2
 of 88% and normal parameters (Hb =13.7 g/dl; HCT = 40.1%; 
reticulocyte count = 1.6%). These authors reported an abnormal fraction of 10-12% eluting “in 
front of HbA” on HPLC. Such an expression does not fit with our results and with the severe 
condition we have seen in our presumed homozygous and could be the honest report of a 
methemoglobin fraction which is regularly seen in front of HbA when running conserved 
samples on HPLC. More compatible with our observations seems to be the expression 































 (83–86 %) with the following parameters: Hb = 13.3 g/dl; HCT = 40.2 %; MCV = 87.0 fl 
and reticulocyte count = 70,000/lL (7). These authors show in their Fig. 1b the electrophoretic 
separation of Hb Lansing in which a band of approximately 1% is visible on position F in a 
further normal separation. 
The proximal histidine α87 residue (F8) anchoring the heme is critical for the molecule 
structure. Substitution of this residue is bound to cause instability and loss of function (8). 
Four other mutations have been reported at codon 87 resulting in other hemoglobin variants. 
The unstable Hemoglobin Iwata variant (His > Arg) was first identified in a healthy Japanese 
carrier with slight reticulocytosis (9). Hemoglobin M-Iwate (His > Tyr), a methemoglobin 
which decreases oxygen affinity and leads to cyanosis (10). Hemoglobin Auckland (His > Asp) 
which causes molecular instability and heme loss leading to mild hemolytic anemia (8). Finally, 
Hemoglobin Grifton (His > Pro) leading to microcytosis without clinical phenotype in the 
carrier (6). 
In our case, Hb Lansing was not disturbing the hematological parameters of the 
consanguineous parents. However, since no other explanations have been found for the 
clinical symptoms of the newborn we could assume that the infant could have inherited 2 
copies of the Hb Lansing mutation and that this genotype could be accounted for the severe 
intrauterine condition. If this is indeed the case, diagnose before conception and intrauterine 
transfusion could have kept the fetus in reasonably good conditions until birth. The question 
is how severe would have been the postnatal condition and our conjecture would be a severe 
transfusion dependent HbH disease like phenotype, similar to homozygosis for Hb Constant 
Spring (11). Mutations affecting the α
2
 gene are generally more severe as they normally account 
for approximately 2/3 of α-globin chain synthesis (12). Low SpO
2
 in healthy patients could be 
due to hemoglobin variants and care should be taken when low SpO
2
 levels are detected (13). 
Case two
Routine diagnosis of beta-thalassemia trait is based on microcytic parameters and elevated 
levels of HbA
2
 measured using dedicated high performance liquid chromatography (HPLC) or 
capillary electrophoresis (CE) devices. Although very precise, these machines are subject to 
some inevitable variability and cutoff values should never be taken for granted (14). While values 
above 4% are in general fairly diagnostic, “grey values” between 3.5 and 4% are not and need to 
be investigated further. Mutations in the promoter region of the beta globin, the evolutionary 
conserved sequences responsible for transcription regulation, have been reported to be 
associated with relatively mild forms of β-thalassemia (15, 16). These motifs includes the CACCC 
boxes at nt −105 to −101 and −90 to −86 from the cap site (17), the CCAAT box at −76 to −72, and 
the TATA box at −30 to −26. 
A common mutation on the promoter region with HbA
2
 values around 3.5% is the C>T 
transition at -101 (18). Another silent promoter mutation (-71 C>T) was recently reported in 
Omani (19) while another promoter region known as direct repeat element (DRE) has been 
suggested to play a role in β-globin transcriptional regulation and found to be an important 
regulatory element required for maximum transcription levels from the β-globin promoter in 
erythroid cells in mouse (20). The novel -52 G>T trasversion described in this paper lies within 
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have been described by Li DZ et al (−50 G→A) (21) and Irenge et al. (−42 C→G) (22). To the best 
of our knowledge the present case is the third report of a mutation in the DRE region. The 
question rises is this mutation a silent polymorphism or a mild β+ thalassemia determinant? 
Due to the presence of alpha thalassemia very common in Oman (23), this question cannot 
be easily answered looking at the hematological phenotype of the plain carriers with borderline 
HbA
2
. Conversely, looking at the two cases compound heterozygous -52 and HbS we can 
observe the specific expression of the two alleles. Then, in the presence of -α3.7 heterozygosis 
the HbS expression should be around 30-35% while it is measured between 38 and 44% in our 
cases. The last measurement in particular could indicate that the -52 mutation is not on the 
HbS allele and that at least a 10% reduction in the expression of the -52 would probably cause a 
potential >50% HbS expression in absence of α-thalassemia. Based only on these calculations, 
the clinical impact of the -52 mutation seems to be very mild. On the other hand one needs 
to see the results of a genotype combination with a βo thalassemia mutation to exclude for 
100% the risk of a (mild) thalassemia intermedia.  Moreover, it is important to mention that 
Hb S-Oman (HBB: c.[20A>T;364G>A]) is a more severe sickling double mutation on the same 
β chain, which clinically manifests as a moderate hemolytic anemia in carriers with only 20.0% 
Hb S, and that the impact of the -52 mutation in combination with Hb S-Oman could be more 
significant than a plain -52/Hb S compound heterozygosity (24).
Take home message
Although rarely observed in homozygous state, rare variants may come together in the 
progeny of consanguineous partners and one can expect to see rare variants in homozygous 
form or in combination with common variants or β and α thalassemia more often in Oman 
than elsewhere. If Hb Lansing, would appear to be relatively frequent in Oman, and if indeed, 
the presumed severe phenotype associated with homozygosis is correct, the condition could 
account for other cases of unexplained neonatal mortality in the country. 
Knowledge on the variant’s clinical implications and predicting the underlying pathology 
is important for genetic counselling but not always uncomplicated and molecular analysis for 
couples presumed at risk becomes essential if unstable variants cannot be detected at the 
hematological level. As carriers of Hb Lansing are asymptomatic and practically undetectable 
on HPLC, one should consider adding SpO
2
 to the premarital screening protocol in isolated 
communities with consanguineous traditions where Hb Lansing is known to occur. 
Likewise, one can expect mild β+ thalassemia alleles with normal or slightly elevated HbA
2
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We describe the molecular characterization of α-globin gene defects in a cohort of 634 Omani 
patients. A total of 21 different α-gene mutations were found in 484 subjects. Overall, we 
identified 3 different large deletions, 3 small deletions, 11 point mutations (2 in the poly A tail 
of α
2
 and 9 alpha-chain variants), 3 αααanti 3.7 triplication, a 21nt duplication in the α
1
 gene and 
2 novel presumed polymorphisms in the alpha 3.7kbp hybrid gene namely; -5 C>T and + 46 
C>A. Out of these defects, 15 have not been previously reported in the Omani population. This 
large heterogeneity of α-thalassemia observed in the Omani population could be expected in 
neighbouring Arab countries. The high frequency of α-thalassemia, solely or in association with 
β-globin gene defects, emphasize the necessity of adding α-thalassemia testing to pre-marital 































Alpha-thalassemia, one of the commonest autosomal recessive diseases in man, results from the 
absence of expression of one or more of the four α-globin genes and can result in phenotypes 
ranging from asymptomatic to severe or lethal hemolytic anemia (1). The majority of the 
mutations causing α-thalassemia are deletions involving one or both α-genes on chromosome 
16, leading to α+ or α0 defects respectively, being the so called rightward (−α3.7kb) deletion the 
most common worldwide (1). However, a growing number of non-deletion defects have been 
identified, being the α
2
 polyadenylation signal mutation (HBA2:c.*94A>G: AATAAA>AATAAG) 
and the α
2
 IVS-I 5-bp deletion (HBA2:c.95+2_95+6delTGAGG) the most common. These two 
mutations have already been reported in a study conducted in Oman, aimed to investigate 
the spectrum of α- thal mutations in HbH patients and in newborns showing the Hb-Bart’s 
fraction (2). However, no studies have been conducted on Omanis to determine the prevalence 
of α-thal mutations in β-hemoglobinopathy patients as well as in individuals with microcytic 
hypochromic red cell indices (low MCV and low MCH). The present work gives a more extended 
picture of the prevalence and spectrum of α-gene mutations in Omanis. Characterization of 
co-existing α-globin gene defects is essential in prevention programs as well as in tailoring 
treatment strategy.
MATERIAL S AND METHODS
Between 2010 and 2013, a cohort of 634 individuals was selected attending Ministry of Health 
Hospitals in Oman for hemoglobinopathy screening. Consent form was obtained from all 
patients through their direct clinicians. The median age was 22 years and the gender ratio 
was 58% males and 42% females. The cohort was subdivided into 7 categories (Table 7.1) based 
on their clinical and/or haematological profiles. Group 1 consisted of 487 patients with either 
β-thalassemia major, β-thalassemia minor, sickle cell trait or sickle cell disease. Group 2 counted 
93 subjects with normal HPLC readings and hypochromic microcytic red cell indices. Group 3 
consisted of 32 patients with normal HPLC and normal red cell indices. Group 4 consisted of 
11 patients with un-known peaks on HPLC and normal β-globin gene sequence. Group 5 of 5 
patients with un-explained anemia. Group 6 of 4 HbH patients and finally group 7 of only two 
patients with low HbA
2
, normal δ-globin gene sequence and normal Ferritin values. 
Blood samples were collected in EDTA, had complete blood count (CBC) and were analyzed 
on High Performance Liquid Chromatography (HPLC) using the Variant II (Bio-Rad Laboratories, 
uSA) as previously described (3). Genomic DnA was extracted from whole blood, using the 
Qiagen kit as per the manufacturer instructions. Alpha-globin genotype of the 634 cases was 
established by gap-PCR for the most common 7 alpha thalassemia deletion defects (4). Groups 




-globin genes using an ABI Prism 3730 DnA 
sequencer (Applied Biosystems, Perkin Elmer Corporation, Foster City, CA, uSA) as previously 































In addition to the expected high prevalence of deletions such as (-α3.7) and (-α4.2) (6), we found 
in group 1 an un-expected number of α-mutations interacting with β-defects. A total of 10 
defective alleles were found in this group. Three have been previously reported in the Omani 
population; the common (-5nt) deletion at the splice donor site of the α
2
-globin gene, the 
α
2
 cd19 (-G) (HBA2:c.56delG) mutation and the α
2
 polyadenylation signal mutation +94 A>G. 
The other 7, are reported for the first time in the Omani population; the αααanti 3.7 triplication, 




-globin genes in groups 1 and 2.
Table 7.1. Subdivision of the 634 subjects based on their clinical and hematological data.
Group no. of patients category
1 487 β - thalassemia minor/major, SCT or SCD
2 93 normal HPLC but with mycrocitic, hypochromic (MCV < 78fl; MCG < 26pg)
3 32 normal HPLC, normal red cell indices (MCV > 78fl; MCH >26pg) 
4 11 un-known fraction on HPLC (Hb X) with a normal β - gene sequence
5 5 un-explained anaemia, normal HPLC ,mycrocitic, hypochromic, not responding 
to iron
6 4 HbH peak on HPLC, anemic, mycrocitic, hypochromic
7 2 Low HbA
2

































 21nt duplication (+GACCCGGTCAACTTCAAGG TG) between IVS-II-3 and IVS-II-4 in a beta-
thalassemia carrier patient (MCV=75.3fl, MCH=18.9pg), the α
2
 polyadenylation signal mutation 
(HBA2:c.*92A>G), Hb Le Lamentine Cd20 CAC>CAA (HBA2:c.63C>A) in HbS carrier with 
HbX=25.8%, Hb Tatras Cd7 AAG>AAC (HBA2:c.24G>C) in another HbS carrier with HbX=12.7%, 
Hb Al Ain Cd18 GGC>GAC (HBA2:c.56G>A) in a third HbS carrier with HbX=1.5%, and finally a novel 
mutation (+46 C>A) in the poly A tail of the alpha2/alpha1 (-α3.7) hybrid gene. The haematology 
of the latter mutation is summarized later in Table 4 as the same allele was also found among 
patients from group 5.
Moreover, among group 1, 78 individuals were carriers of HbS (SCT). Thirty were 
homozygous (-α/-α) (38.5%), 24 heterozygous (-α/αα) (30.8%), 3 heterozygous for 
α-chain variants mentioned above (3.8%) and 21 normal (αα/αα) (26.9%). HbS levels in SCT 
were inversely proportional to the associated number of alpha-thalassemia genes. Average 
levels were as follows; -α/-α (HbS % »26.6), -α/αα (HbS% » 32.5), αα/αα (HbS % »37.7) 
(Table 7.2). 
Table 7.2. The effects of α-thalassemia on the average HbS% in Omani SCT individuals.
Hb S (%) MCV (fl) MCH (pg)
(-α/-α) n=30 26.6 62.8 20.9
(-α/αα) n=24 32.5 72 23.9
(αα/αα) n=21 37.7 79 26.4
In group 2, besides high percentages of (-α3.7) and (-α4.2) deletions, we found a 12 year old 
female who presented with a normal clinical picture with low MCV = 64.2fl and MCH = 19pg, 
and was found to be heterozygous for the -α3.7 deletion and hemizygous for the α
2 
Hb Dagestan 
variant Cd 60 AAG>GAG (HBA2:c.181A>G). This electrophoretically I-like variant is not associated 
with any clinical symptoms or haemoglobin instability in the carrier state.
In group 3, although patients had a normal haematological data, 43.75% and 6.25% of the 
patients were carrier of the (-α3.7) and (-α4.2) deletions respectively. 
In group 4, we report the identification of 6 alpha-variant alleles that are reported for the 
first time in Omani. Two of these variants have been also observed in two HbS carriers from 
group 1. The variants detected were; the α
2
 Hb Fontainebleau Cd21 GCT>CCT (HBA2:c.64G>C), 
α
2 
Hb-Tatras Cd7 AAG>AAC, α
2 
Hb Al-Ain Abu Dhabi Cd18 GGC>GAC, α
1 
Hb Evanston Cd14 
TGG>CGG (HBA1:c.43T>C), α
2 
Hb Constant Spring Cd142 TAA>CAA (HBA2:c.427T>C) and the α
2 
Hb J-Paris-I Cd12 GCC>GAC (HBA2:c.38C>A) (Table 7.3).
We found a new single nucleotide substitution in the 3’ PolyA tail (+46 C>A) on the (α-3.7) 
alpha2 alpha1 hybrid gene in homozygous state (-α3.7 (+46 C>A)/ -α3.7 (+46 C>A)) in 4 anaemic patients 
from group 5. This allele was also observed in heterozygous state in 3 patients from group 1 
(-α3.7 (+46 C>A)/αα). Among group 5, two patients had borderline ferritin values and were treated 






























Table 7.3. Hematological data of group 4 with Hb alpha chain variants.





/αα HBA2:c.64G>C 1.1 8.7 60.2 18.7
1.2 5.8 82.2 26.5
    1.3 11.6 69.7 20.7




HBA2:c.64G>C 2.1 9.8 57.2 16.5





/αα HBA2:c.24G>C 3.1 19.7 70.6 24.2
    3.2 12.7 73.3 24.2




HBA2:c.56G>A 4.1 22.2 78.4 24.2






























8.1 36.7 82.9 25.2
Table 7.4. Hematological findings of the 3’ PolyA tail (+46 C>A) cases found in the alpha2/alpha1 3.7 hybrid 



















2y 4.3 8.8 55.1 16.5 normal mild anemia
1.2 HBB:c.92+5G 
>C (HR)
1y 5.9 9.2 56.5 18.2 normal mild anemia
  1.3 HBB:c.93-21_ 
96del (HR)
7y 6.1 10.4 57.6 18.1 not 
done
mild anemia
2. -α3.7 (+46 C>A)/ 
-α3.7 (+46 C>A)




2.2 normal 15y 1.8 9.2 57.6 18.7 normal anemia










3. -α3.7 (-5 C>T)/  
-α3.7




































Cd38/39(-ACC) genotype in a patient 
with a mild anaemia (Hb=6.8, MCV=66.8 and MCH=22.5). We believe that this is the first study 
reporting the α
1
 Hb Taybe Cd38/39 –ACC (HBA1:c.118_120delACC) deletion allele in Omani. 
In group 6, 4 HbH genotypes were identified, three genotypes in a combination that has 




 genotype which is 
observed for the first time in a patient from northern Oman (Khasab). 
Among group 7, we characterized two single nucleotide substitutions, one in the 5’ promoter 
(-5 C>T) in the alpha2/alpha1 hybrid gene which was found in heterozygous form in a patient 
with homozygous α-3.7kbp deletion (-α3.7 (-5 C>T)/-α3.7). The patient presented with hypochromic 




and normal ferritin value. The 
second, in a patient homozygous for Hb Icaria variant Cd142 TAA>AAA (HBA2:c.427T>A) with low 
HbA
2 
(1.6%) and microcytic hypochromic (MCV=76.3fl, MCH=24pg). The first mutation could be 
a novel thalassemia defect down regulating the hybrid gene and the second is described for 
the first time in Oman. 
Mutations found in all groups are summarized in Table 7.5.
Table 7.5. Summary of the spectrum of alpha-globin genotypes found in our cohort subdivided into 













Group 1 (n = 487) -α 3.7/-α 3.7 171 35.1
β-hemoglobinopathies -α 3.7/-αα 145 29.8
-α 3.7/-α 4.2 10 2.1
-α 4.2/-αα 10 2.1
αααanti 3.7 /αα 3 0.6






































 +94 A>G α
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Table 7.5. Summary of the spectrum of alpha-globin genotypes found in our cohort subdivided into 













Group 2 (n = 93) -α 3.7/-α 3.7 72 77.4
normal HPLC, -α 3.7/-αα 17 18.3
hypochromic, mycrocytic -α 3.7/-α 4.2 3 3.2





Group 3 (n = 32) -α 3.7/-αα 14 43.75
normal HPLC, -α 4.2/-αα 2 6.25
normal red cell indices αα/αα   16 50




/αα HBA2:c.64G>C 3 27.2










































Group 5 (n = 5) -α3.7(+46 C>A)*/-α3.7 (+46 C>A)* 4 80




Cd38/39 (-ACC) HBA1:c.118_120delACC 1 20



















  -α3.7/ -αMedI   1 25
Group 7 (n =2) -α3.7 (-5 C>T)*/ -α3.7 1 50
low HbA
2











The broad range of α-thalassemia defects identified in the current study, demonstrate that 
the heterogenic pattern prevalent in Oman is similar to that reported in Saudi (7). This can be 
accounted to gene-flow within the nomadic populations of the Arab peninsula and to the past 
trade with other countries as well as to the past Portuguese domination in Oman. A total of 21 
different α-gene defects have been reported in this study. Six defects have been previously 
identified in the Omani population (2,6,8). These include the most common α3.7, α4.2 and --MEDI 






























polyadenylation signal site (+94 A>G) point mutation of the α2 globin gene affecting the RnA 
transcription termination (9) and the point deletion Cd19 (-G) which was first reported in the 
Iranian population, resulting in premature termination of the α-globin chain (5). 
The majority of our cohort carried the large α3.7 deletion either in homozygous or 
heterozygous states followed by α4.2 and a minority consisted of α-small deletions or point 
mutations including Hb-variants. In one patient, a 21nt duplication was identified which most 
probably arose as a consequence of homologous crossing over between the two alpha-1 globin 
genes. Although the original splice donor site remains intact but having two sites might result 
in the mutant allele using most times the original one and sometimes the other one resulted 
from the duplication which is located in the intron creating an instable mRnA due to nonsense 
mediated decay. This might also explain why having this mutation appears very mild.
Among group 1, an important remark is made with respect to genetic counselling on one 
hand and the alpha spectrum on the other hand is when the group of beta-thalassemia carriers 
or sickle cell trait couples are counselled for a beta-thalassemia major or sickle cell disease 
in the offspring overlooking an important alpha-thalassemia mutation that can result in a 
severe HbH disease in the offspring in combination with an alpha zero-thalassemia carrier that 
can go ‘unnoticed’ by only looking at the beta-thalassemia parameters and not to the alpha-
thalassemia mutation spectrum. 









 followed by -α3.7/--MED (2). We found the same two genotypes 









The latter has been previously reported in an Omani family study (8).
It is not clear to which extent the homozygous mutation -α3.7(+46 C>A)/ -α3.7(+46 C>A) found in 
four patients in group 5, with haemolytic anaemia, might affect the phenotype by reducing the 
expression of the -α3.7 gene. If the same -α3.7(+46 C>A) allele reported by Alkindi’s in 4 HbH patients 
with -α3.7(+46 C>A)/-α3.7 genotype (2) would suggest a total expression failure, then our homozygous 
case should have been lethal hydrops foetalis, which was not the case. Hb H disease is the only 
intermediate form of α-thalassemia compatible with postnatal life and the clinical severity of 
the disease is associated with the type of mutation (1). The typical genotype of Hb H disease 
results from the loss of three functional genes due to large deletions. Less frequently, more 
severe combinations of α° deletion defects with point mutations such as Hb Constant Spring 
or other similar defects, while less severe HbH forms may arise from combinations with poly 
A signal mutations (10). However, a point mutation on the -α3.7 hybrid might down regulate or 
disrupt the allele expression causing severe forms. The risk of developing anaemia in case of 
homozygous + 46 C>A on the alpha2/alpha1 hybrid gene highlights the importance of screening 
for α-thalassemia defects by molecular analysis rather than by routine blood count alone which 
is based on detecting hypochromic microcytic red cell indices.
Although not always clear, we have provided additional evidence that besides cases with 
delta thalassemia or consistent iron deficiency, a reduction in HbA
2
 level can be associated with 
α-thalassemia as shown for the novel -5C>T allele in the -α3.7(-5C>T)/ -α3.7 genotype. Therefore, in 
patients originating from areas where haemoglobinopathies are common, it is necessary to 
perform molecular tests to clearly differentiate between iron deficiency and alpha- or delta- 






























In conclusion, four α-thalassaemia categories were recognized in this cohort: the silent 
carrier, the alpha-thalassemia trait, the α -variant and the anaemic form of Hb H disease. 
Moreover, we have shown that 40% of the α-alleles were normal while 56% of the alpha 
thalassemia alleles studied were large α-thalassemia deletion and 4% non-large deletions/
point α-thalassemia mutations. The consistent occurrence of point mutations could represent 
a risk factor for severe haemolytic anaemia in combination with large deletions (11). The + 46 
C>A on the alpha2/alpha1 hybrid gene might be a candidate mutation since it is associated with 
anaemia, however larger number of genotype/phenotype correlation studies should be carried 
out to confirm our findings. Identifying the α-globin gene spectrum is not only clinically 
important but also fundamental for a better genetic counselling.
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Although delta thalassemia is not categorised as a severe disease, it is essential to know the 
molecular spectrum of the delta gene mutations frequently occurring in specific areas in 
particular if these areas are characterized by a high rate of beta thalassemia such as Oman. 
This is because co-inherited delta globin gene defects can interfere with the basic diagnosis of 
β-thalassemia carrier when this is based upon the measurement of the HbA
2
 only. For that, we 
have investigated 33 patients with low HbA
2
 levels collected from different hospitals in Oman. 
Some cases had a second HbA
2
 fraction, while others had only significantly lower HbA
2
 levels. 
Among these patients, 20 did carry a δ-globin gene mutation, the rest were carrier of alpha 
thalassemia defects or could be iron depleted or both. In total, eight different known mutations 
and 2 novel delta determinants were found. The characterization of the δ-gene mutation 
spectrum will improve carrier diagnostics and genetic counseling in the Omani population 























After the age of two, postnatal haemoglobin A (HbA) is the major haemoglobin component 
of the red cells. Besides HbA and in normal conditions, about (2.5-3.5%) of the haemoglobin 




) while traces of HbF (<1%) will present in adult life 
(1). Mutations that occur in the δ-globin gene (HBD, MIM# 142000) can affect the structure or 
the expression of the delta globin chain as it is the case for all other globin genes. Structural 
defects, if stable, will produce a second and usually visible Hb A
2
 fraction (2). If unstable, the 
mutation will behave as a thalassemic defect and be undetectable using basic methods such 
as high performance liquid chromatography (HPLC) or capillary electrophoresis (CE). Thus, 
DnA analysis will be required to differentiate between low Hb A
2
 due to iron deficiency, alpha-
thalassemia or delta gene defects (3). If a person is heterozygous for a δ-globin gene defect, an 
abnormal Hb A
2
 and/or a reduction in the Hb A
2
 level will be measured. It is important to identify 
the presence of delta gene defects, particularly during first level beta thalassemia diagnostics 
(screening) for the identification of couples at risk of getting a child with a severe disease. This 
is because a delta defect can mask the presence of beta thalassemia trait. The co-existence 
of a delta gene defect will decrease the HbA
2
 level of the beta thalassemia carrier to a normal 
range, and microcytosis could be attributed to alpha thalassemia which is very frequent in many 
countries and particularly in Oman (6). This could compromise the basic diagnosis of beta 
thalassemia trait during genetic counseling. For that, it is essential to be aware of the existence 
of delta gene defects for diagnostic purposes. In this study, we present the occurrence of 
common, rare and new delta gene mutations in a cohort of independent Omani patients.
MATERIAL AND METHODS
Out of a total of approximately 3,400 individuals, we have selected 33 independent cases 
attending our clinics for haemoglobinopathy screening. All cases were of Omani ethnicity. The 
age average was 31 and the gender was 60% females and 40% males. Samples were selected 
upon giving a low value of Hb A
2
 (<1.9%) and/or showing second Hb A
2
 fractions. Measurements 
were done using High Performance Liquid Chromatography (HPLC) on the Variant II (Bio-Rad 
Laboratories, uSA) as previously described (4). DnA was extracted from whole blood, using 
the Qiagen kit as per the manufacturer instructions. Polymerase Chain reaction was performed 
as previously reported (5). The PCR products were sequenced using an ABI Prism 3730 DnA 
sequencer (Applied Biosystems, Perkin Elmer Corporation, Foster City, CA, uSA). Iron status 
was not performed in all samples as it is not a mandatory test in Oman. Beta and alpha gene 
defects were examined at the molecular level as previously described (6).
RESULTS
Out of the 33 cases selected, 20 were found to either carry a known and/or a novel delta-globin 
gene mutation revealing a frequency of at least 60% in the selected group and of at least 0.6% 






















The 2 novel mutations:
Cd147 TGA>TTA
This new mutation (HBD: c.443 G>T) resides in the stop codon of the delta gene and was found in 
one patient with 1.8% Hb A
2
 (Figure 8.1a). The mutation results in an elongation of the transcript 
with 15 extra amino acids before reaching the new stop codon (TAG). 
Cd110-Cd111 (+GT)
Another new delta-thalassemia mutation (HBD c.333-334 insGT) was found in a patient with 
1.5% Hb A
2
. The mutation involves an insertion of 2 nucleotides (+GT) between condon 110 and 
codon 111 (Figure 8.1b). The outcome of this insertion is a frameshift with a new stop codon 
(TAG), 102 amino acids beyond the insertion site. All data are summarized in Table 8.1.









1 2.1 1.5 Cd16 GGC>CGC c.49G>C αα/αα
2 1.3 1.2 Cd16 GGC>CGC c.49G>C –α/–α
3 1.5 1.4 Cd16 GGC>CGC c.49G>C –α/αα
4 1.7 1.1 Cd16 GGC>CGC c.49G>C αα/αα
5 1.5 1.0 Cd16 GGC>CGC c.49G>C –α/–α
6 1.3 Cd116 CGC>CAC c.350G>A –α/αα
7 1.6 Cd116 CGC>CAC c.350G>A αα/αα
8 1.4 Cd116 CGC>CAC c.350G>A –α/αα
9 1.7 Cd27 GCC>TCC c.82G>T –α/–α
10 1.6 Cd27 GCC>TCC c.82G>T –α/αα
11 0.6 Cd27 GCC>TCC/ 
IVS-I-128 G>C
c.82G>T/c.93-1 G>C –α/αα
12 1.2 Cd136 GGT>GAT c.410G>A –α/–α
13 1.3 Cd136 GGT>GAT c.410G>A –α/–α
14 1.9 – 68 C>T c.-118C>T –α/αα
15 5.1 1.7 – 68 C>T c.-118C>T –α/–α HBB:c.20A>T/ 
c.92+5G>C
16 1.3 Cd4 ACT>ATT c.14C>T –α/αα
17 1.6 IVS-I-128 G>C c.93-1 G>C –α/αα
18 4.4 Cd100 CCT>TCT c.301 C>T –α/–α HBB:c.+108_ 
+112delAATAA
19 1.8 Cd147 TGA>TTA* c.443 G>T –α/–α






















Out of these 33 cases, 16 had the (-α/-α) genotype, 13 had the (-α/ αα) genotype and only 
4 cases were normal for the alpha genes. In 13 cases, no association was found between low Hb 
A
2
 levels and delta-globin mutations.
DISCUSSION
Delta-gene defect were found in 73.3% of the cases with low or abnormal Hb A
2
 separation while 
in 13 out of 33 individuals, no association was found between the low Hb A
2
 levels and mutations 
in the delta-globin gene. Iron deficiency and/or alpha thalassemia can cause a reduction in the 
normal Hb A
2
 level while lower amount of total hemoglobin loaded on the HPLC column can 
also be accounted for artifacts (3).
Hb A2’ or HbB2 
Hb A
2
’ is stable and produces a second Hb A
2
 peak and is mainly found in Africans (7). This 
mutation could have arrived to Oman by gene flow due to the past trading contact between 
Oman and Zanzibar. In one case, this delta variant was linked to codon 97 (HBD:c.294C>T) 
with a neutral change of the amino acids (His>His). This neutral polymorphism was previously 




















































Hb A2 – Coburg 
The Hb A
2
 Coburg peak cannot be detected on HPLC because it co-migrates in the tail of HbA 
(9). This variant has been described in Sicilian families in trans to a beta thalassemia allele, 
reducing the Hb A
2
 level to normal (10). Due to the Arab domination in Sicily, the mutation 
could be of African origin. 
Hb A2 – yialousa
Hb A
2
-Yialousa is the most frequent delta-globin mutation in the Mediterranean area, probably 
indicating a common South European origin (11). Being Hb A
2
-Yialousa one of the common 
delta defects found in the Portuguese (12), the presence of the mutation in Omanies could be 
associated with the history of the Portuguese domination in Oman (1507 – 1650) (13). 
Hb A2 – Babinga 
HbA2-Babinga was primarily described in Babinga pygmies living in the Central African Republic 
and other African populations (14) and it could be compatible with the African ancestry of 
Omani tribes. A homology of this defect was also found in the beta globin gene (Hb Hope, 
β136 Gly>Asp) (15). We have found this mutation in 2 individuals from the northern part of the 
country. These patients were anemic, presenting with low Hb A
2 
levels (1.2 and 1.3% respectively) 
and had a normal iron profile. 
5’UTR (- 68 C>T)
The delta-thalassemia promoter defect (HBD c.-118C>T, -68 C>T), has no homology to the 
β-globin gene (5) but the CCAAT sequence residing in the β-globin gene promoter is considered 
to be a regulatory element, critical for the correct initiation and high level of transcription in the 
globin genes (16). Therefore, the δ (CCAAC to CCAAT) mutation can be considered responsible 
for the lower transcription level of the δ -globin gene.
Cd4 ACT>ATT
The nucleotide change C to T at the second position of codon 4 resulting in a Thr > Ile single 
amino acid substitution was first described in a Greek patient (8). The variant is unstable and 
behaves as a thalassemic defect with a low Hb A
2
 value (1.3%) slightly lower than what was found 
in the Greek patient (1.4%) (8), possibly due to the coexisting heterozygous -α 3.7 deletion in our 
patient.
(δo): IVS-I-128 G>C
A 59-year-old male from Muscat, showed a very low Hb A
2
 value (0.6%). Sequencing of the 
δ-globin gene revealed compound heterozygosis for two different mutations: The known 
A
2
 Yialousa (HBD c.82G>T) and IVS-I-128 G>C (HBD: c.93-1 G>C). We believe that the IVS-I-128 
mutation reduces or nearly abolish the efficiency of the 3’ splicing site, leading to a deficiency 
in mRnA production. Compound heterozygosis for delta globin gene defects with very low Hb 
A
2
 values observed in our patient have been reported in few cases. Amirian et al. reported a 
patient from Iran with two delta defects (HBD:c.92+5G>T and c.428C>A) with 0.6% Hb A
2
 (17). We 
found the δo IVS-I-128 mutation also solely in another patient with Hb A
2























We have observed this recently reported delta variant (HBD c.301 C>T ) with a Serine 
substituting a Proline in a single patient who was also a carriers of a beta thalassemia mutation 
(HBB:c.110_114del) This delta mutation was recently published by Colaco et al. as Hb A
2
-
Saurashtra (20) and was found in cis with (HBB:c.110_114del). This is the same beta-thalassemia 
mutation found in the present paper, indicating that the HBD:c.301C>T and HBB:c.110_114del 
mutations may also be in cis.
(δo): Cd147 TGA>TTA
This novel δ-stop codon mutation (Cd147 TGA>TTA) results in an elongation of the transcript 
with 15 additional amino acids, stopping at the 16th codon (TAG). . The elongated chain is 
unsuitable for functional tetramer formation and is probably proteolysed.
(δo): Cd110-Cd111 (+GT)
Finally, the last sample showed a novel insertion of two nucleotides between codon 110 and 
codon 111 in exon 3 of the delta globin gene. The frame shift results in an elongated sequence 
with a new stop codon (TAG) 102 amino acids further from the insertion site. This mutation 
could also be the result of a duplication event as the region is characterized by a nucleotide 
repeat of (GTGTGTGT). 
CONCLUSIONS
We have shown that lower Hb A
2
 levels are often associated with δ-globin gene defects that may 
compromise screening for β-thalassemia trait when the diagnosis is based on the Hb A
2
 level 
solely. Moreover, low levels of Hb A
2
 can also be due to iron deficiency and/or alpha thalassemia 
due to preferential binding of the erythroid elements (3). The latter was observed in the 13 
samples that had a normal delta- gene sequence. Hb A
2
 levels can be moderately lowered in 
patient with iron deficiency due to the preferential binding of the heme to the beta and alpha 
chains rather than to delta chains (18). 
Our results show that δ gene mutations are present in Oman at a considerable frequency 
and that attention should be paid during haemoglobinpathy screening to not miss beta 
thalassemia carriers. Double Hb A
2
 fractions must be summed up to calculate the real Hb A
2
 
level. Samples with low Hb A
2
 and microcytosis should always be checked for iron depletion 
before checking the alpha genotype and the δ and β globin genes sequences. Eventually, 
loading a more concentrated sample on HPLC is advisable when an unstable δ-globin gene 
variant is suspected (19). It should also be noted that in δβ-thalassemia deletions, the level of 
Hb F is usually raised while the level of Hb A
2
 will remain normal. Only in solely δ-thalassemia 
cases, the Hb F level will stay normal (17).
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Despite the fact that patients homozygous for the sickle cell disease (SCD) mutation have an 
identical genotype, the severity of the disease can be extremely variable. The HbS mutation has 
been described on five different haplotypes with different clinical expression. Identifying the 
genotypes, haplotypes and sub-haplotypes of the β gene cluster in Oman needs to be studied 
in more details to establish a correlation between the genotype/haplotype and phenotype 
diversity observed in SCD patients for prognostic purposes, accurate diagnosis and thus 
planning for the best tailored treatment. 
Methods
We have investigated 125 HbS homozygotes from different parts of Oman and determined 
their haplotypes and sub-haplotypes and correlated this to the hematological and clinical 
expression. 
Results
We have found 11 haplotype combinations differently distributed in the country. The Asian/
Asian HbS haplotype was the most predominant (37.6%) and was associated with a milder 
disease. The Benin/Benin came second (20.0%) and was associated with a more severe 
condition. A new haplotype, in combination with Asian, which we called Asian/OmanI was the 
third most common (11.2%), CAR/CAR (10.4%) and CAR/OmanI were fourth (10.4%) and CAR/
Asian fifth (6.4%). Other haplotype combinations were found at a lower frequency (4%). In 
patients with CAR/OmanI haplotype, 3 different sub-haplotypes were found. As expected, the 
correlation between haplotypes, sub-haplotypes and disease severity was mainly associated 
with HbF expression.
Conclusion
Our study on haplotype/phenotype correlation has shown which major haplotypes occur in the 
different regions of Oman. Furthermore, neither the haplotype or sub-haplotype nor the HbF 
alone appeared to be fully associable with the variable clinical phenotypes. External factors do 
































Sickle cell disease (SCD) is one of the most common autosomal recessive disorder in human and 
was first described by Herrick in 1910 (1). The disease is caused by a single nucleotide transversion 
at codon 6 GAG>GTG (HBB:c.20A>T) (nM_000518.4) of the beta globin gene resulting into the 
commonest haemoglobin variant worldwide (HbS) characterized by the single Glu®Val amino 
acid substitution at position β6 (2). Despite the fact that all patients homozygous for the HbS allele 
have an identical genotype, the severity of the disease can be extremely variable among affected 
subjects (3). The disease may manifest with full blow severity, with chronic and acute infarctions in 
organs and tissues causing excruciating pain episodes (crisis), brain infarctions, splenic infarction, 
massive hemolytic events and acute chest syndrome with risk of premature death. Other cases 
however, may present with milder symptoms and the variability is mainly associated with the 
haplotype, sub-haplotype, alpha thalassemia (4) and the presence of fetal hemoglobin (HbF) 
(α2γ2) (8) which may be attributed to the coinheritance of Xmn-I polymorphism. This marker is 
important for early prevention or reduction of morbidity in SCD patients treated with hydroxyurea 
therapy (10) or to decide whether or not bone marrow transplantation should be considered (11).
The HbS mutation has been described on five distinct haplotypes based on the presence 
or absence of the 5 different restriction enzyme sites in the beta-globin gene cluster located 
on the 5’ and two restriction enzyme sites on the 3’ sides of the beta gene. These haplotypes 
are known as Benin, Bantu or Central African Republic (CAR), Senegal, Cameroon and Asian 
(5). The first four are African haplotypes, named after their origin and ethnic group (6) while 
the last was described in Central India and Saudi Arabia (7). It has been previously reported 
that the CAR haplotype is usually associated with a more severe disease when compared with 
the intermediate phenotype of the Benin haplotype and to the milder conditions associated 
with the Senegal and Asian haplotypes (9). Therefore, analysis of the polymorphic sites of the 
β  genes cluster is of genetic, anthropologic and clinical interest, and it can also be used to 
predict the prognosis of the disease and to plan a tailored treatment. 
The work reported here involves the investigation of a serial of polymorphic sites (SnP’s) 
within the beta globin gene cluster to identify the HbS haplotype of Omani patients. For this, 
we have selected 125 Omani SCD patients with homozygous HbS conditions and compared 
their haplotype with haematological and clinical data. Moreover, to look if there are any sub-
haplotypes within each known haplotype that might be associated with the clinical differences 
seen in patients with the same HbS haplotype, extra SnP’s, in addition to the common ones have 
been studied. Looking for correlations with the clinical phenotypes, we have also charted the 
distribution of the beta gene haplotypes in different regions of the country and characterized 
the different haplotypes and sub-haplotypes using advanced molecular technologies
MATERIAL S & METHODS
Subjects
We have collected, with signed consent of patients and families, EDTA blood samples from a 
cohort of 125 SCD patients, whether admitted or following up in one of the Ministry of Health 
Hospitals in Oman. Gender distribution was; 84 males (45%) and 103 females (55%). The age of 






































































































Cation-exchange high performance liquid chromatography (HPLC) was performed on all 
samples on either D-10 (short and extended programs) device and/or Variant II (Bio-Rad 
Laboratories, Hercules, CA, uSA) to measure the rate of HbF/HbS (12) in absence or before 
blood transfusion. DnA was extracted using the Qiagen kit according to the manufacturer 
instruction as previously described (13). 47 SnP’s, covering 13 sites in the β-globin gene cluster 
that are known to be variable and informative were analysed (Figure 9.1). This was carried out 
by an asymmetric PCR (31) and analysed by melting curve analysis (MCA) (14). The common 
haplotyping of the β-globin gene cluster was determined according to the presence (+) or 
absence (-) of a composition of single nucleotide polymorphisms (SnP’s) corresponding to the 
traditional five 5’ known polymorphic restriction endonuclease sites (F1, F2 (SnP 2), F3 (SnP 2), F4 
and F5) (31). The remaining 42 SnP’s were used to look for sub-haplotypes to find out if there are 
nucleotide variations within similar haplotypes that might be associated with the phenotypical 
differences observed. F1 contains 1  SnP in the 5’ region of the ε-gene. The preGframe in the 
5’ region of the Gγ-gene contains 5 SnPs that are linked and only occur in a limited number 
of combinations. The promoter regions of the γ-genes; promGγ and promAγ contain 10 SnPs 
each, among which are the non-deletional HPFH point mutations. Also among the Gγ promoter 
is the Xmn-I site which is known to cause continued expression of HbF during adult life in case 
of erythropoietic stress. F2, in intron 2 of the Gγ-gene, and F3, in intron 2 of the Aγ-gene both 
contain 4 SnPs. F4 contains 1 SnP in the pseudo β-gene. F5 contains 1 SnP in the 3’ region of the 
pseudo β-gene. F6 contains 1 SnP in the 3’ region of the δ-gene. The voBRsa1 fragment in the 





repeat located after SnP 1 that includes SnP 2. The β-frame in the β-gene contains 3 linked SnPs 
that only occur in a limited number of combinations. The naBHpa1 fragment in the 3’ region of 
the β-gene contains 1 SnP. F7 in the 3’ region of the β-gene contains 1 SnP.
figure 9.1. Schematic representation of the β-globin gene cluster. The arrows indicate the locations 
of the 13 different regions that contain the 47 SnPs, including the 5 sites screened for the traditional 
haplotypes. In addition, the XmnI site has also been indicated in the figure.
Genotyping procedures
Genotypes of PCR products were determined using the Light Scanner, (Idaho Technologies 































oligonucleotide probes (31). The PCR was performed asymmetrically so that the strand 
complementary to the probe is produced in excess, allowing probe annealing at the SnP site. 
The primers were designed to yield a product not larger than 200bp as it is the optimal length for 
accurate scanning and genotyping with MCA. A fluorescent dye (LC Green plus) that emits light in 
the presence of double stranded DnA was added to the reaction and as the temperature increases, 
the fluorescence decreases as the dsDnA melts out; this produces a characteristic melting curve 
(15). unlabelled oligonucleotide probes were designed and used to genotype targeted sequence 
variations. These probes increases specificity of the melting reaction as it decreases the size of the 
product that is melted. Therefore, the probe is designed to anneal to either the wild type or the 
mutant allele; the characteristic melting curves identify the genotype of each sample (15). 
The shape of the PCR amplicon melting curve reveals the presence or absence of the SnP 
in comparison to the wild type sequence, allowing clear recognition and genotyping (14). The 
haplotype/sub-haplotype is then drawn from the obtained genotypes. In case of homozygosity 
for all markers, the haplotype can be defined. In the case of a single SnP difference, two distinct 
haplotypes can be defined. In case of two or more SnP differences, the most likely/frequent 
haplotype in the population is defined. SnP’s that were doubtful were sequenced by Sanger 
sequencing for confirmation. 
Phenotype Classification
In order to define disease severity, a number of well-defined clinical parameters were 
analyzed: hemoglobin level, frequency of transfusion which is based on episodes of acute 
hemolysis (e.g pulmonary hypertension, jaundice, gallstones, splenic crisis), number of annual 
hospitalization, frequency of painful crises, splenectomy (indicated by acute splenic sequestration 
and chronic hypersplenism), acute chest syndrome (ACS), body pain (e.g  abdomen, chest, 
bones, joints, episode of dactylitis) and records of any major organ damage such as heart and 
liver (Table 9.1).
The severity of disease expression was then correlated with the haplotype and hematological 
parameter readings of HbF and HbS.
Table 9.1. Classification criteria for the 125 homozygous HbS/S patients to assess SCD severity into mild, 
intermediate and severe.







Haemoglobin level ↑ 9.1 ↓ 8.5 ↓ 8
Transfusions/haemapheresis not required Occasional Frequent
Hospitalizations per year 1 - 2 2 - 4 > 5
Crisis frequency ↓ 3 per year ↑ 3 per year ↑ 6 per year
Splenectomy Yes Yes Yes
Acute Chest Syndrome (ACS) no no Yes
Body Pain mild moderate intense
































Determination of Genotypes and Haplotypes
A total of 125 selected patients with SCD that were found to be homozygous for HbS were 
studied for their β-gene cluster haplotype. The 250 chromosomes from the 125 patients with 
identical homozygous HbS/S genotype showed 11 different haplotype combinations that were 
defined by melting curve analysis. The homozygous Asian haplotype was the most predominant 
(37.6%). The second most prevalent was the homozygous Benin haplotype (20.0%). The 
remaining haplotypes were distributed as follow: compound heterozygous Asian/OmanI 
(11.2%), homozygous CAR (10.4%), compound heterozygous CAR/OmanI (10.4%), CAR/Asian 
(6.4%), homozygous OmanI (0.8%), compound heterozygous of Senegal/OmanI (0.8%), Benin/
OmanII (0.8%), Benin/OmanIII (0.8%) and finally Asian/OmanIV (0.8%). Data are summarized 
in Table 9.2.
Clinical severity
The phenotypes of the patients were classified into mild, intermediate and severe based on the 
described criteria (Table 9.1). Data were obtained from patient’s medical records anonymously 
provided by the doctor. Among the Asian/Asian haplotype, mostly were presented with a 
mild disease and none with a severe form. Conversely, Benin/Benin ranged from severe to 
intermediate while none presented with the mild form. Among the Asian/OmanI haplotype, 
the percentage was equal between mild and intermediate. The majority of homozygous CAR 
and compound heterozygous CAR/OmanI beta cluster had a severe clinical profile. Finally, the 
phenotype of Asian/CAR haplotype ranged from mild to intermediate and even severe cases. 
Data are summarized in Table 9.2. 
Hematological data
The Hb F value correlates with the different haplotypes, giving a direct indication of the 
disease severity. The average hemoglobin values, HbF and HbS percentage of each haplotype 
are summarized in Table 9.3. The Asian haplotype, being associated with a mild phenotype, 
presented with the highest expression of HbF% and the lowest HbS% when compared to the 
other haplotypes. Patients with Asian/OmanI haplotype had a mild to intermediate phenotype. 
This can be attributed to the elevated expression of HbF% (Table 3). Conversely, the homozygous 
CAR and compound heterozygous CAR/OmanI haplotypes had the most severe clinical picture 
with the lowest Hb F values (Table 3).
Table 9.3. Summary of hematological data (average) for each haplotype
Asian/Asian Benin/Benin Asian/OmanI CAR/CAR CAR/OmanI CAR/Asian
Hb g/dl 9.5 ±1.3 9.3 ±1.7 10.3 ±1.9 7.5 ±1.1 8.7 ±1.2 9.1 ±1.4
Hbf % 18.2% ±5.9 6% ±3.1 14.2% ±5.5 5.9% ±4.9 5% ±3.5 12.6% ±5.4















































































































































































































































































































































































































































































































































































































































































































































figure 9.2. The geographical distribution of the β globin gene cluster haplotypes within Oman.
Geographical distribution
The overall distribution of each haplotype in our SCD patients in the different regions of 
Oman is presented in percentages in Table 9.4. The occurrence frequency of each haplotype 
in a particular region is depicted in Figure 9.2. In Musandam, CAR/Asian is the only haplotype 
found. In Batinah, Asian/OmanI is the most abundant. In Muscat, CAR/OmanI is found at the 
highest frequency and in Sharqiya, the Asian haplotype was the most prevalent. In Dhakhiliya, 
Benin was the major haplotype found and finally in Dhahira, the CAR haplotype was the most 
prominent. Data are summarized in Figure 9.2.
Sub-haplotypes
Based on additional SnP’s, a subdivision could be made from the original five HbS haplotypes. Trying 
to find a molecular explanation for the different phenotypes seen within similar basic haplotypes, 
sub-haplotypes were determined by looking at a total of 42 SnP’s in all the125 homozygous HbS 
patients. Out of the 42 SnP’s, only 15 SnP’s were found modifying the 11 identified haplotypes. 
However, no sub-haplotypes were found to be associated with a specific haplotype except for the 































located in the G-gamma promoter region from which three different sub-haplotypes were 
defined (a,b and c) (Table 9.5). This site might be associated with the different clinical expression 
observed in CAR/OmanI patients. The patient with sub haplotype (CAR/OmanI - c) presented 
with a very severe clinical manifestations and no improvement was seen even after doubling the 
dosage of hydroxyurea. This patient appears to be homozygous for the wild type 6 nucleotides 
(CTTTAA) at the G-gamma promoter. On the other hand, another patient with sub haplotype 
(CAR/OmanI - b) was homozygous for the deletional mutation of the 6 nucleotides at the same 
position and had a milder clinical presentation and was not taking hydroxyurea consistently as the 
patient was feeling better after a short period of being on the drug. The remaining patients with 
sub-haplotypes (CAR/OmanI – a) had the compound heterozygous composition of CTTAA/6nt 
del at the G-gamma promoter region, needed higher than the average dose of hydroxyurea in 
order to observe a reduction of the severe phenotype. Although more case studies are needed to 
confirm our hypothesis, our data allow us to assume that carrying the 6 nucleotide deletion might 
be beneficial to CAR/OmanI patients for better response to hydroxyurea.
Table 9.5. The different genotypes observed at the G-gamma promoter (SnP1) among CAR/OmanI 
patients, suggesting the existence of three different sub-haplotypes (a,b and c).
CAR/OmanI sub-haplotype Gγ(1) No. of patients Response to HU 
a CTTTAA/6nt del 11 Mild 
b 6nt del/6nt del 1 Positive 
c CTTTAA/CTTTAA 1 none 
Hydroxyurea (preliminary data)
The clinical symptoms in severely affected patients that were put on hydroxyurea therapy 
improved in general but at different levels. As mentioned above, only in patients with CAR/
OmanI haplotype, the drug dosage had to be doubled to see some improvements in the 
treated subjects. However, the different effect of hydroxyurea therapy in correlation with the 
haplotypes requires further analysis and results will be presented in another study.
Table 9.4. The frequency distribution of the 6 most common haplotypes in 6 different regions in Oman.
Region\  
Haplotype
Asian/Asian Benin/Benin Asian/OmanI CAR/CAR CAR/OmanI CAR/Asian 
Musandam – – – – – 12,50%
Batina 31,90% 12% 35,70% – – 12,50%
Muscat 21,30% 52% 35,70% 46,20% 66,70% 50%
Sharqiya 44,70% 4% 14,30% 15,30% 8,30% 25%
Dhakhiliya 2,10% 28% 14,30% 7,70% 8,30% –
Dhahira – 4% – 23,10% 16,70% –
































Haplotypes distribution and disease severity
The Omani populations are known for their high incidence of hemoglobinopathies, including 
alpha and beta-thalassemia as well as sickle cell disease (13). As mentioned above, patients 
with SCD present with a variable clinical picture ranging from severe to very mild forms, where 
haplotypes have been found to be associated with the severity of the disease (20, 21). In Daar et 
al, a study conducted in Oman in 2000 on 52 HbS/S individuals, it was found that the Benin/Benin 
haplotype was the most prevalent and twice more frequent than the Asian/Asian (16). In the 
present study however, the Asian/Asian haplotype was the most prominent while Benin/Benin 
was the second in rank (Table 9.2). The reason for the higher percentages of Benin haplotype in 
Daar et al, might be due to a selection among patients attending the Sultan Qaboos university 
Hospital which are mainly from the Dhakhiliya region and based on our findings, the Benin 
haplotype has been observed to be present at a high rate in this region (Figure 9.2). Although 
the effect of these haplotypes on the phenotypes is clearly correlating with the HbF expression, 
disease severity remains variable within the same haplotypes and more molecular and external 
factors need to be taken into consideration. The high frequency of alpha-thalassemia reported 
in the Omani population (13) is another modulating factor influencing the clinical outcome of 
the disease. The effect of alpha thalassemia on the clinical expression of SCD is under evaluation 
in our cohort and will be presented in another paper.
Gene flow
The distribution of the HbS haplotypes in Oman is explained by the historical migrations from 
Zanzibar and India. The presence of the Asian haplotype can be attributed to ancient migrations 
and to centuries of trade with India and Pakistan. Contacts with East Africa, Zanzibar and 
Mombasa, explain the presence of the Benin and CAR haplotypes (16). Muscat, being the capital, 
had the widest diversity of different haplotypes. This reflects more recent migrations of “native 
people” from the interior to the capital seeking for jobs and better lives. The Asian haplotype was 
highest in Sharqiya and Batinah and these regions are known to have SCD patients with a mild 
clinical profile in comparison to Dhakhiliya and Dhahira regions in which they have a more severe 
manifestation of the disease and this could be explained by the Benin and CAR haplotypes in these 
regions respectively (Figure 9.2). Only one haplotype combination was found among patients 
from Musandam (CAR/Asian) and this can be due to the isolation of this region from the rest of 
the country by mountains and the uAE. SCD is absent in Wusta and Dhofar due to low levels of 
malaria in the past in these two regions (17). The 4 identified haplotypes which we have referred 
to as OmanI, II, III and IV are expected in an admixed population such as Oman and might have 
been derived differently by recombinant events (32). OmanI could have probably been derived 
from CAR with a mutation at F5. It is also possible to say that it is a result from a recombination 
event between CAR and Cameroon haplotypes but this is less likely as Cameroon haplotype was 
not found in the Omani population. Oman II could be a result of a recombinant event between 
Benin and CAR while OmanIII could be the outcome of a recombination between Asian and CAR 
haplotypes. Oman IV could be a derivative of OmanII with a mutation at F1. However, these are just 































Early diagnosis, haplotype, Hbf and prognosis
Identifying the disease at an early stage and defining genotype and haplotype allows clinicians 
to predict to some extent the prognosis and to plan a tailored treatment. Early prediction of 
the clinical expression will help in preventing or reducing acute painful episodes (crisis) in this 
cohort, which is the most common traumatic experience in SCD (18), and acute chest syndrome 
(ACS) which is the most common cause of death in Omani SCD patients (19). 
The Asian haplotype was associated with highest HbF levels, fewer hospitalizations and 
painful episodes and patients did not develop acute chest syndrome although vaso-occlusive 
events did occur. Our study also confirms that the CAR haplotype whether homozygous or 
combined heterozygous is associated with lowest HbF level and the highest incidence of organ 
damage and renal failure as reported elsewhere (22, 23).
Carriers of the HbS gene on the Asian haplotype on one chromosome and OmanI 
haplotype on the other presented in our cohort high HbF levels (average 14.2%) and a milder 
clinical course than other compound heterozygous haplotypes. Bakioglu al. (25) reported mild 
SCD cases of Asian/Benin haplotype with high levels of Hb F (average 22.2%). This shows that 
carrying the HbS mutation on an Asian haplotype on one chromosome could still contribute to 
elevating the HbF expression.
Higher concentrations of HbF in the cell lead to lower concentrations of HbS (24), better 
oxygenation and less clinical severity. A potential threshold of 20% HbF has been suggested to 
effectively prevent recurrent vasoocclusive episodes (26). This is true in most cases, however, in 
another study, some patients with HbF levels near 20% had a devastating disease manifestation 
(18). The same observation was seen in one of the patients in our cohort, with the Asian/CAR 
haplotype. Despite the high HbF (19.7%), the patient is frequently admitted to the hospital with 
vaso-occlusive crisis, dactilitis and severe abdominal pain. This patient has no iron overload and 
is heterozygous for the α-3.7 deletion. This finding imply that other circumstantial or genetic 
factors or external transacting determinants such as blood viscosity, elevated PCV, vascular 
adherence, acidosis and dehydration as well as patient’s life style and diet might contend with 
the beneficial effect of the high HbF level. Our findings support the conclusion by Acquaye et 
al. (27) and Seltzer et al. (28) that fetal hemoglobin levels are very important but not the only 
parameters that mitigate the severity of the disease and we are at the moment inquiring which 
other factors could be associated with the severity of this case.
Sub-haplotype
The sub-haplotype study of 42 SnP’s on the 11 haplotype combinations observed in our 125 
SCD patients revealed that 15 different positions differentiate the 11 identified haplotypes. no 
sub-haplotypes were determined except in patients with the CAR/OmanI haplotype, which 
revealed variation at the G-gamma promoter SnP-1 giving 3 different sub-haplotypes (Table 9.5; 
a, b and c). One patient with sub-haplotype-c who presented with homozygosity for the wild 
type 6 nucleotide sequence (CTTTAA) at the G-gamma promoter, a very severe phenotype 
and not responding to high doses of Hyrdoxyurea treatment. This element could be the cause 
of low HbF expression and of non-response to Hydroxyurea and this hypothesis seems to be 































deletion of the 6 nucleotides at the same position became better as soon as being on the drug. 
The presence or absence of the 6nt sequence in at the G-gamma promoter in the CAR/OmanI 
patients could be associated with the differences in clinical presentation and with response to 
hydroxyurea therapy, probably an element is in linkage to the 6nt deletion and is responsible 
for the positive response to the drug.
CONCLUSION
Our study on haplotype/phenotype correlation has shown the existence of at least 11 different 
haplotype combinations in Oman. These are differently distributed among the six main regions 
of the country. Sub-haplotype was only observed in CAR/OmanI combination and could 
be associated with the clinical differences observed in patients with the same haplotype. 
Identifying haplotypes and sub-haplotypes in early life may allow a better prognosis and a 
more accurate risk predictions and a better tailored therapy, to match disease-related risks 
and to facilitate planning of clinical trials to prevent the development of severe complications 
later in life. nevertheless, we have shown that when the phenotypes are classified into; mild, 
intermediate and severe, neither the haplotype or the HbF alone appeared to be fully associable 
with the clinical phenotypes as also been observed by Alexander et al (29). External and/or 
modifying, or epistatic factors, which potentially modulate the phenotype of SCD do occur and 
more efforts should be done trying to chart them. The implementation of primary prevention 
with simple cost effective interventions for SCD are essential (30) and are likely to lead to lower 
incidence, lower costs for public health and improved survival rate of SCD patients in Oman.
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To describe the effect of hydroxyurea (Hu) treatment in Omani sickle cell disease (SCD) patients 
with different beta-globin gene cluster haplotypes. 
Materials and Methods
A total of 52 cases treated with Hu were enrolled in this study. Response to the drug was 
compared between patients with and without the XmnI polymorphism in the different beta-
globin gene cluster haplotypes. We have classified our cohort into three categories: good 
responders to Hu for those patients who had no crises and no hospitalization after 6 months 
of treatment; partial responders for those who had a reduction in the number of crises after 
the same period and non responders for those that remained clinically unchanged even after 
doubling the Hu prescription.
Results
Most patients homozygous or heterozygous for the Xmn I polymorphism (T/T or T/C) had 
higher levels of HbF prior treatment than those having the CC genotype and were classified 
under good or partial responders. 
Conclusions
Being the Xmn-I polymorphism associated with the haplotypes frequent in Oman and acting as 
enhancer of the already elevated HbF expression, Hu treatment can be prospectively applied 
to predict responsiveness and treatment can be given to those with low HbF expression for 
beneficial lowering of cellular adhesion. Hu treatment can ameliorate the clinical phenotype of 






















The mutation responsible for sickle cell disease (SCD) is the GAG > GTG transversion at codon 
6 of the beta globin gene, resulting into a Glu>Val amino acid substitution and in the change of 
the wild type HbA tetramer into the commonest abnormal Hb variant (HbS). The condition is 
recessive and carriers of HbS are in general asymptomatic while the mutation in homozygous 
or compound heterozygous form in combination with β-thalassemia is in most of the cases a 
severe condition. Although HbS is the causal allele, the combination of HbS with other common 
alleles (HbC, HbE, HbD) and a number of less common ones, may also cause the disease with 
large phenotype variability (1). 
Milder forms may be caused by the combination of HbS with a less severe β+-thalassemia 
allele with residual HbA expression or with δβ-thalassemia deletion because of the characteristic 
elevated HbF expression. The ameliorating role of HbF in SCD and β-thalassemia and the 
association of high HbF with specific genotypes / haplotypes have been known for a long 
time. In spite of strenuous efforts, no effective cure associated with a permanent increase of 
HbF expression in post-natal life has been found so far while different drugs have been tested 
that can temporarily increase the HbF level with acceptable collateral effects. Among these 
drugs the most successful thus far is hydroxyurea (Hu) a medication that may reduce the 
severe symptoms in different ways in SCD patients (2). A better practical knowledge on these 
differences may allow an early prognosis for severe patients that are likely to respond to Hu 
and for others that are not responding or respond in a different way, allowing early planning 
for an alternative treatment for non-responders such as bone marrow transplantation which, if 
successful, could be an alternative curative solution (3). 
Response to Hu has been shown to be largely associated with the presence of the C>T 
polymorphism at -158 Xmn-I site (HBG2:c.-53-158C>T) upstream of the Gγ globin gene and it is 
thus far the most studied nucleotide change to have a significant association to drug response. 
This particular polymorphism acts as an enhancer of HbF expression during erythropoietic 
stress, resulting in a beneficial effect in SCD patients (4). The frequency of Xmn-I polymorphism 
in SCD patients has not yet been investigated in the Omani population. Therefore we have 
studied the association of the XmnI polymorphism and the response to hydroxyurea treatment 
in HbS/S and S/β-thalassemia patients in Oman and we have further investigated if the HbS 
haplotype is accountable for a more differentiated response to Hu in patients with identical 
Xmn-I genotype.
MATERIAL S AND METHODS
A total of 52 SCD patients attending the Ministry of Health Hospitals in Oman (between January – 
June 2012) and started the treatment with Hu were randomly enrolled. These patients were then 
followed for the subsequent 6 months afterwards. Gender distribution was; 52% males and 48% 
females. The age range of the subjects was 23- 32 years. At the laboratory level, high performance 
liquid chromatography (HPLC) was performed on all samples, prior treatment, either on D-10 
(short and extended programs) device and/or the Variant II (Bio-Rad Laboratories, Hercules, 





















CA, uSA). The XmnI (–158 (C>T) polymorphism of the Gγ gene promoter) (rs 7842144, HBG2:c.-
53-158C>T) and the haplotype of the HbS/S beta globin cluster were defined by melting curve 
analysis (LightScanner HR96, Idaho Technology, Inc) as previously described (5). The β globin 
gene sequencing was performed on an ABI PRISM® 3700 DnA Analyzer (PE Biosystems, Foster 
City, CA, uSA) and the α-cluster genotype was obtained by GAP-PCR as previously described 
(6). The initial hydroxyurea dosage was 500 mg (capsule). If no improvement was observed 
after 3 months the dosage was increased to 1000 mg. Classification of responders was as follow: 
Good responders: Patients became clinically asymptomatic 6 months after the therapy (no 
crises, no hospitalization, no definitive pain). Partial responders: Significant decrease is noted 
in number of vaso-occlusive crises and hospitalizations (<3/year) and experienced much milder 
pain. non responders: no clinical improvement despite dosage increase after 6 months.
RESULTS
DnA analysis revealed 40 cases homozygous for HbS/S and 12 S/β-thalassemia patients. Of these 
52 patients, 22 were either homozygous or heterozygous for the Xmn I (C>T) polymorphism 
at position -158 site at the G-γ promoter. Of the patients homo- or heterozygous for the -158 
C>T, 18 (82%) showed good response to Hu, 3 (13.6%) partial response and 1 (4.5%) showed no 
response. In those without Xmn I polymorphism (n=30), only 1 (3.3%) showed good response, 24 
(80%) showed partial response and 5 (16.7%) showed no response. On average, good responders 
became asymptomatic after 6 months of being on Hu, partial responders had significant 
decrease in complications within the same time span while non-responders had no significant 
reduction after 6 month even after doubling the Hu dosage. Among the 40 HbS/S patients, 
15 that had at least one copy of the T allele, were all good responders while among those 21 
that became better (partial responders) only two had at least one copy of the T allele. Of the 
remaining 4 patients that did not respond, even after double prescription, none had the T allele. 
Prior to treatment, HbS/S patients with the genotype T/T or T/C had on average an elevated 
expression of HbF% (15.2%) and (13.5%) respectively. Patients having the genotype C/C had a 
lower HbF level (5.6%). 
none of the S/β-thal patients, had the TT genotype, however, HbF levels prior treatment 
were found to be on average high in S/β individuals bearing the TC genotype (11.3%) and lower 
in those with the CC genotype (7.3%). Among the S/β-thal group, we found 4 patients that were 
good responders to Hu, 6 became better in terms of severity while 2 did not respond to the 
drug. Data are summarised in Table 10.1. One of the non responders was found to have the Xmn 
I T/C polymorphism and the β IVS-I-1 G>A mutation while the other had the C/C polymorphism 
and the β Cd36/37 (-T) mutation. Data are summarized in Table 10.2. Over all, the clinical 
symptoms improved in most patients and the best response was associated with the presence 
of the Xmn I polymorphism. 
Haplotype analysis of the HbS/S is summarised in Table 10.3. The 4 non responders all had 
the CAR/Oman haplotype. The Oman haplotype differs from CAR by a mutation at SnP position 
49994 (4). Moreover, the presence of the T allele at the XmnI polymorphism was linked to the 
Asian haplotype. Our findings show that the presence of Xmn I polymorphism in Omani SCD 





















Table 10.1. Association between improvement of disease after Hu treatment and the presence of the 
polymorphic site (C>T) at position -158 Xmn I at the G-γ promoter region in the S/S (i) and S/β (ii) cohorts.
(i)
S/S patients T/T (%) (n=11) T/C (%) (n=6) C/C (%) (n=23)
Good responders 91% (n=10) 83.3% (n=5) -
Partial responders 9% (n=1) 16.7% (n=1) 82.6% (n=19)
non responders - - 17.4% (n=4)
(ii)
S/β patients T/C (%) (n=5) C/C (%) (n=7)
Good responders 60% (n=3) 14.3% (n=1)
Partial responders 20% (n=1) 71.4% (n=5)
non responders 20% (n=1) 14.3% (n=1)
Table 10.2. Genotypes of the HbS/β compound heterozygote patients treated with Hu.
β genotype XmnI genotype response to HU
Cd6 GAG>GTG/IVS-I-5 G>C (n=7) T/C (n=2) Excellent (n=2)
 HBB:c.20A>T/ HBB:c.92+5G>C   Partial (n=0)
    none (n=0)
  C/C (n=5) Excellent (n=1)
    Partial (n=4)
    none (n=0)
Cd6 GAG>GTG/Cd121 GAA>CAA (n=2) T/C (n=1) Excellent (n=1)
 HBB:c.20A>T/ HBB:c.364G>C   Partial (n=0)
    none (n=0)
  C/C (n=1) Excellent (n=0)
    Partial (n=1)
    none (n=0)
Cd6 GAG>GTG/Cd44 (-C) (n=1) T/C (n=1) Excellent (n=0)
 HBB:c.20A>T/ HBB:c.135delC   Partial (n=1)
    none (n=0)
Cd6 GAG>GTG/IVS-I-1 G>A (n=1) T/C (n=1) Excellent (n=0)
 HBB:c.20A>T/ HBB:c.92+1G>A   Partial (n=0)
    none (n=1)
Cd6 GAG>GTG/Cd37(-T) (n=1) C/C (n=1) Excellent (n=0)
 HBB:c.20A>T/ HBB:c.112delT   Partial (n=1)





















Table 10.3. Summary of the HbS/S haplotypes in patients treated with Hu.
Haplotype XmnI genotype response to HU
Asian/Asian (n=11) T/T Good (n=10)
Partial (n=1)
    none (n=0)
Asian/CAR (n=1) T/C Good (n=1)
Partial (n=0)
    none (n=0)
Asian/Oman (n=4) T/C Good (n=3)
Partial (n=1)
    none (n=0)
Senegal/Oman (n=1) T/C Good (n=1)
Partial (n=0)
    none (n=0)
Benin/Benin (n=9) C/C Good (n=0)
Partial (n=9)
    none (n=0)
CAR/CAR (n=3) C/C Good (n=0)
Partial (n=3)
    none (n=0)
CAR/Oman (n=11) C/C Good (n=0)
Partial (n=7)
    none (n=4)
DISCUSSION
Bakanay et al. reported the highest incidence of organ damage and the poorest response to Hu 
in SCD patients with the XmnI C/C genotype (7). Likewise, our patients bearing the C/C allele at 
the XmnI site, had a poorer response to the drug than those carrying the T allele.
In patients with the genotype TT, high HbF levels and the best response to Hu were 
measured as previously reported by other authors (8) with significant reduction in both 
anaemia and the frequency of vaso-occlusive events (9). Studies on Hu treatment for 
β-thalassemia have produced contradictory results. While Karimi et al. found no relationship 
between XmnI polymorphism and Hu clinical response in their patients (10), Yavarian et al. (4) 
found that the C>T polymorphism at position -158 of the Gγ promoter was the most significant 
parameter correlating with Hu response in β-thalassemia patients. In our study as many as 91% 
of the HbS/S patients with the T/T genotype fully responded to Hu therapy while none of the 
patients with the C/C polymorphism were classified under ‘good responders’, confirming that 
this polymorphism is highly correlated with a positive response to Hu treatment in the Omani 





















In Oman, Hu is only used for SCD but not for β-thalassemia major and thus far a restricted 
inclusion criterion have been used to decide if SCD patients were eligible to be given Hu or not. 
These include some severe symptoms noted by the clinician, such as frequent hospitalization 
(>4-5/year) with recurrent episodes of acute chest syndrome, vaso-occlusive events, severe 
pain crisis and severe, un-subsiding body and limp pain that last for days. The daily dose given 
is the recommended 500mg and it is only increased to reach a maximum of 1000mg when no 
improvement is seen with the 500mg dose. Although Charache et al, proved the effectiveness 
and safety of hydroxyurea usage and the improved outcomes (11), Hu is not widely accepted 
by Omani patients and their families, due to the negative perception toward this treatment 
and the fears of birth defects, infertility, malignancy and concerns on long-term risks. non-
compliance may be found in patients because of anxiety and minor but disturbing side 
effects such as nausea or when a pregnancy is perceived. More studies have proven that Hu 
(20 mg/kg/d) is a safe therapy even for very young children with SCD (starting at 9 months 
of age) and that the cure is in general associated with significantly lower rates of recurrent 
episodes of pain, dactylitis, acute chest syndrome and hospitalization (12). However, response 
prediction to Hu treatment is not always straightforward. Also in our study some patients 
having the T/C XmnI polymorphism, did not improve with the standard 500mg dose which had 
to be doubled to observe some improvement. The few patients that did not show improvement 
after treatment with Hu even after increasing the dose were all carries of the compound 
heterozygous haplotype (CAR/Oman). Our findings suggest that the C/T polymorphism at 
the XmnI site, although in most cases associated with good response, is neither a guarantee 
nor the only determinant that can ameliorate disease severity in SCD patients treated with Hu 
and that other factors either haplotype and/or sub-haplotype related or associated with other 
regulatory elements might be involved. Therefore, increasing the dosage of Hu to the maximal 
tolerated dose might be necessary for having some clinical response in SCD patients with 
African haplotypes (13) whereas SCD children with Asian haplotype treated with a dose as low 
as 10 mg/kg/day have shown some good clinical response (14). Moreover, it has been proved 
that Hu a nitric oxide (nO) provider has an anti-adherence effect that may prevent cells to get 
stuck to the capillary walls and herewith improving the rheology of the blood during the critical 
passage of the deoxygenated HbS cells (15). 
Alpha thalassemia has been proposed as a factor possibly associated with good response 
to Hu therapy in β-thalassemia intermedia in addition to the presence of Xmn I polymorphism 
(16). While another study reported that co-inheritance of α-thalassemia in SCD patients may 
reduce the clinical response to Hu therapy (17). Although we may imagine that α-thalassemia 
may partially restore the balance in β-thalassemia, we believe that this mechanism has little 
to do with the response mechanisms of Hu in SCD. As a matter of fact when we correlated 
the presence or absence of α-thalassemia (very common in our cohort) to the Hu response 
(HbS/β-thal included) we find no association between coexisting alpha deletions and good 
response to Hu (data not shown). 
In conclusion, being the Xmn-I polymorphism associated with haplotypes frequent in 
Oman and acting as enhancer of the already elevated HbF expression, Hu treatment can be 





















expression for beneficial lowering of cellular adhesion. Hu treatment can ameliorate the clinical 
phenotype of the large majority of Omani patients with SCD. 
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We report the general phenotype severity and the hematological presentation in a cohort of 125 
sickle cell anemia (SCA) patients with identical homozygous HbS/S genotype and categorized 
by identical βS haplotype, both with and without alpha thalassemia. no clear general phenotype 
correlation was found when patients were compared regardless of the haplotype but overall, 
patients with homozygous alpha thalassemia (α–/α–) had the highest Hb, HCT, RBC and the 
lowest MCV, MCH and MCHC levels. When patients with identical haplotype were compared, 
the mildest hematological and clinical conditions were observed in patients of the Asian/Asian 
haplotype, also known as Arab-Indian haplotype, and carriers of α-thalassemia, suggesting an 
additional ameliorating effect of alpha thalassemia. In conclusion, our results show that alpha 
thalassemia improves the hematological conditions but amelioration of the general disease 






















Sickle cell anemia (SCA) is in general a severe condition caused by different genotype 
combinations of which HbS homozygosis is the most common. The pathophysiology of SCA 
is complex and involves HbS polymerization in hypoxic conditions in the post-capillary veins, 
erythrocyte sickling, chronic and acute vaso-occlusive events, hemolysis and progressive 
organ and tissue damage at variable levels (1). Although it is known that both environmental 
and genetic factors may contribute to this variability (2), patients with the same HbS/S 
genotype often display very different phenotypes in which the clinical manifestations may 
range from very severe to milder or can even in some cases be almost asymptomatic and be 
diagnosed accidentally (3,4). The clinical and hematological severity of SCA can be influenced 
by a number of factors among which the main one is the level of fetal hemoglobin (HbF) in 
postnatal life which is related to the beta globin gene haplotype (5). The role of co-inherited 
alpha thalassemia influencing or not the phenotype of SCA has been long debated (6). 
The alpha-globin chains that are needed to form sufficient Hb tetramers are coded by two 
alpha genes located on the short arm of chromosome 16. The two α-globin genes, alpha 2 and 
alpha 1, are separated by less than 4 kb and code for identical alpha globin chains. 
Alpha thalassemia occurs at a high prevalence in Oman (7) with -α3.7 kb deletion being the 
commonest (8).
The influence of alpha-thalassemia on SCA has been reported to ameliorate the 
hematological and clinical manifestation of the disease in several populations (9). Alpha-
thalassemia lowers the mean cell volume (MCV) and the mean cell hemoglobin (MCH), and 
both these changes might be expected to be beneficial to patients with sickle-cell disease 
improving rheology and reducing the concentration of the Hb molecules in the red cells (2). 
However, to study the effect of alpha thalassemia on the severity of the disease one needs to 
compare cohorts of patients with identical genotype (HbS/S mutation) and haplotype (beta 
globin cluster). 
Both alpha thalassemia and SCA are frequent in Oman (7) and the HbS mutation is present 
on severe and mild haplotypes. Therefore, in order to establish if alpha thalassemia has any 
effect on the severity of the disease, we have studied the hematological and general clinical 
phenotype of 125 patients, all HbS/S homozygous, with or without alpha thalassemia and 
categorized in specific and different haplotypes. We premise therefore that our study is not 
meant to go deeply into clinical details. Our goal is to build a bridge between the clinician 
and the geneticists, comparing the general clinical phenotype with the genetic background of 
the patients.
MATERIAL S AND METHODS
Blood samples were collected in EDTA at the Ministry of Health Hospitals in Oman. 
Hematological and clinical data were obtained from routine hematology and from patient’s 
medical history documented by the treating physician. We subdivided the phenotypes as mild, 
intermediate and severe by the occurrence of symptoms such as: acute chest syndrome, stroke 
and the presence of avascular necrosis (absence = mild, presence = severe); number of painful 





















The cohort consisted of individuals that had been previously diagnosed with SCA. The 
diagnosis was confirmed on HPLC (Variant II, Bio-Rad Laboratories, Hercules, CA, uSA) (10) 
and molecular characterization of the genotypes and haplotypes was performed at Leiden 
university Hemoglobinopathies center. A group of 125 individuals confirmed homozygous 
HbS/S were enrolled in this study. The median age was 24 years. DnA extraction was done 
using the commercial Qiagen kit as per the manufacturer instruction (8). The beta genotype 
was confirmed by direct Sanger DnA sequencing. The haplotype of the β-globin gene cluster 
was determined by melting curve analysis as previously reported (11) and genotyping errors 
were ruled out by random sample sequencing. We found a Central African Republic (CAR) 
derivative haplotype in some patients and named it the Oman haplotype. This haplotype differs 
from CAR by a single variation at HcII RFLP G>A (SnP F5, position rs968857 5260458) (11). Five 
patients were not included in the haplotype grouping analysis because each had a single unique 
haplotype with no comparable cases. Alpha-globin genotype was established by GAP-PCR for 
the most common 7 alpha thalassemia deletion defects (12) for all the samples while the alpha 
globin genes were sequenced for selected samples. To asses if presence or absence of alpha 
thalassemia has an effect on disease expression, clinical and hematological comparison of the 
patient’s history was made between genetically equivalent cohorts with and without alpha 
thalassemia.
RESULTS
α-thalassemia’s frequency in the different cohorts
The gene frequency of α-thalassemia among HbS/S patient was confirmed to be very high. 
Homozygosis or compound heterozygosis (-α/-α), was found in 55 patients (44%). Specifically 
54 had the (-α3.7/-α3.7) and 1 had the (-α3.7/-α4.2) combination while 42 patients (33.6%) had 
the heterozygous genotypes (-α3.7/αα) and 28 individuals (22.4%) had a normal alpha globin 
genotypes (αα/αα). no alpha° deletions or point mutations were found in the studied samples. 
When HbS/S patients classified as mild, intermediate and severe, based upon their 
disease history, were compared with the presence or absence of α-thalassemia regardless the 
haplotype, no clear correlation was found.
Effect of α-thalassemia in HbS/S patients of specific haplotypes
HbS/S patients with Asian/Asian haplotype (also known as Arab-Indian) had a mild presentation 
in 82% and 87% of the cases with (-α/-α) and (-α/αα) thalassemia respectively. This in contrast 
with 66% of the cases without alpha thalassemia. Similarly, an intermediate state, was twice 
more frequent in absence of alpha thalassemia. none of the Asian/Asian presented with a 
severe condition (Table 11.1a). 
In the smaller cohorts of HbS/S patients with Asian/Oman haplotype, the milder condition 
was present in 75% of the patients with (-α/-α) while none had the mild condition in absence of 
alpha thalassemia and none of them were severe (Table 11.1b). 
In the few HbS/S patients with Asian/CAR haplotype and (-α/-α) all three conditions (mild, 
intermediate and severe) were observed but the severe phenotype was 3 time higher in absence 





















Table 11.1. Association between alpha-thalassemia, different β-cluster haplotypes and clinical severity. 
 (a)Asian/Asian haplotype
Genotype Mild Intermediate Severe
-α/- α  (n=20) 82.4% 17.6% -
- α/αα (n=9) 87.5% 12.5% -
αα/ αα (n=18) 66.7% 33.3% -
(b)Asian/Oman haplotype
Genotype Mild Intermediate Severe
-α/- α  (n=5) 75% 25% -
- α/αα (n=7) 57.1% 42.9% -
αα/ αα (n=2) - 100% -
(c)Asian/CAR haplotype
Genotype Mild Intermediate Severe
-α/- α  (n=3) 33.4% 33.3% 33.3%
- α/αα (n=3) - 66.7% 33.3%
αα/ αα (n=2) - - 100%
(d)Benin/Benin haplotype
Genotype Mild Intermediate Severe
-α/- α  (n=16) - 25% 75%
- α/αα (n=8) - 57.1% 42.9%
αα/ αα (n=1) - - 100%
(e)CAR/Oman haplotype
Genotype Mild Intermediate Severe
-α/- α  (n=5) - 40% 60%
- α/αα (n=6) - 16.7% 83.3%
αα/ αα (n=1) - - 100%
(f)CAR/CAR haplotype
Genotype Mild Intermediate Severe
-α/- α  (n=4) - - 100%
- α/αα (n=5) - 20% 80%





















In spite of the limited number of cases found on other haplotypes, the same pattern seems 
to appear in the Benin/Benin and in the CAR/Oman cohorts (Table 11.1d and 11.1e) while no 
association seems to be present in the severe CAR/CAR cohort (Table 11.1f). 
Effect of α-thalassemia in grouped HbS/S patients of mild and severe haplotypes
HbS/S patients with Asian/Asian and Asian/Oman were grouped under mild haplotype while 
those with Benin/Benin, CAR/Oman and CAR/CAR under severe haplotype. Asian/CAR was 
not included in the 2 groups as it had an intermediate phenotype. Patients grouped as mild 
haplotype had a mild presentation in cases with (-α/-α) and (-α/αα) thalassemia than cases 
without alpha thalassemia (Table 11.2a). Among the severe haplotype, all patients without alpha 
thalassemia were presented with a severer phenotype (Table 11.2b).
Table 11.2. Association between alpha-thalassemia, mild and severe β-cluster haplotypes and clinical 
severity. 
(a) Mild haplotype
Genotype Mild Intermediate Severe
-α/- α  (n=25) 77.3% 22.7% -
- α/αα (n=16) 73.3% 26.7% -
αα/ αα (n=20) 60% 40% -
(b) Severe haplotype
Genotype Mild Intermediate Severe
-α/- α  (n=25) - 24% 76%
- α/αα (n=19) - 31.6% 68.4%
αα/ αα (n=6) - - 100%
Effect of α –thalassemia on the hematological parameters of HbS/S patients
The presence of alpha-thalassaemia homozygosis (-α/-α) resulted in significantly higher mean 
hemoglobin (Hb) levels, hematocrit (HCT), red blood cells counts (RBC) but lower levels of 
fetal hemoglobin (HbF), mean cell volume (MCV), mean cell hemoglobin (MCH) and mean 
cell hemoglobin concentration (MCHC) than the group with a normal alpha genotype (αα/
αα). Patients with heterozygous alpha complement (–α/αα) showed intermediate mean 
hematological values. The overall distributions of hematologic parameters in Hb S/S patients 





















Table 11.3. The effects of the various α-thalassemia genotypes on the mean hematological parameters in 
HbS/S patients regardless of the haplotype.
Hb f(%) Hb (g/dl) HCT (%) RBC (x1012/L) MCV (fl) MCH (pg) MCHC (g/dl)
-α/-α (n=55) 10.4 9.7 29.2 4.2 69.3 22.9 33.2
-α/αα (n=42) 10.8 9.1 26.7 3.3 79.9 27.3 34.2
αα/αα (n=28) 15.9 9.0 25.8 3.1 84.8 29.8 35.1
Influence of α-thalassemia on hematological parameters in HbS/S patients of 
different haplotypes
Alpha-thalassemia increased the mean Hb, HCT, RBC and lowerd HbF, MCV, MCH and MCHC in 
patients with Asian/Asian, CAR/Oman and CAR/CAR haplotypes (Table 11.4 a, e and f). In patients 
with Asian/Oman and Asian/CAR haplotypes the HbF level was however found increased (Table 
11.4 b and c). In HbS/S patients of the severe Benin/Benin haplotype only a decreased MCV and 
MCH were observed. Data are summarized in Table 11.4.
Table 11.4. Effects of various α-thalassemia genotypes on the average hematological parameters in 
HbS/S patients based on their haplotype:
(a)Asian/Asian haplotype
Hb f(%) Hb (g/dl) HCT (%) RBC (x1012/L) MCV (fl) MCH (pg) MCHC (g/dl)
-α/- α  (n=20) 13.5 9.6 29.1 4.1 69.9 23.1 33.1
- α/αα (n=9) 18.4 9.6 27.8 3.7 74.9 25.7 34.3
αα/ αα (n=18) 20.4 9.2 26.2 3.1 83.9 29.6 35.2
(b)Asian/Oman haplotype
Hb f(%) Hb (g/dl) HCT (%) RBC (x1012/L) MCV (fl) MCH (pg) MCHC (g/dl)
-α/- α  (n=5) 9.7 11.2 33.5 5.0 66.6 22.3 33.4
- α/αα (n=7) 17.3 10.6 31.8 3.9 79.8 26.7 33.5
αα/ αα (n=2) 9.2 8.4 23.5 2.8 82.1 29.7 35.6
(c)Asian/CAR haplotype
Hb f(%) Hb (g/dl) HCT (%) RBC (x1012/L) MCV (fl) MCH (pg) MCHC (g/dl)
-α/- α  (n=3) 12.7 10.1 29.9 4.1 74.5 25.2 33.7
- α/αα (n=3) 14.1 8.1 23.9 3.1 77.7 26.5 34.0






















Hb f(%) Hb (g/dl) HCT (%) RBC (x1012/L) MCV (fl) MCH (pg) MCHC (g/dl)
-α/- α  (n=16) 5.9 9.3 28.5 4.0 69.2 22.7 32.9
- α/αα (n=8) 3.6 8.7 26.1 3.4 76.2 25.5 33.4
αα/ αα (n=1) 4.2 11.0 34.6 4.3 80.1 25.6 32.0
(e)CAR/Oman haplotype
Hb f(%) Hb (g/dl) HCT (%) RBC (x1012/L) MCV (fl) MCH (pg) MCHC (g/dl)
-α/- α  (n=5) 4.7 9.3 28.5 3.9 72 23.3 32.6
- α/αα (n=6) 5.3 8.3 23.7 2.8 84.9 29.3 34.6
αα/ αα (n=1) 5.0 9.1 25.8 2.9 87.9 31.0 35.3
(f)CAR/CAR haplotype
Hb f(%) Hb (g/dl) HCT (%) RBC (x1012/L) MCV (fl) MCH (pg) MCHC (g/dl)
-α/- α  (n=4) 4.6 9.2 27.4 3.9 68.7 23.1 33.6
- α/αα (n=5) 5.8 7.5 21.6 2.5 86.2 30.1 34.9
αα/ αα (n=4) 7.5 7.6 22.1 2.4 89.3 30.8 34.5
DISCUSSION
When performing correlation studies between genotype and phenotype it is important to 
compare cohorts that are not only phenotypically similar but genotypically identical in order 
to reduce genetic variables to a minimum. Therefore we have selected groups with identical 
genotypes and haplotypes with and without alpha thalassemia. Although external and 
accidental factors cannot be avoided, we do believe that our cohorts are as comparable as 
possible. As mentioned in the introduction, our study is not meant to be a detailed clinical 
report but rather a correlation study based upon the occurrence of general symptoms that may 
indicate mild, intermediate or severe conditions.
The frequency of alpha thalassemia in the present cohort (72%) was higher than the (58.3%) 
measured by our self in a previous study (8) and by AlKindi et al (48.5%) (7). This is probably due 
to a bias deriving by the selection of homozygous HbS/S patients with a much higher chance of 
being the progeny of consanguineous parents. 
Previous and present studies
In a similar study reported by Mukherjee et al., all SCA patients from Western India with 
homozygous α-thalassemia had a mild phenotype (13). The clinical presentation of our total 
cohort with homozygous alpha-thalassemia ranged from mild (38.2%), to intermediate (21.8%) 
and to severe (40%) cases. Mukherjee et al. studied patients of the Asian/Asian haplotype 
Table 11.4. Effects of various α-thalassemia genotypes on the average hematological parameters in 





















with high HbF levels (13, 14) and our data on the 47 patients with Asian/Asian haplotype shows 
that among cases with (-α/-α), 82.4 % were mild and 17.6% intermediate while no severe cases 
were present. Considering the variability of the definition “intermediate” our results are quite 
compatible with the observations of the Indian study and with the conclusions of other authors 
reporting milder conditions among Saudis and Kuwaitis carrying the Asian haplotype with 
α -thalassaemia, when compared with Asian haplotypes without α-thalassaemia (15). The same 
correlation was also observed in patients with Asian/Oman haplotype and (-α/-α) in which 75% 
had a mild disease and 25% were intermediate. On the other hand, our results also show that 
alpha thalassemia, although ameliorating the hematological parameters, is of little effect in 
reducing the symptoms of the HbS/S homozygous with the severe CAR and Benin haplotypes. 
Hematological data and Hbf
Alpha thalassemia is believed to improve the survival of the erythrocytes in SCA resulting in 
a milder form of anaemia due to decreased hemolysis (16). How relative can be the effect of 
alpha thalassemia in SCA is shown by many contrasting reports (17). In our study, the presence 
of alpha-thalassemia in Hb S/S homozygotes resulted in significantly higher mean Hb and HCT 
levels as well as higher RBC counts and these three parameters indicate a better RBC survival as 
a consequence of lower hemolysis. In addition, patients with homozygous alpha-thalassemia 
had on average lower levels of fetal Hb (HbF) and a lower MCHC than patients with a normal 
alpha globin genotype (αα/αα). 
In our study the reduction of HbF expression was particularly relevant in patients with the 
mild “high HbF” (Asian) haplotypes and (-α/-α) alpha thalassemia. Conversely, in patients with 
severe “low HbF” haplotypes (CAR and Benin) the HbF remained either unchanged or increased 
in the presence of alpha thalassemia while little changes were observed in these patients also at 
the RBC level. Other studies have shown that coexistence of α-thalassemia enhances the levels 
of HbF associated with a specific haplotype such as the Senegal (18) and Benin haplotypes (19). 
Higgs et al. (20) reported a decrease in the level of HbF in SCA patients with homozygous 
alpha-thalassemia while Embury et al. (21) reported an increase in HbF levels (9). 
Higgs et al. (20) also observed that (-α/-α) individuals had the lowest cell volume and 
hemoglobin content per cell (MCHC) which reduce the polymerization risk of the Hb molecules 
in the smaller and less dense cells. In addition, low MCV in (-α/-α) generates a relatively larger 
cellular surface compared to (αα/αα) which might give the cells the property of increased 
membrane redundancy, providing a larger reserve of internal volume per given amount of polymer 
and thus giving protection against the deleterious consequences of membrane stretching during 
deoxygenation (21). We do believe that smaller cells (low MCV) might just be faster, passing the 
risk area of the post-capillary veins as this seems to be the same rheological advantage observed 
in mild SCA phenotypes with microcytic hypochromic parameters due to iron deficiency (12). 
In conclusion the lower MCV, MCH and MCHC associated with alpha-thalassemia 
should diminish the amount of intravascular sickling while the decreased intra-erythrocytic 
hemoglobin S concentration associated with α-thalassemia should diminish polymerization 
(sickling) and herewith the degree of chronic hemolytic anemia typical of SCA (17). However, 
other factors (both genetic and environmental) are involved making the interpretation of 






















Although some of the haplotype cohorts are small, it seems evident from the present study that 
alpha-thalassaemia can modulate the hematological picture of HbS/S but not clearly the overall 
severity manifestation in patients of all haplotypes. However, when the cohort was subdivided 
into larger groups of similar haplotypes, differences in the mild and severe forms became more 
evident. In addition, variability in clinical outcomes of sickle cell disease is not modulated by 
genetic factors alone, but also by environmental factors and life style.
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Hemoglobinopathies, such as sickle cell disease (SCD) and beta thalassemia major (TM), 
are severe diseases and the most common autosomal recessive condition worldwide and in 
particular in Oman. Early screening and diagnosis of carriers is the key for primary prevention. 
Once a country-wide population screening program is mandated by law, a sequencing 
technology that can rapidly confirm or identify disease-causing mutations for a large number 
of patients in a short period of time will be necessary.   
While Sanger sequencing is the standard protocol for molecular diagnosis, next generation 
sequencing starts to become available to reference laboratories. using the Ion Torrent PGM 
sequencer, we have analysed a cohort of 297 unrelated Omani cases and reliably identified 
mutations in the beta globin (HBB) gene. Our model study has shown that ion torrent PGM 
can rapidly sequence such a small gene in a large number of samples using a barcoded uni-
directional or bi-directional sequence methodology, reducing cost, workload and providing 
accurate diagnosis. Based on our results we believe that the Ion Torrent PGM sequencing 
platform, able to analyse hundreds of patients simultaneously for a single disease gene can be a 
valid molecular screening alternative to ABI sequencing in the diagnosis of Hemoglobinopathies 























Severe Hemoglobinopathies (HBP), such as sickle cell disease (SCD) and thalassemia major 
(TM) are the most common recessive disorders in Oman and β-thalassemia and sickle cell 
disease carriers are widely present in the country. A national premarital screening program for 
the detection of carriers for primary prevention of β-thalassemia major and sickle cell disease 
is available but not mandatory by law. Following carrier detection at the haematological and 
biochemical level, a high-throughput screening approach is needed to facilitate a population 
targeted molecular analysis program for HBP (or any other common genetic disorder) for 
rapid confirmation. new DnA sequencing technologies and platforms are continuously 
being updated to accommodate the fast growth of science and research trying to improve 
molecular methods and techniques that can lead to fast and reliable molecular diagnosis. 
next-generation sequencing technologies have been offering reliable approaches to rapid 
DnA genotyping. These newly evolved technologies have demonstrated advantages over 
Sanger sequencing by generating megabases to gigabases of data, allowing direct detection 
of sequence variants (1) in a very short period of time. If these new sequencing platforms are 
to be used routinely for diagnosis purposes, a number of factors such as sample scalability 
and cost should be addressed. Ion Torrent’s Personal Genome Machine (PGM) (Guilford, CT, 
uSA; now owned by Life Technologies, Carlsbad, CA, uSA), is one of the options available (2) 
since late 2010 (3) and capable of generating 100 Mb of sequence data on a 314 chip, within 
several hours of machine run time (4). Sequence data are obtained by directly sensing the 
ions produced by template-directed DnA polymerase synthesis. The ion chip contains ion-
sensitive, field-effect transistor-based sensors in 1.2 million wells on a 314 chip, which can 
measure independent sequencing reactions (3). DnA from different patients can be evaluated 
on the same sequencing chip using the barcoding methodology (5), allowing simultaneous 
sequencing for hundreds of patients.
To test the feasibility of using the Ion Torrent PGM for clinical variant analysis, we assessed its 
performance to detect variants in the beta globin gene (HBB) responsible for beta thalassemia 
and sickle cell disease. Most next generation sequencing studies involve investigating regions 
of interest of a large number of exons (up to 50,000 exons), from ten to thousands of genes on 
few patients (6). Instead, we have used the same platform to screen a large cohort of patients 
of 297 patients simultaneously for a relatively small single gene (HBB). Ion Torrent’s PGM proved 
to be a valuable tool in identifying variants in high throughput analysis. It is suitable for large 
scale diagnostic screening for such a common disease gene, responsible for sickle cell disease 
and beta thalassemia in Oman.
METHODS
Sample collection and experimental design
We performed ion torrent PGM sequencing on 297 unrelated individuals. These samples were 
preselected based on the traditional hematological tests, Cell Blood Count (CBC) and High 
Performance Liquid Chromatography (HPLC) patterns. HPLC detects HbS carriers based 
























 fraction. Patients suspected to be carriers of beta thalassemia (n=137), beta thalassemia 
major (n=15) and sickle cell disease (n=132) as well as normal controls (n=13) were all involved 
in the molecular study. A signed consent form of each patient has been provided by their 
designated clinician. DnA was isolated from peripheral blood using the Dneasy Blood 
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Figure 12.1: A schematic presentation of the beta globin gene (HBB). Exons are 
indicated in bold and introns in italics. The positions of the PCR primers are indicated as 
arrows above the sequence and the PCR products are highlighted. The frequently 
occurring mutations in the Omani population are underlined. 
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Table 4.2. Regionwise variation in the distribution of Omani β–thalassemia mutations  
 
Region Omani alleles studied 
Omani 
mutations found Type of mutation 
Regional 
prevalence (%) 
Musandam 4 3 Codon 30, G>C, Hb Monroe 75.0 
1 Cd 8/9, +G 25.0 
Batinah 19 
14 IVS-I-5, G>C 73.7 
4 IVS-I (-25bp) 3' end  21.0 
1 Codon 30, G>C, Hb Monroe 5.3 
Muscat 53 
46 IVS-I-5, G>C 86.6 
3 Codon 5, -CT 5.6 
2 Codons 8/9, +G 3.8 
1 Codon 16, -C 1.9 
1 Codon 41, -C 1.9 
Dakhiliyah 6 5 IVS-I-5, G>C 83.3 
1 IVS-I-1, G>A 16.7 
Total 82 82 8   
 
 
Table 4.3. Spectrum of α-thalassemia mutations in Oman 
(a) Allele frequencies   
Mutation Allele frequency (%) Prevalence (%) 
-α 3.7 (rightward) 41.7  
 
58.3 
-α 4.2 (leftward) 1.2 
Total 42.9 
   
(b) Genotype frequencies   
Mutation n Genotype frequency (%) 
Rightward homozygotes  22 26.2 
Rightward heterozygotes 25 29.8  
Compound rightward/leftward 1 1.2  







Figure 12.2. Schematic representation of the PCR showing the dual barcode design 
 
 
Table 12.1. Primer sequence of each fragment including the product size and the optimum annealing 
temperature.
fragment Primer fragment size Tm
1 fw: TGAAGTCCAACTCCTAAGCCA
  Rv: GTGTCAGAAGCAAATGTAAGC 189 bp 55 °C
2 fw: AGGGCAGAGCCATCTATT
  Rv: TCTCTGTCTCCACATGCC 230 bp 55 °C
3 fw: GAAGACTCTTGGGTTTCTGA
  Rv: CTTGAGGTTGTCCAGGTGA 229 bp 56 °C
4 fw: AAGTGCTCGGTGCCTTTAGTG
  Rv: AGAAGGGGAAAGAAAACATCAAG 155 bp 55 °C
5 fw: GCATATTCATAATCTCCCTAC
  Rv: GCCCTGAAAGAAAGAGATTA 221 bp 55 °C
6 fw: GAATAACAGTGATAATTTCTGGG
  Rv: AAAGGGCCTAGCTTGGACTC 188 bp 55 °C
7 fw: TGCTAATCATGTTCATACC
  Rv: AATAGAAATTGGACAGCAAG 186 bp 53 °C
8 fw: CCACAAGTATCACTAAGCTC
  Rv: GTTTTAAATGCACTGACCTC 218 bp 53 °C
full coding regions, in the HBB gene, 8 separate PCR primer pairs were designed using the 
Primer3 oligonucleotide design tool (7). The primers sequences and the product size for 
each amplicon are listed in Table 12.1. The location of the primers within the HBB gene is 
depicted in Figure 12.1 covering the mutation spectrum present in the Omani population (11) 
that are underlined in the figure. 
Ten different barcode primers consisting of 6 nucleotides were designed. For each 
fragment, the 5’ end of the forward primer was tagged with M13 and the 10 barcodes giving 10 
different primer sequences, whereas the 3’ end of the reverse primer contained the P1-adapter 
sequence. Furthermore, the A-adapter - M13 primer was also tagged with the same 10 barcodes 
to enable indexing of a large number of patients using a relatively limited set of only 10 different 
barcodes (Figure 12.2); thus 10 barcoded target forward primers were designed to be combined 
with 10 barcoded A- adapter primers for a total of 100 (10x10) barcode combinations to perform 






















analysis on 100 patients in a single run. The sequences of the barcodes are listed in Table 12.2. To 
ensure sequencing the total length of the amplified fragment, amplicon sizes were restricted to 
230bp (including primers).
PCR conditions and library preparation
After PCR optimizations, amplifications were performed in a GeneAmp® PCR System 9700 
(Applied Biosystems) in a total volume of 8μl PCR mix consisting of 1x PCR buffer, 1.8 mM 
MgCl
2
, 200 μM dnTPs, 300 nM P1-adapter reverse primer, 300 nM A-adapter forward primer, 
50 nM M13-target forward primer, 0.4 u FastStart High-Fidelity enzyme blend (5 u/μl, Roche 
Applied Science) and 10ng genomic DnA. Thermal cycling parameters were as follows: initial 
denaturation for 10 minutes at 95°C, followed by 35 cycles of 20s at 95°C, 30 s annealing at 
different temperatures (Table 12.1) and 40s at 72°C. Final extension was performed for 5 minutes 
at 72°C. The success rate of the amplifications was checked by adding 1μl of 20x EvaGreen® 
fluorescent dye (Biotium) to the wells of the PCR plate. By performing a melting analysis in the 
LC480 (Roche), the PCR yield of individual reactions could be visualised. PCR reactions deriving 
from 100 barcode-combinations were pooled according to their fluorescent levels after 
melting analysis. Size selection was done by isolating the correct band after electrophoresis on 
a 1.5% agarose gel. All fragments gave a single band except fragment 3 which had double bands. 
The correct band was cut out and the product was purified using the MinElute Gel Extraction 
Kit (Qiagen). The remaining pools were purified using Agencourt AMPure XP beads (Beckman 
Coulter) according to the manufacturer’s instructions. The concentration and integrity of the 
library was determined by measuring the sample with a Bioanalyzer on a High Sensitivity DnA 
chip Agilent Technologies. The final library concentration that was used for emulsion PCR was 
set at 25pM.
Table 12.2. List of the 10 barcode sequences used in this study model. The same 10 barcodes were 
tagged to the A-adapter-M13 primer and to the forward primer, giving (10x10) 100 different combination 
sequences for tagging/identification of 100 samples per run.
































Emulsion PCR, sequencing and data analysis
Emulsion PCR was performed using the Ion OneTouch™ 200 Template Kit v2 DL (Life 
Technologies) and the percentage of ion sphere enrichment was checked with a Qubit 
fluorometer (Life Technologies). Sequencing was done by using the Ion PGM Sequencing 
200  Kit. Mutation analysis was done on patient-specific files using the nextGEn software 
version 2.3 (Softgenetics). Sanger sequencing was performed on few samples that were found 
to have a normal gene sequence in the carriers and one mutation in the homozygotes by ion 
torrent analysis. 
RESULTS
using our design, we were able to achieve overall very good coverage of the targeted 
regions. The coverage output for the first 100 patients is shown in Figure 12.3. nearly identical 
coverage results were obtained from the other two runs. A subset of the base pair changes 
detected (Table12.3) were observed in all sequences of fragment 3 in controls and patients 
and therefore were excluded as artefacts. Seven patients that were suspected to carry one 
or two β-thalassemia mutation, revealed a normal sequence in the carriers and one mutation 
in the compound heterozygous diseased cases. These cases were re-sequenced by Sanger 
sequencing using a PCR with different primers and it confirmed the presence of one mutation 
in the HBB gene in the heterozygotes and two mutations in the compound heterozygotes. Four 
cases were found to carry the HbE mutation (Cd26 GAG>AAG), 2 in carriers and 2 in association 
with another β-mutation, and 3 cases to have the IVS-I-128 T>G mutation, 1 in a carrier and 2 in 
association with another β-mutation. To investigate why the Ion Torrent PGM sequencer did 
not detect these 2 mutations, another Ion Torrent run was performed on the same 7 samples 
for the 2 fragments that carried the mutation identified by Sanger sequence; fragment 2 and 
fragment 3. This was performed using a bi-directional method with a reverse barcode primer 
in addition to the forward barcode primer in order rule out strand-specific effects. The HbE 
mutation was detected by bi-directional sequencing but ambiguous results still remained in 
the 3 cases. Further investigation showed that the reason for these ambiguous results was that 
the primers used were not HBB specific and that the HBD gene was co-amplified generating a 
mixed sequence. The mutations found in the HBB gene are summarised in (Table 12.4).
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Figure 12.3: Coverage output of the evenly distributed sequence covering the first 100 
samples. 
 
Artefact given by the Ion Torrent  Corresponding HBB  Corresponding HBD  
softaware in the HBB gene position and nucleotide position and nucleotide 
c.[93-30G>C] IVS-I-101, C IVS-I-101, G 
c.[93-28C>G] IVS-I-103, G IVS-I-103, C 
c.93-24_93-23delAT IVS-I-107 - 108, AT IVS-I-107 - 108, TG (AT is deleted) 
c.[93-19A>C] IVS-I-112,T  IVS-I-112,T 
c.[93-16T>C] IVS-I-115,A   IVS-I-115,T 
c.[93-9G>A] IVS-I-122, C  IVS-I-122, C 
c.[93-3A>G] IVS-I-128, T   IVS-I-128, G 
c.[93C>T] Cd30, G Cd30, A 
c.[94G>A] Cd31, C Cd31, T 
c.[96C>T] Cd31, G Cd31, A 
c.[151T>A] Cd50, A Cd50, T 
 
Table 12.3: Summary of the artefacts obtained by the Ion Torrent sequence software due 
to the co-amplification of HBB and HBD fragments, showing the corresponding position 
































Table 12.3. Summary of the artefacts obtained by the Ion Torrent sequence software due to the co-
amplification of HBB and HBD fragments, showing the corresponding position in the HBB and HBD genes. 
These artefacts reside within fragment 3 of the HBB gene.
Artefact given by the Ion Torrent Corresponding HBB Corresponding HBD 
softaware in the HBB gene position and nucleotide position and nucleotide
c.[93-30G>C] IVS-I-101, C IVS-I-101, G
c.[93-28C>G] IVS-I-103, G IVS-I-103, C




c.[93-9G>A] IVS-I-122, C IVS-I-122, C
c.[93-3A>G] IVS-I-128, T IVS-I-128, G
c.[93C>T] Cd30, G Cd30, A
c.[94G>A] Cd31, C Cd31, T
c.[96C>T] Cd31, G Cd31, A
c.[151T>A] Cd50, A Cd50, T
Table 12.4. List of mutations found in the Omani population by the ion torrent PGM sequencer. 
(HO = Homozygous, HR =Heterozygous). (Continued)
Genotype β-mutation HGVS name no. of patients
Cd6 GAG>GTG (HO) HBB:c.20A>T 85
IVS-I-5 G>C (HR) HBB:c.92+5G>C 80
Cd6 GAG>GTG/IVS-I-5 G>C HBB:c.20A>T/HBB:c.92+5G>C 26
Cd121 GAA>CAA (HR) HBB:c.364G>C 9
Cd44 (-C) (HR) HBB:c.135delC 9
IVS-I-1 G>A (HR) HBB:c.92+1G>A 6
IVS-II-1 G>A (HR) HBB:c.315+1G>A 6
IVS-I-3’ (-25bp del) (HR) HBB:c.93-21_96del 5
Cd39 CAG>TAG (HR) HBB:c.118C>T 5
IVS-I-5 G>C (HO) HBB:c.92+5G>C 4
Cd6 GAG>GTG/Cd44 (-C) HBB:c.20A>T/HBB:c.135delC 4
Cd6 GAG>GTG/Cd121 GAA>CAA HBB:c.20A>T/HBB:c.364G>C 4
Cd6 GAG>GTG/IVS-I-1 G>A HBB:c.20A>T/HBB:c.92+1G>A 3
Cd6 GAG>GTG/Cd39 CAG>TAG HBB:c.20A>T/HBB:c.118C>T 3
Cd5 (-CT) (HO) HBB:c.17_18delCT 3
Cd30 AGG>ACG (HR) HBB:c.92G>C 3
Cd26 GAG>AAG (HR) HBB:c.79G>A 2






















Table 12.4. List of mutations found in the Omani population by the ion torrent PGM sequencer. 
(HO = Homozygous, HR =Heterozygous). (Continued)
Genotype β-mutation HGVS name no. of patients
Cd6 GAG>GTG/IVS-II-1 G>A HBB:c.20A>T/HBB:c.315+1G>A 2
Cd5 (-CT) (HR) HBB:c.17_18delCT 2
Cd8 (-AA) (HR) HBB:c.25_26delAA 2
5’ (-88) C>A (HR) HBB:c.-138C>A 2
Cd6 GAG>GTG/Cd26 GAG>AAG HBB:c.20A>T/HBB:c.79G>A 1
IVS-II-1 G>A (HO) HBB:c.315+1G>A 1
IVS-I-5 G>C/IVS-I-3’ (-25bp del) HBB:c.92+5G>C/HBB:c.93-21_96del 1
IVS-I-128 T>G (HR) HBB:c.93-3T>G 1
Cd5 (-CT)/3’(+113) A>G HBB:c.17_18delCT/HBB:c.+113A>G 1
3’(+108) - 3’(+112) 5nt del (HR) HBB:c.+108_+112delAATAA 1
Cd26 GAG>AAG/IVS-I-3’ (-25bp del) HBB:c.79G>A/HBB:c.93-21_96del 1
Cd129 TGC>TGT (HR) HBB:c.389C>T 1
Cd22 GAA>TAA (HR) HBB:c.67G>T 1
IVS-I-5 G>C/IVS-I-128 T>G HBB:c.92+5G>C/HBB:c.93-3T>G 1
IVS-I-6 T>C (HR) HBB:c.92+6T>C 1
Cd6 GAG>GTG/Cd121 GAA>AAA HBB:c.20A>T/HBB:c.364G>A 1
Cd6 GAG>GTG/Cd6 GAG>AAG HBB:c.20A>T/HBB:c.19G>A 1
Cd6 GAG>GTG/Cd5 (-CT) HBB:c.20A>T/HBB:c.17_18delCT 1
Cd6 GAG>GTG/IVS-I-128 T>G HBB:c.20A>T/HBB:c.93-3T>G 1
Cd121 GAA>CAA/IVS-I-1 G>A HBB:c.364G>C/HBB:c.92+1G>A 1
Cd(8/9) +G (HR) HBB:c.27_28insG 1
normal controls   13
Total   297
DISCUSSION
The purpose of this study was to investigate if Ion Torrent PGM can be a suitable diagnostic 
method to sequence large number of samples for a small sized gene (e.g HBB) for a country 
wide Hemoglobinopathy screening program. Samples were preselected to contain 1 or 2 
mutations in the beta globin gene by haematological and HPLC screening. Our primer design 
almost covered the complete HBB mutation spectrum worldwide except for a region in intron 
2 as mutations in this region are very rare in the general population, at least not present in the 
Arabian area and not in the studied Omani population. 
The reason for the observed artefacts in our samples and the discrepancy obtained in 
few cases was due to the co-amplification of the HBD gene in fragment 3. Existing sequence 
homology co-amplification is not always easily prevented. However, it should not cause a 






















can be used as a confirmatory test. Moreover, although we have shown that a uni-directional 
method, by using a single barcode primer in the forward direction, is sufficient to give a unique 
sequence for each sample, it is always recommended to use bi-directional sequencing to 
discriminate between strand-specific artefacts and real mutations.
Based upon our results, we believe that Ion Torrent PGM could be a convenient option 
for diagnostic screening. One advantage of the PGM is its speed (8) and its ability to prepare 
a low-cost library with many different sample tags, allowing large number of samples to be 
pooled together and thus dividing sequencing costs among that many samples, generating 
sufficient data in a short period of time and avoiding lengthy hours of waiting to run samples 
in several batches. Moreover, PGM requires much less maintenance when compared to Sanger 
sequencing (4). Another advantage is that it uses a sequencing strategy where hydrogen ions 
(H+) are detected (8), thus, no lasers, cameras or fluorescent dyes are needed, making it a 
cost-reasonable machine to purchase. Also, ion torrent’s sequencing chips match the common 
manufacturing standards used for commercial microchips, meaning that it can be used for 
other technologies at equal low cost (9). Moreover, Ion Torrent requires as little as 10ng/ul of 
DnA to generate accurate results for challenging samples (10) whereas the traditional method 
of Sanger sequencing requires higher amount of DnA. Alternatively buccal swaps may be used 
instead of blood in a large scale screening programs. Although we have not tested the use 
of buccal swap DnA on Ion Torrent, we do believe that it should not be a problem for rapid 
population screenings. On the other hand, using buccal swap means having the DnA sample to 
be directly sequenced without haematological tests (CBC, HPLC) may save time and costs but 
will not provide with supportive data. 
We have shown that the Ion Torrent PGM can be used to sequence relatively small genes (e.g 
HBB) of a large number of specimens rather than its traditional practice of sequencing highly 
complex genes on a small number of patients. However, before introducing Ion Torrent PGM 
sequence as a new diagnostic tool, few technical parameters should be focused at. First, manual 
PCR plate preparation raises chances of error; secondly, preparation of PCR plates is a lengthy 
procedure when multiple fragments are to be looked at. However, this could be avoided by the 
possibility of performing a multiplex PCR, amplifying the 8 fragments in a single PCR reaction in 
our case, thus, having 8x less PCR work. The reason why we amplified the fragments separately 
in this study was to ensure even coverage of every fragment since we used for the first time 10 
x 10 combined barcodes to sequence 100 patients per run to have a robust and controllable 
amplification. To make PGM more feasible, more barcodes can be used to run as many patients 
(up to 400 samples) per chip. The reason why we have used a uni-directional sequencing in 
the first place was to reduce the number of primers and herewith the costs. However, when 
strand-specific sequence artefacts are expected, it is optimal to sequence bi-directionally. 
Economically speaking, cost will always remain an issue to see how worthy the new instrument 
can be in routine molecular analysis. However, increasing the sample size from 100 to 400 per 
run will reduce the costs per sample considerably and as the price per base continues to drop, 
PGM will soon be applicable routinely.
In conclusion, phenotypes cannot be predicted, explained or treated without determining 






















genome sequencing in specialized reference labs and could be used within the screening 
program in Oman. With the new technology of PGM, multiple DnA sequence reads can be 
produced in a single run, generating sufficient data to solve the clinical and epidemiologic 
problems in a short time. Technically, the key to success would be to choose a methodological 
approach that avoids massive uneven PCR efficiencies and biased quantification and thus 
sequencing errors. A limitation of the ion torrent is the errors that arise from homo-polymeric 
stretches (4) that are being under- or over- called. However, HBB is very suitable to be analyzed 
by Ion Torrent PGM as it does not have homopolymers interfering with proper base-calling. 
Considering all that, Ion torrent could be a suitable technology for a national population 
screening program in Oman or elsewhere once DnA testing for HBP (or other diseases) 
becomes mandatory prior to marriage, promoting a quick tool of identification (diagnosis) and 
thus early prevention.
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Hemoglobiopathies (HBP) are the most common genetic disorder in Oman and are in need 
of prevention programs due to the high incidence of beta-thalassemia major and sickle cell 
disease. Prenatal diagnosis (PD) and selective pregnancy termination is shown to be the most 
effective prevention tool for the control of HBP. However, PD is not available in Oman thus 
far because abortion is subject to religious, cultural and ethical issues. We have examined the 
attitude of a number of Omani HBP carrier couples towards prenatal diagnosis and selective 
abortion. We have interviewed 35 couples at risk visiting the main pre-marital clinic in Muscat 
between Jan 2011 and Jan 2012. Couples were interviewed using a pre-structured questionnaire. 
The majority would have accepted prenatal diagnosis (94%) if the service would be available in 



























Severe hemoglobinoapthies (HBP), such as β-Thalassemia major (TM) and sickle cell disease 
(SCD), are endemic in Oman. These diseases cause a huge suffering to patients and families 
and create an enormous healthcare burden to the country. Around ~6% of the population are 
carriers of sickle cell whereas about ~3% are carriers of beta-thalassemia (1,2).    
The diseases can be prevented by screening carriers before marriage, before reproduction 
or in early pregnancy and by offering genetic counselling. If the couples are already married, 
the most usual preventative option is prenatal diagnosis (PD) which is offered to couples at 
risk in many countries (3,4). In order to implement PD in Oman, one should know if these 
interventions would be accepted by the population and if pregnancy termination, in case of 
a severely affected foetus, would be accepted since selective abortion on medical indication 
is restricted in Oman because of religious, legal, ethical and social implications. Omanis are 
Muslims with a high rate of consanguineous marriages and couples at risk for HBP are therefore 
quite common. If these couples are to seek for PD, they are forced to do it abroad.  
Different Muslim countries and institutions have different opinions towards medical 
abortion. Most prohibit pregnancy termination at any time unless the mother’s life is at threat. 
Others allow it only within the first 120 days of gestation if the foetus is severely affected (5). In 
some Muslim Arab countries such as Tunisia (6) and Egypt (7), PD and interruption of pregnancy 
is well accepted and currently offered to couples at risk to prevent severely affected progeny. 
Premarital screening for β-thalassemia is subsidised and funded by the Omani government 
but it is not mandated by law as it is the case with neighbouring Muslim countries such 
as uAE and Iran. The national prevention program in Oman involves; carrier detections, 
molecular diagnostics in case of un-clear haematological findings, and genetic counselling. 
The prevention option thus far is not to marry if both partners are at risk. This study evaluates 
the implementation of HBP prevention in Oman in view of carrier couples towards PD and 
pregnancy termination.
MATERIAL AND METHODS
Data were obtained from the primary pre-marital clinic in Muscat. Detection of carriers was 
confirmed by haematological tests. A questionnaire was designed (Appendix) and couples 
in which both partners were carriers were surveyed. The survey questionnaire included sex, 
age, degree of consanguinity, risk acceptance and opinion concerning prenatal diagnosis and 
medical abortion in case of an affected foetus. The concept of prenatal diagnosis was explained 
to all participants. The median age of participants was 25 years old and all participants were of 
Omani nationality and Muslim.
RESULTS
From 420 couples visiting the main pre-marital clinic in Muscat between January 2011 to January 
2012, 38 couples were found in which both partners were carriers of either beta-thalassemia 
trait or sickle cell trait. Three carrier couples did not want to undergo the survey, so 35 couples 


























couples (71%) underwent premarital testing and genetic counselling prior to marriage while 
the remaining 29% visited the premarital clinic after getting married and after getting an 
affected child. Out of the 25 couples who received counselling prior to marriage, 10 couples 
still decided to continue with the marriage while 15 broke the engagement and went to seek for 
a “non-carrier” partner. Out of the 10 couples who got married, 6 couples accepted the risk of 
getting an affected child while 4 couples did not and decided not to get any children. From the 
carrier couples who were counselled after getting an affected child, 20% travelled abroad for 
PD. The remaining decided not to get pregnant again. Out of the 35 couples, 33 couples would 
have undergone prenatal diagnosis if the service was available in the country but out of these 
33 couples, 10 would not undergo selective abortion even if it was religiously allowed. Results 
are summarised in Table 13.1.
Table 13.1. Summary of the Omani couple views towards PD and pregnancy termination of affected foetus.
no. of couples interviewed 35
no. of consanguineous 14
no. in which both couples are carriers 35
no. of couples counselled before marriage 25
no. of couples counselled after marriage 10
no. of couples who would go for PD 33
no. of couples who would abort if religiously allowed 25
We further surveyed 20 selected couples in which only one partner was found to be a carrier; 
10 male carriers engaged to normal female partners and 10 female carriers engaged to normal 
male partners to see if there is any bias between the different genders in marrying a carrier 
partner. Among the first group, 4 out of 10 were first cousins and one couple broke the 
engagement after finding out the female was a carrier. Among the second group, 2 out of 10 
were first cousins and all couples continued with their marriages.
DISCUSSION
Prenatal diagnosis (PD) is a highly sensitive issue in Oman. In order to establish PD service in 
the country, awareness and knowledge should be clearly addressed to the targeted group 
and religious authority for a further discussion on the issue of medical abortion in case of a 
severely affected foetus. Based on our survey, the majority of the informed couples accepted 
to undergo PD if the service would be available in Oman but only if termination of pregnancy 
would be approved by the country’s Mufti. 
The majority of the participants were unaware of the Fatwa approved in some Arab-Muslim 
countries allowing selective abortion within the first trimester in case of an affected foetus 
based upon Islamic jurisprudence (Council of the World Islamic League, 15-22/07/1410 Hijri/ 


























Participant’s attitude was greatly influenced by Oman’s Mufti’s opinion and country’s policy. 
Although it might seem reasonable, the relation between PD and abortion is not absolute. 
As a matter of fact, in countries offering PD, couples getting a positive PD result may still 
decide to keep the affected foetus. On the other hand, because of the 1-2% chance of losing 
a foetus due to procedure risk, PD is discouraged if the couples are not planning to interrupt 
pregnancy in case of a severely affected foetus. Therefore the abortion debate should not be 
an issue for health care leaders to discourage the implementation of a national PD service. 
PD can help the couple to decide whether or not to interrupt the pregnancy abroad or can 
prepare them if they decide to keep an affected child so they are mentally and psychologically 
ready on how to cope with such a situation. PD would be a useful tool for clinicians as well in 
order to plan a properly tailored treatment at an early stage. 
Although the majority of our enquired couples were in favour of PD, accepting abortion was 
tightly bound to religious rules. This emphasise the critical role of religion in decision making in 
the Omani population who are known for their strict Islamic practice in the Arabian Gulf. The same 
impact of religious convictions on accepting PD has also been previously described in Saudies (8).
In a number of Muslim countries, the national premarital programs are mandatory and 
aimed at limiting marriage between carriers. In Iran, renouncing to marriage have been 
gradually replaced by PD and selective abortion and national incidence of TM has fallen from 
over 2000 cases a year to nearly zero affected newborn in some well managed regions of the 
country (9). Iran, with the majority being of Shia’a sub-religion, some of the Shia’a scholars 
allowed medical abortion before the 16th week of gestation under certain circumstances (10).
Although most Muslim countries are of Sunni sub-religion, some countries have accepted 
pregnancy termination under specific circumstances while others prohibited it absolutely. This 
is due to the four orthodox divisions in the Sunnis leading to diverse opinions towards medical 
abortion (11) as well as to the legal base system in a country which might not be exclusively 
religion-based but could be civil-based or a combination of both (11). 
In Oman, medical abortion is thus far prohibited by religion and law. The majority of the 
people in Oman are of Abadhi sub-religion. The main Abadha scholar in Oman, who is also 
the country’s Mufti, believe that human should not interfere with God’s will and perceive that 
termination of a pregnancy should only take place if the pregnancy is putting the mother in a 
life threatening condition. 
Despite well organised pre-marital clinics, the birth of HBP children is still very high in 
Oman. A large portion of the population may remain un-diagnosed due to social stigmatisation 
and unawareness. The concept of recessive disease might be difficult to understand for non-
medically-educated couple and the reaction “why should I get an affected child if I am a totally 
healthy person?” might explain why people continue with their marriage plans regardless the 
25% risk of getting a severely affected child.
Since PD is not offered to couples at risk in Oman thus far, the other primary prevention 
option besides not marrying, is selecting healthy gametes for fertilisation by pre-implantation 
genetic diagnosis (PGD) which is also not available in the country. PGD is permissible in 
Islam provided that the gametes are from the husband and wife (12). PGD may be socially a 


























have to undergo the option of terminating the pregnancy (13). However, clinically it involves 
a considerable hormonal treatment for the woman. Moreover it is a technically complex 
procedure and has some limitation with concerns of multiple pregnancies or un-successful 
implantation and of course economically this procedure is quite expensive. Only couples who 
are financially capable to cover the costs can travel abroad for PGD where’s the majority have to 
cope with the risk of getting another affected child or decide not to plan another pregnancy.
In a country such as Oman, where there are high rates of both consanguinity and 
hemoglobinopathies, it is the task of the health care authorities to debate the issue with the 
Country’s Islamic leader or Mufti to consider medical abortion for severe genetic conditions. 
Moreover, public health authorities should be concerned with the awareness of the public 
and should educate couples at risk on the availability of alternative preventative services. For 
the time being, early population screenings and genetic counselling are the only available 
preventative measures for the control of sickle cell disease and β-thalassemia major. With good 
infrastructure and implementing successful strategies, incidence of hemoglobinopathies could 
be dramatically reduced in Oman. 
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Relationship to partner (e.g 1st cousins)?
Screened prior/after marriage? 
Counselled prior/after marriage?
understood all the information provided by the counsellor? (yes/no).
Carried with the marriage regardless of the risk? (yes/no)
Accepted the risk of ¼ chance of getting an affected child? (yes/no)
Heard of PnD before? (yes/no)
Would undergo PnD if service is available in the country? (yes/no)
In case of carrying an affected fetus, would accept terminating the pregnancy? (yes/no) 



























Despite well-organized pre-marital clinics and the dramatic improvement in public health in 
the last few decades, the birth of children severely affected with sickle cell disease (SCD) or 
beta thalassemia major (BTM) is still high in Oman. Patients with severe hemoglobinopathoes 
(HBP) and their families are facing heavy suffering while treatment requires intensive, 
burdening and expensive efforts to be provided by public health which is offered free of charge 
to Omani citizens. 
For further improvement of HBP management, effective prevention programs are needed. 
Better detection and counseling of couples at risk should be offered to make an informed 
reproductive choice possible for healthy carrier couples at risk of having children with severe 
hemoglobin disorders. Introducing these options is complex but essential and is currently 
limited by the restrictions imposed upon prenatal diagnosis (PD) and medical abortion 
in Oman. 
Developing an efficient prevention strategy for HBP is a complex process both at the 
cultural and at the technical level. The essential technical and cultural elements involved in the 
process have been studied in this thesis providing the necessary knowledge to be used for the 
implementation of the most suitable strategy. Fundamental in the process towards establishing 
the necessary technical tools is an adequate knowledge of the molecular spectrum of HBP 
mutations in the country. 
MOLECUL AR SPECTRUM
We have studied the molecular spectrum of beta- and alpha- thalassemia in a large cohort 
of Omani patients demonstrating the widest spectrum of mutations reported thus far in the 
country, including the characterization of the most common mutations in the different regions 
of the country (Chapters 4-7). Our analysis has shown not only a broad range of common 
mutations, some of which are tribe specific and indicating a founder effect and genetic drift, 
but also many less common or rare mutations associated with historical migration patterns. 
From these studies, at least 32 different β-thal determinants were found among the Omanies 
(Table 5.1) with one novel beta-globin gene transversion in the promoter region (Table 6.2). In 
regard to the alpha globin gene, at least 21 defects were found with two novel mutations in the 
alpha 3.7 hybrid gene (Table 7.5). In Chapter 8, a total of 10 delta gene defect was characterised 
in the studied cases among which 2 novel delta determinants were found (Table 8.1). The 
necessity to characterize the molecular spectrum of delta globin gene defects is important in 
countries with high rate of beta thalassemia, especially when diagnosis of β-thalassemia carrier 
is based upon the measurement of HbA
2
 fraction only as this can be overlooked when it is co-
inherited with a delta mutation. 
The broad range of HBP defects identified in these studies (Chapters 4-8), demonstrate the 
existence of a heterogenic pattern in the country accounting to gene-flow and the past trade 
with other countries. Molecular detection of hemoglobinopathies is essential for providing 
accurate genetic counseling following premarital screening as well as in tailoring treatment 
plan in affected patients.
Moreover thorough characterization of the spectrum of common and rare beta- and 






















of the most appropriate current molecular technologies. In addition the molecular spectrum is 
essential for genotype/ phenotype prediction and risk assessment, for treatment and prenatal 
diagnosis and also for designing advanced molecular methods for future application to detect 
all mutations simultaneously. For the latter we evaluated the use of the Ion Torrent PGM in 
beta thalassemia diagnostics (Chapter 12). Based on our findings, we have concluded that Ion 
Torrent could be a convenient sequencing platform for large scale diagnostic screening in 
Oman during premarital or in early pregnancy testing. 
PHENOT yPE PREDICTION
Predicting the severity of the disease is not always straightforward. Also when the only available 
option is adapting partner choice, an accurate knowledge of the molecular spectrum examined 
in the totality of the genotype, is of great importance for a thorough premarital counseling of 
couples at risk. Therefore we have focused upon a number of technical elements essential for 
risk prediction and counseling and we have been able to show the following. Some defects, 
mild or silent, that cannot be easily detected at the hematological level may generate complex 
genotypes in association with the beta and/or alpha globin genes (Chapter 6). 
Delta gene defects occur at a considerable frequency in Oman and may interfere with the 
diagnosis of beta thalassemia using hematological parameters (Chapter 8). 
The co-existence of alpha thalassemia, very frequent in Oman, may modify the phenotype 
of the progeny of couples at risk and make risk prediction more complex. Therefore alpha 
thalassemia should not be overlooked during premarital screening when diagnosis is made on 
hematological parameters alone. If the couples are carriers of an alpha° or a relevant alpha+ 
defect, there is a 25% risk of getting a hydrops fetalis or severe HbH disease in the child and it 
is therefore necessary to perform molecular tests to define the alpha thalassemia defect and 
to differentiate between iron deficiency and/or alpha- or delta- thalassemia (Chapters 6 and 7). 
PHENOT yPE PREDICTION AND CURE VERSUS TREATMENT
Treating a disease does not always lead to a cure. This is in general the case for most genetic 
disorders and for HBP’s in particular. 
Different HBP phenotypes may require different treatment and the only “cure option” for 
severe HBP is a successful stem cell transplantation using a HLA identical sibling as the donor. 
This expensive option can reduce morbidity and prolong survival but is not easily accessible 
to the great majority of HBP patients in Oman. Therefore we have focused in this thesis upon 
elements involved in modulating phenotype and influencing the efficacy of treatment.
We have conducted a countrywide analytical study on the correlation between the genetic 
makeup (beta-cluster haplotype, coexisting alpha-thalassemia and XmnI polymorphism) and 
phenotype (Chapter 9, 10 and 11) in patients with sickle cell disease (SCD). 
Given the genetic heterogeneity of the Omani population, many different beta-cluster 
haplotypes were identified in SCD patients, and therefore we have explored the genotype-
phenotype correlations which is important for healthcare providers so that better disease 






















We have further observed that the hyroxyurea drug (Hu) can ameliorate the severe 
phenotype of the large majority of Omani SCD patients and that the XmnI C>T polymorphism 
is highly associated with a positive response to Hu treatment. Few patients that did not show 
improvement after treatment with Hu even after increasing the dose were all carries of an 
identical compound heterozygous beta gene cluster haplotype (Chapter 10). Thus we conclude 
that the presence of Xmn I polymorphism in Omani SCD population is a predictor of response 
to Hu but other factors such as either haplotype and/or sub-haplotype are also involved. These 
findings allow an early planning for an alternative treatment for those who are less likely to 
respond to the drug.
Moreover we compared the clinical severity of SCD patients of identical homozygous 
HbS/S genotype that are categorized by identical beta globin cluster haplotype with different 
alpha globin genotypes and shown that alpha-thalassemia can modulate the hematological 
picture of Omani SCD patients but not clearly the overall severity manifestation in patients of 
all haplotypes (Chapter 11). 
Overall, our results suggest that multiple determinants are involved in predicting disease 
severity in SCD patients and that these determinants should be considered for better 
assessment and treatment. Drawing correlation lines between the genetic make up and clinical 
severity is essential for prognostic purposes, accurate diagnosis and thus planning for the best 
tailored treatment. 
PREVENTION OPTIONS
Primary prevention has been achieved in different countries through information and screening 
at different levels. School, premarital, early pregnancy and neonatal screenings have been 
applied with different results. The approach involving screening early in pregnancy followed by 
PD and eventually selective medical abortion has shown to be the most effective and the most 
accepted prevention method, lowering the incidence of severe HBP cases in many countries. 
Therefore in this thesis we have studied the attitude of a representative Omani cohort toward 
prevention by PD and medical abortion in view of the ethnic, cultural and religious backgrounds 
(chapter 13). 
In our survey we have found that the majority of the couples inquired would have chosen 
for PD if this service would have been available in Oman but only if termination of pregnancy 
would be approved by law and by the country’s main religious Mufti. 
The issue of PD and selective termination of pregnancy in case of an affected fetus has 
been debated and legally approved in different Muslim countries but for the time being, early 
population screenings and the advice not to marry for carrier-couples at risk are the only 
available preventative measures in Oman. However, often the advice not to marry is ignored 
and high rates of both consanguinity and HBP frequency would benefit from the acceptability 
and availability of PD and medical abortion. 
The results of our enquiry and the incidence of the diseases in the country show that these 
issues should be discussed and solved with the approval of the country’s Islamic leader (Mufti) 
and public health authorities and that appropriate prevention measures should be offered 






















concerned with the awareness of the population and should educate couples at risk on the 
availability of alternative preventative options. 
IN CONCLUSION
This thesis has investigated most of the technical aspects necessary for a state of the art 
prevention programme for HBP in Oman. Currently the most rational way to offer appropriate 
prevention in Oman, whilst simultaneously respecting cultural and religious aspects, is to 
provide the relevant information and screening at the preconception level because it leaves 
either the option not to marry or to seek PD and medical abortion abroad (the latter for those 
couples who can afford it). With appropriate infrastructure this strategy could dramatically 
reduce the incidence of severe hemoglobinopathies in Oman and herewith, the suffering of 
patients and parents and the need for long lasting supporting therapy with the associated 







Hemoglobinopathies (HBP) are the most common autosomal recessive genetic disorder 
world-wide and in particular in the African continent, India, Far East, the Mediterranean and 
Middle Eastern countries including Oman. HBP can be the consequence of mutations causing 
structural abnormality in the hemoglobin molecule (abnormal hemoglobins) or a reduction/
abolishment in the overall synthesis of the hemoglobin components (thalassemia), leading 
to anemia. Carriers are usually asymptomatic but carrier couples are at 25% risk of getting a 
severely affected child.  
One of the main challenges faced by most Arab countries and by Oman in particular are 
the high prevalence rates of HBP [mainly sickle cell disease (SCD) and beta thalassemia major 
(TM)]. The prevalence is high in these areas due to the positive selection in the presence of 
malaria tropica. Moreover, due to consanguinity, a socio-cultural habit, the incidence of 
severely affected children is high in Oman. Around 10 % of Omanis are SCD carriers, 3 % carry 
a defect causing β-thalassemia and at least half of the population are carriers of α-thalassemia. 
Although the disease could be treated, there is no definite cure until now except for a matched 
bone marrow transplant. Public health authorities have focused not only on state of the art 
management and patient care but also on prevention. national premarital clinics aiming at 
identifying partners at risk prior reproduction and offering genetic counselling and prevention 
have been working in the country for the last decade. The focus of this thesis is to study the 
molecular spectrum of HBP and the associated genetic determinants to work towards the 
development of prevention strategies for severe HBP’s in Oman. 
In order to develop and improve risk assessment during pre-matrimonial counselling we 
have defined the molecular spectrum of the disease all around the country. In Chapter 4, we 
present a first study on 87 un-related Omanies either heterozygous or homozygous for beta 
thalassemia mainly coming from four different regions in Oman. We found 11 beta determinants 
with at least 56% of the cases with heterozygosity or homozygositiy for the common alpha-
thalassemia deletions; alpha 3.7kb and/or alpha 4.2kb. We have further extended our analysis 
to reveal a broader spectrum of beta globin gene mutations in Chapter 5, studying larger 
number of subjects (n=446) of different tribal origin, covering all the seven regions in the 
country. Thirty-two different beta mutations were identified with 11 being described for the 
first time among the Omani population. We then analysed the alpha globin gene defects in 
details in Chapter 7. A total of (n=634) subjects were divided into seven groups based on their 
hematological readings and were analysed at the molecular level. Twenty-one different alpha 
defects were categorised of which 15 were described for the first time among Omanies with 
two defects presumed to be new. We further reported in Chapter 6 two new cases among the 
Omani. The first is an alpha variant found in a consanguineous couple that probably resulted in 
a severe fetal hemolytic anemia while the second is a novel β-globin gene promoter mutation 
associated with borderline/slightly elevated HbA
2
, indicating a very mild de novo β+ thalassemia 
mutation. The high heterogeneity of common, rare and novel beta- and alpha- globin genes 
defects observed among Omanies (Chapters 4,5,6 and 7), outlines the historic migration pattern 
and the mixed ethnicity among the population and emphasize the necessity of implementing 
DnA testing during pre-marital screening for accurate risk prediction and genetic counselling 
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especially when both beta and alpha defects coexist making genotype prediction more complex 
and herewith providing the state of the art for prenatal diagnosis in the future. 
In Chapter 8, we looked at the interfering effect of factors such as delta gene defect or iron 
deficiency that may influence HbA
2
 measurement in the Omanies and herewith the diagnosis of 
beta thalassemia trait. This is particularly important during beta-thalassemia carrier screening 
because coexisting delta thalassemia defect with a beta thalassemia carrier status can 
normalise HbA
2
 level and preclude a correct diagnosis. For that, we investigated 33 cases with 
low HbA
2
 levels. Ten different defective delta alleles of which two are reported for the first time 
in literature were categorised in 20 subjects. The characterization of the delta-gene mutation 
spectrum is bound to make premarital screening and genetic counseling more reliable in the 
Omani population screened for beta thalassemia.
Patients with sickle cell disease (SCD) may show a strong variability in morbidity and 
response to therapy from case to case, depending from the often complex genotypes and 
haplotypes. The classical associated determinants were investigated in Chapters 9,10 and  11. 
In Chapter 9, the haplotype/sub-haplotype and phenotype in SCD patients (n=125) was 
investigated. A total of 11 different haplotype combinations were identified with the Asian 
haplotype being the most common and associated with a milder clinical form. In Chapter 10, a 
cohort of (n=52) SCD patients treated with hydroxyurea (Hu) were tested for their response to 
Hu based on their XmnI polymorphism. Patients homozygous or heterozygous for Xmn I (T/T 
or T/C) showed better response and improvement in clinical phenotype than patients bearing 
the (C/C) genotype. In Chapter 11, we assessed if presence or absence of alpha thalassemia in 
the same 125 SCD patients with identical beta genotype and haplotypes can ameliorate disease 
severity. We found that alpha thalassemia improves the overall hematological conditions but 
amelioration of the general disease severity is only noticed when compared in cohorts of the 
same haplotype. We conclude from these correlative studies that neither the haplotype or 
sub-haplotype nor the XmnI polymorphism nor alpha-thalassemia alone appears to be fully 
associated with the variable clinical phenotypes in SCD and that presumably other external 
factors can play a role in the different expression of the disease. nevertheless, identifying 
genetic determinants is necessary for prognostic purposes, accurate diagnosis and planning 
for the best-tailored treatment to the affected children.
In Chapter 12, we tested the application of Ion Torrent PGM as a diagnostic ultra high-
thoughput sequencing method for beta globin gene during beta thalassemia screening. We 
scanned a total of 297 Omani cases using a barcoded uni-directional sequence methodology 
and reliably identified beta-thal mutations in hundreds of patients simultaneously. Our 
results show that ion torrent can replace Sanger sequencing in the future and is a powerful 
diagnostic method to detect HBP carriers and carriers of other common genetic disorders in 
a national screening setting and that these molecular methods may become more practical if 
financially affordable.  
Pre-matrimonial counselling, although thorough, is the only formal option available in 
Oman to couples at risk. This leaves only two options for couples whenever a presumed genetic 
risk has been suspected: to change the choice of partner or to continue with the marriage 
and hope for a healthy child from each pregnancy. Therefore the most effective prevention 
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method for HBP disorders thus far seems to be also in Oman, is prenatal diagnosis followed 
by the option of pregnancy termination. In Chapter 13 we investigated the attitude of 35 
Omani couples at risk towards prenatal diagnosis and medical abortion. Although the majority 
would have accepted prenatal diagnosis if the service was available in the country, pregnancy 
termination was greatly influenced by the Islamic view as interpreted in the country by the 
main religious Muftee. However, prenatal diagnosis may be eventually considered in Oman 
with improved public awareness and once the public health authorities have reached a sensible 
agreement with religious authorities, as has been the case in other Muslim countries.
In conclusion, while providing tools for a better care and a better insight on the management 





Hemoglobinopathieën (HBP) behoren tot ‘s werelds meest voorkomende autosomaal recessief 
overervende aandoeningen, en komen vooral voor in Afrika, India, het mediterrane gebied, 
het Verre- en nabije Oosten, waaronder ook Oman. HBP zijn het gevolg van mutaties die 
structurele afwijkingen veroorzaken in het hemoglobine molecule (abnormale hemoglobines) 
of de expressie van de globine genen beïnvloeden waarbij de globine synthese verlaagd of zelfs 
geheel afwezig is, met anemie tot gevolg. Dragers van HBP zijn doorgaans asymptomatisch, 
echter als risicopaar hebben zij 25% kans op een ernstig aangedaan kind. 
Een van de belangrijkste uitdagingen op het gebied van volksgezondheid voor de meeste 
Arabische landen en Oman in het bijzonder, is de hoge prevalentie van HBP, m.n. sikkelcelziekte 
(SCZ) en beta-thalassemie Major (TM). De hoge prevalentie voor HBP in deze gebieden is het 
gevolg van positieve selectie van dragers door malaria tropica. Bovendien draagt in Oman de 
sociaal-cultureel bepaalde traditie van consanguine huwelijken bij tot een verhoogde incidentie 
van kinderen met een ernstige vorm van HBP. Ongeveer 10% van de Omaanse populatie is 
drager van SCZ, 3% is drager van beta-thalassemie terwijl tenminste de helft drager is van alfa-
thalassemie. Ook al is de ziekte behandelbaar, op een HLA identieke beenmergtransplantatie 
na zijn er tot op heden geen mogelijkheden tot genezing. De Omaanse autoriteiten op het 
gebied van publieke gezondheidszorg hebben zich niet alleen gericht op de beste behandeling 
en patiëntenzorg, maar ook op het terugdringen van het aantal aangedane geboorten. 
De  laatste tien jaar heeft het premaritaal identificeren van risicoparen en het aanbieden van 
genetisch advies door speciaal hiervoor opgerichte nationale klinieken, een bijdrage geleverd 
aan de preventie van HBP. Dit proefschrift beschrijft het onderzoek naar het mutatiespectrum 
van HBP en de genetische determinanten die de ernst van de ziekte beïnvloeden om zo een 
bijdrage te leveren in het ontwikkelen van een preventie strategie voor de ernstige vormen van 
HBP in Oman. 
Om via premaritale counseling het genetisch risico op HbP in het nageslacht beter te 
kunnen bepalen werd het moleculaire spectrum aan globine genmutaties die voorkomen in 
Oman onderzocht. Hoofdstuk 4 heeft betrekking op een eerste studie onder 87 niet-verwante 
Omani , homo- of heterozygoot voor beta-thalassemie, afkomstig uit vier verschillende 
gebieden in Oman. Daarbij werden 11 verschillende beta-thalassemie mutaties aangetoond, 
waarbij tenminste 56% van de individuen eveneens hetero- of homozygoot bleek te zijn voor 
de meest voorkomende alfa-thalassemie deleties, m.n. de alfa3.7kb en alfa4.2kb deletie. Een 
breder spectrum aan mutaties werd verkregen door de studie beschreven in hoofdstuk 5 
waarbij nog eens een groot aantal individuen (n=446), behorende tot verschillende stammen 
en afkomstig uit zeven verschillende gebieden, werden onderzocht. Hierbij werden 32 
verschillende beta-thalassemie mutaties gevonden, waarvan 11 voor het eerst beschreven in 
de Omaanse populatie. Hoofdstuk 7 beschrijft de analyse van de alfa-globine gendefecten. 
Op basis van de hematologische bepalingen werden de in totaal 634 individuen ingedeeld in 
7 groepen en op moleculair niveau onderzocht. Er werden 21 verschillende alfa-gendefecten 
gevonden, waarvan 15 voor het eerst in Oman. Twee nieuwe alfa-gendefecten werden in deze 
studie voor het eerst beschreven. In hoofdstuk 6 worden twee casussen apart beschreven, 
de eerste is een alfa-globine variant gevonden in een consanguin echtpaar die vermoedelijk 
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de ernstige hemolytische anemie verklaart bij de foetus. De tweede betreft een nieuwe 
promotor mutatie van het beta-globine gen geassocieerd met een borderline/licht verhoogde 
HbA
2
, indicatief voor een mild β+-thalassemisch effect. De sterke heterogeniteit van veel 
voorkomende, zeldzame en nieuwe beta- en alfa-globine gendefecten (hoofdstuk 4, 5, 6 
en 7) weerspiegelt het historisch migratiepatroon en etnische vermenging van de Omaanse 
bevolking en benadrukt de noodzaak van het implementeren van DnA tests om het genetisch 
risico in pre-maritale screening en counseling adequaat te kunnen bepalen. Vooral wanneer 
alfa- en beta-thalassemie defecten gecombineerd voorkomen, zijn DnA tests onmisbaar om 
een voorspelling van het risico voor het nageslacht op basis van het genotype te kunnen doen 
en cruciaal voor de ‘state-of-the-art’ prenatale diagnostiek in de toekomst.
In hoofdstuk 8 is gekeken naar factoren in de Omaanse HbP populatie die de HbA
2
 meting 
en daarmee de diagnose beta-thalassemie trait beïnvloeden, zoals delta-gendefecten en 
ijzerdeficiëntie. Dit is met name belangrijk bij dragerschapscreening van beta-thalassemie 
aangezien een co-existerend delta-gendefect (delta-thalassemie of delta-globine variant) in 
een drager de HbA
2
 normaliseert met een verkeerde diagnose tot gevolg. Hiertoe werden 33 
gevallen met een verlaagd HbA
2
 percentage onderzocht. Er werden 10 verschillende delta-gen 
defecten gevonden in 20 individuen, waarvan twee niet eerder in de literatuur gerapporteerd. 
Het bepalen van en kennis over het delta-globinegen mutatiespectrum draagt stellig bij 
tot de  betrouwbaarheid van pre-maritale screening en genetische counseling voor beta-
thalassemie in de Omaanse populatie. 
Afhankelijk van de complexiteit van het genotype en het haplotype kunnen 
sikkelcelpatiënten onderling een enorme variabiliteit in morbiditeit en reactie op therapie 
vertonen. In hoofdstuk 9, 10 en 11 worden de klassieke hiermee geassocieerde determinanten 
onderzocht. In hoofdstuk 9 werd de associatie tussen fenotype en (sub)haplotype onderzocht 
in 125 patiënten met sikkelcelziekte. Van de in totaal 11 verschillende haplotype combinaties 
bleek het klinisch mildere Aziatische HbS haplotype het meest voor te komen. In hoofdstuk 
10 werd in 52 met Hydroxy-ureum (Hu) behandelde sikkelcelpatiënten gekeken naar de 
responsie op behandeling in relatie tot de aanwezigheid van het XmnI polymorfisme (T/T of 
T/C) in de promotoren van de gamma globine genen. Hieruit bleek dat sikkelcelpatiënten, 
homo- of heterozygoot voor het XmnI polymorfisme (T/T of T/C), effectiever reageerden op 
Hu behandeling en daarmee een milder klinisch fenotype vertoonden dan patiënten zonder dit 
XmnI polymorfisme (C/C). In hoofdstuk 11 werd in hetzelfde cohort van 125 sikkelcelpatiënten 
naar de invloed gekeken van de aan- of afwezigheid van alfa-thalassemie op de klinische 
ernst in patiënten met hetzelfde beta-genotype en haplotype. Daarbij werd gevonden dat 
de algehele hematologische condities door aanwezigheid van alfa-thalassemie gunstiger 
zijn, maar dat een verbetering in de algemene ernst van het ziektebeeld alleen merkbaar is 
wanneer groepen patiënten met eenzelfde haplotype met elkaar worden vergeleken. Van deze 
correlerende studies kan worden geconcludeerd dat noch haplotype of sub-haplotype, noch 
het XmnI polymorfisme, noch alfa-thalassemie alleen volledig de variatie in klinisch fenotype 
kan verklaren in patiënten met SCZ en dat andere, waarschijnlijk externe factoren een rol spelen 
in het verschil in expressie van de ziekte. Desalniettemin is het identificeren van genetische 
factoren noodzakelijk voor het stellen van de juiste diagnose en prognose en voor de beste 
behandeling op maat van aangedane kinderen.
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In hoofdstuk 12 werd het nut van next Generation Sequencing (nGS) tools zoals de Ion 
Torrent PGM als diagnostische screeningsmethode voor beta-thalassemie en HbS onderzocht. 
Hierbij werden DnA monsters van in totaal 297 Omaanse patiënten en dragers van beta-
thalassemie en HbS getest op het voorkomen van mutaties in het beta-globine gen. Door 
gebruik te maken van barcode primers en uni-directionele sequentie-analyse werden van 
100  individuen simultaan de mutaties in het beta-gen betrouwbaar gedetecteerd. Deze 
resultaten toonden aan dat de Ion Torrent in de toekomst de traditionele Sanger sequencing 
zou kunnen vervangen en dat het, mits financieel haalbaar, een krachtige diagnostische 
methode is voor toepassing in grootschalige nationale screeningsprogramma’s voor HbP 
dragers of dragers van andere veelvoorkomende genetisch aandoeningen. 
Een gedegen counseling voor het huwelijk is momenteel de enige formele optie in Oman 
om risicoparen te informeren over erfelijkheidsrisico. Hiermee zijn de opties voor preventie 
beperkt tot aanpassing van de partnerkeuze wanneer sprake blijkt te zijn van genetisch risico 
voor het nageslacht of continuering van het huwelijk in de hoopvolle verwachting van een 
niet-aangedaan kind. Het aanbieden van prenatale diagnostiek met als doel beëindiging 
van aangedane zwangerschappen is tot op heden het meest effectief in de preventie van 
ernstige vormen van hemoglobinopathie. In hoofdstuk 13 wordt beschreven wat de houding 
is van 35 Omaanse risicoparen ten aanzien van prenatale diagnostiek en abortus op medische 
indicatie. Hoewel de meerderheid van de risicoparen om prenatale diagnostiek zou hebben 
verzocht indien de mogelijkheid bestond, wordt de kijk op zwangerschapsbeëindiging sterk 
beïnvloed door de Islam en de opvattingen van de Muftee, de belangrijkste religieuze autoriteit 
van het land. Wanneer echter de publieke bewustwording over prenatale diagnostiek toeneemt 
en de autoriteiten op het gebied van volksgezondheid overeenstemming zouden bereiken met 
de religieuze autoriteiten, zou prenatale diagnostiek op den duur een mogelijkheid kunnen 
worden in Oman, zoals in andere moslim landen al het geval is. 
Tot slot wil ik de hoop uitspreken dat de resultaten van dit proefschrift zullen bijdragen tot 
een betere zorg, een groeiend inzicht in de vraag hoe om te gaan met deze ernstige erfelijke 
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